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ABSTRACT 
Cancer is one of the leading causes of death worldwide. In recent years, with the aid of 
high-throughput genomic technologies, large cohorts of tumor samples have been analyzed to 
characterize molecular aberrations in many cancer types. These studies have generated 
enormous amount of cancer genomics data, providing not only new opportunities to 
understand tumor evolution and cancer progression mechanisms but also new challenges in 
efficiently and rigorously analyzing the data. Heterogeneity is an important feature of cancer 
and has significant impact on the diagnosis and treatment of the disease. My dissertation 
focuses on developing new bioinformatics and biostatistical approaches to study the 
heterogeneity and evolutionary history of cancer genomes. Under this theme, my thesis 
consists of four main chapters. First, I have developed an algorithm to infer aneuploid and 
euploid cell mixing ratios using allele-specific DNA copy number alteration (CNA) data, and 
made a striking discovery that gene expression patterns in brain and ovarian tumors are 
strongly influenced by aneuploid content. The ability to infer mixing ratios allowed me to 
revise the current classification system for glioblastoma, with better predictive power of 
clinical outcome than previous results. Second, I developed a Clonal Heterogeneity Analysis 
Tool (CHAT) that estimates cellular fractions for individual CNAs and individual somatic 
mutations, allowing us to use the distribution of these fractions to inform the macroscopic 
clonal architecture and the relative order of occurrence of somatic changes. For example, a 
! xiii!
CNA with a higher frequency in the cell population may have occurred earlier in tumor 
development or conferred a greater growth rate, therefore is more likely to contain driver 
genes. Third, I developed a method to detect short tandem repeat (STR) variation using 
paired-end short-read next-generation DNA sequencing data. Unlike previous methods which 
are limited to finding short STR alleles, my method is capable of finding both STR alleles 
shorter than a read and those longer than the read or the read pair (i.e., the insert size of the 
library). This capability addresses the need to reliably detect expanded STR alleles in 
germline DNA that underlie many rare inherited diseases as well as somatic aberrations 
characterized by microsatellite instability. In sum, my dissertation work led to the 
development of several new methods to study tumor heterogeneity. Their applications in 
multiple tumor types have made important contributions in understanding the mechanisms of 
tumor evolution. The work of my thesis is not only helpful to study the nature of tumor 
heterogeneity and evolution, but also provides a basis for assessing the impact of diverse 
tumor cell population on clinically important aspects such as subtype classification, prognosis 
and therapeutic resistance.
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Chapter 1. Introduction  
 
1.1 Background 
 
1.1.1 Significance of Tumor Heterogeneity  
Cancer is a leading cause of death in the US and worldwide (Jemal et al., 2008). Between 100 
and 200 billion dollars are spent each year in US alone on cancer patient care (National 
Cancer Institute: http://costprojections.cancer.gov/). Despite decades of intensive efforts, it 
remains difficult to provide early diagnosis or effective treatment to many types of cancers. 
Most advanced cancers remain incurable. Oncologists commonly apply chemotherapies or 
radiotherapies to kill proliferating cancer cells. Nonetheless, eradication of tumor cells via 
cytotoxic therapies is rarely complete, and in most scenarios tumor eventually develops drug 
resistance, i.e., becomes insensitive to the treatment (Marusyk and Polyak, 2010). Emerging 
evidence has linked the resilience of cancers to its intrinsic heterogeneity, suggesting that a 
tumor can survive multiple environmental challenges, including immune response, 
inflammatory stimuli, clinical treatment etc., due to its large pool of genetically divergent 
cells that allow rapid adaptation and continued evolution (Yates and Campbell, 2012, Marte, 
2013). Understanding such adaptation and evolution is a major focus of today's cancer 
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research.  
Tumor heterogeneity refers to genetic and functional differences between cells in a tumor cell 
population (Heppner, 1984). Historically, studies on this topic dated back to 1950s when 
histologists dissected ascites tumors in mice and observed uneven chromosome numbers 
among individual tumor cells under microscope (Levan and Hauschka, 1953). In the past 
decade, with the development of high-throughput technologies, the paradigm of cancer 
research has shifted from physiological manifestations into mechanistic study of the 
underpinning molecular signatures of tumor heterogeneity (Marusyk et al., 2012). These 
studies have provided a progressively deeper understanding of this complex human disease.  
 
1.1.2 Levels of Tumor Heterogeneity 
Heterogeneity in tumors can be organized according to different levels of biological 
organization: inter-tumor heterogeneity, which refers to the differences among tumors 
between patients or within the same patient; and intra-tumor heterogeneity, which includes 
both tumor/normal cell mixing and potential co-existence of multiple subclones in the tumor 
cell population.  
Inter-tumor heterogeneity refers to the genetic and phenotypic differences between individual 
tumors. This heterogeneity includes inter-patient differences, including how cancer patients 
have distinct clinical outcomes, such as responding differently to the same therapies. Such 
inter-patient differences reflect genetic, developmental, and environmental differences.  For 
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example, breast cancers can be categorized by grade, by recurrent mRNA expression patterns 
or characteristic mutations, or by the presence and absence of certain hormone receptors. The 
classification of a patient's cancer into discrete subtypes—by clinical and/or cellular and 
molecular features—is an important area of research and patient care. In the example of 
breast cancers, the triple-negative subtype is defined by the absence of the estrogen receptor, 
progesterone receptor, and the her2 receptor. This subtype is more aggressive than others and 
leads to the worst prognosis. Studies of inter-patient heterogeneity require a large sample size 
to adequately discover recurrent events and subtypes. Many of these studies do not consider 
intra-tumor heterogeneity, rather they treat each patients tumor sample as a uniform entity, 
containing a homogeneous population of cells.  
Inter-tumor heterogeneity also includes differences among tumors within a cancer patient 
(Vogelstein et al., 2013), both among primary tumors and between primary and metastatic 
tumors. The metastatic tumors, while originated from the primary tumor, may have acquired 
additional molecular aberrations and may be different from each other as they adapt to 
distinct local environments (Yachida et al., 2010).  
Intra-tumor heterogeneity could simply involve different levels of Tumor-Normal mixing.  
A surgically obtained tumor specimen could contain many cell types, including tumor cells, 
surrounding stromal cells, blood vessels, and infiltrating immune cells. Although many 
studies have applied extensive sample selection according to histological tumor "purity", 
these procedures cannot completely remove the admixture of normal non-cancerous cells; 
and as a result, the data may not derive solely from the tumor cell populations, but may 
include the contribution of other cells. 
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Even when the sample contains 100% tumor cells, these cells may belong to different tumor 
subclone, adding another layer of intra-tumor heterogeneity. Even 1 mm3 of tissue material 
may contain millions of cells and they may be partitioned into multiple recognizable groups, 
with the variability among cells within a group to be much smaller than that between groups 
(Kleppe and Levine, 2014). Each of such a group is referred to as a subclone. Sometimes the 
subclones are spatially segregated, and can be revealed by multi-regional sampling and 
analysis of a single tumor (Sottoriva et al., 2013, Gerlinger et al., 2012). In other cases, cells 
with different molecular features may be interspersed thoroughly, such that the subclonal 
structures are not apparent even with regions sampling down to smaller spatial units. 
Ultimately, single-cell profiling is the most effective strategy to study intra-tumor 
heterogeneity, but it incurs much higher costs in time and resources (Navin et al., 2011, Hou 
et al., 2012, Zong et al., 2012). Nonetheless, molecular difference among tumor subclones 
represents the fundamental source of drug resistance: even the most effective treatment can 
eradicate all subclones, and the drug-resistant cells that remain after treatment can expand 
and grow into the recurrent tumor.  Being able to monitor clonal structure in bulk tissue 
samples is both an important research question and a valuable clinical capability.   
 
1.1.3 Biological Sources of Tumor Heterogeneity 
 
Phenotypic variability of tumor cells could be driven by multiple molecular sources of 
variation. One of them is genetic variation. While a person's germline genome could carry 
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different alleles that confer cancer susceptibility, the genome of individual cancer cells 
accumulates additional somatic alterations (Meyerson et al., 2010) that include copy number 
changes (Hanahan and Weinberg, 2000, Albertson, 2006, Beroukhim et al., 2010), 
translocations (Mitelman et al., 2007) and single nucleotide mutations (Sjoblom et al., 2006, 
Ley et al., 2008, Stratton et al., 2009).  The rate of these aberrations can be increased due to 
impaired DNA damage repair mechanism (de Gruijl et al., 2001) or compromised 
surveillance of genomic instability (Negrini et al., 2010). Genetic variation is one of central 
components of the clonal evolution process (Nowell, 1976), which also involves natural 
selection, population expansion and migration, random genetic drift, interactions with local 
environment, and, upon effective treatment, a significant collapse of population size (Greaves 
and Maley, 2012). As is often the case in population genetics concerning humans or other 
species, only a minority of somatic mutations are capable of promoting cell survival, 
proliferation, and clonal expansion, and are referred to as "drivers".  The majority of 
mutation has no discernible phenotypic impact and is referred to as "passengers" (Greenman 
et al., 2007).  
Besides genetic variation, differences in epigenetic modifications also contribute to cancer 
heterogeneity (Esteller, 2008, Sharma et al., 2010). Different alterations of DNA methylation, 
nucleosome positioning and gene expressions among tumor cells contribute to intra-tumor 
heterogeneity. Such epigenetic variations also underlie the Cancer Stem Cell (CSC) Model, 
which emphasizes the possibility that the phenotypic variability among tumor cells can be 
due to epigenetic factors. Extensive studies have been conducted under this model for many 
cancer types (Singh et al., 2003, Prince et al., 2007, Charafe-Jauffret et al., 2009). 
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In addition to genetic and epigenetic heterogeneities, recent advances also highlight the 
interplay between tumor cells and their local tissue environment (Egeblad et al., 2010, 
Junttila and de Sauvage, 2013). For example, cancer associated fibroblasts promote tumor 
growth via secretion of multiple growth factors; active vasculature delivers necessary 
nutrition to proliferating tumor cells, and immune cells can be recruited and converted by 
tumor cells to suppress adaptive immunity and enhance tumor development. Differences in 
fibroblast behaviors and responses, uneven vascularization and vascular maturity, and diverse 
invasive immune cell types and their localizations all contribute to the observed inter- and 
intra-tumor heterogeneity, and must be considered when trying to overcome therapeutic 
resistance.  
 
1.1.4 Applications of High-throughput Technologies in Tumor Heterogeneity Research 
 
In recent years, the maturation of high-throughput technologies has rapidly enhanced our 
ability to study complex cancer genomes. For example, whole-genome sequencing of tumor 
samples provides a nearly complete catalog of somatic changes, including single-nucleotide 
variations, small insertion and deletions, and structural variations. Likewise, RNAseq 
technology has enabled the discovery of gene fusion (Tomlins et al., 2005, Soda et al., 2007), 
novel transcripts (Maher et al., 2009), and RNA editing (Sommer et al., 1991). Other 
high-throughput technologies, including SNP genotyping arrays, gene expression arrays, 
micro-RNA expression arrays, DNA methylation arrays, etc., enable the simultaneous 
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analyses of multiple levels of biological regulation, and have contributed to an increasingly 
integrative understanding of the mechanism of tumor development.  
Many large-scale, coordinated studies have been conducted during the past decade to 
understand the etiology of cancers by applying genomic technologies. The Cancer Genome 
Atlas (TCGA) project and the International Cancer genome Consortium (ICGC) are two 
examples of such consortium-scale, highly collaborative initiatives. By the February of 2014, 
TCGA has analyzed more than 9,000 tumor samples for 29 types of cancers, and has publicly 
released both the clinical data and many types of genomic profiling data. These data 
resources have provided a valuable opportunity to study the molecular basis of multiple of 
cancer types from multiple 'omics perspectives. A limitation of these datasets, as I will 
discuss further in this dissertation, is that they treat each tumor sample as a unitary, 
homogeneous entity, and have not considered the intrinsic heterogeneity within each tumor 
samples.  I will show in Chapter 2 that information about intra-cellular heterogeneity can be 
extracted from datasets originally intended to study the average behavior of bulk tumor 
samples, and intra-cellular heterogeneity can explain a substantial portion of the observed 
inter-tumor heterogeneity.   
 
1.2 Challenges in studying intra-tumor heterogeneity using bulk tumor datasets 
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1.2.1 Normal Tissue Contamination in Inter-tumor Heterogeneity Studies 
Large cancer cohorts mentioned above routinely used molecular materials collected from 
bulk tumor tissues that usually contain normal cells. Low tumor content reduces the power to 
detect somatic events using genomic DNA data, especially for subclonal mutations—those 
that appear in only a fraction of the tumor cells (Carter et al., 2012). Tumor-normal mixing 
also affects every other molecular profiles, including mRNA expression, DNA methylation, 
micro-RNA expression etc., by presenting a weighted average of the signatures carried by 
tumor cells and those carried by the normal calls. Variable ratios of tumor-normal mixing 
affect tumor subtype classification, thus directly complicating the clinical applications of the 
patients' molecular profiling data.  I present a case study using Glioblastoma Multiforme 
samples showing this problem. GBM was one of the first cancers TCGA analyzed (TCGA, 
2008). GBM is a malignant brain cancer (WHO grade IV astrocytoma).  Despite intensive 
treatment, the outcome is poor since the median survival time is only 18 months. (Johnson 
and O'Neill, 2012). Researchers have studied the molecular subtypes to characterize the 
inter-tumor diversity of this cancer (Phillips et al., 2006a, Verhaak et al., 2010a). Verhaak et 
al applied the mRNA expression data from TCGA samples and discovered four subtypes. 
However, many TCGA studies including this one failed to consider the impact of intra-tumor 
heterogeneity, in Verhaak’s classification, different subtypes show no significant survival 
difference.  
In the following paragraph I am going to review the general principle on how to infer 
tumor/normal mixing. TCGA applied genome-wide SNP array to profile the copy number 
alterations in tumor samples. SNP array is an efficient technique to estimate copy number 
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changes and allelic imbalances both at high resolution and throughout the whole genome 
(Zhao et al., 2004, Dutt and Beroukhim, 2007). There are two main commercial platforms for 
SNP array analysis, Affymetrix and Illumina. Both platforms produce allele specific copy 
number estimates, initially derived from the intensity of fluorescent assay signals. For each 
SNP, the two alleles from a diploid genome are denoted by A and B. The intensity of both 
alleles (A+B) provides an estimate for the total copy number. In practice, it is convenient to 
use !"#! !!!! = !"#! ! + ! − 1 (logR ratio, or LRR) to represent copy number, since it 
takes value zero for normal diploid loci. The fraction of B allele signal intensity (B/(A+B)), 
normally referred to as B-allele frequency or BAF, provides evidence for allelic-imbalances. 
Although profiled on genomic DNA from bulk tissue, SNP array data contains intra-tumor 
heterogeneity information and a number of algorithms have been developed to extract 
tumor/normal mixing ratios using SNP array (Popova et al., 2009, Yau et al., 2010, Van Loo 
et al., 2010, Song et al., 2012). When the sample contains a fraction of euploid cells, in a 
copy number variation region, not all the cells are carrying the CNV, and instead of 
theoretical LRR and BAF values based on copy numbers, the observed LRR and BAF will be 
closer to zero, a phenomenon referred to as ‘contraction’. BAF and LRR contraction is 
helpful to infer tumor/normal mixing ratios. 
In Chapter 2, I re-examined Verhaak et al.’s cohort by considering intra-tumor heterogeneity. 
I first developed an algorithm to estimate the tumor/normal mixing ratios for individual 
samples using SNP array data, and discovered that the variation of mRNA expression pattern 
among samples is driven by different levels of euploid cell fractions of individual tumors. I 
then revised the classification of mRNA expression subtypes with joint use of mRNA and 
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CNA data. The new scheme I proposed has stronger predictive power on clinical outcome. 
Using inferred normal cell mixing ratios and reference datasets of known neuronal cell types, 
I was able to identify microglia/macrophage as the likely source of the euploid cells in the 
mesenchymal GBMs.  
 
 
1.2.2 Tumor Subclone Analysis Using Bulk Tissues 
 
As discussed above, intra-tumor heterogeneity is a hallmark of cancer and reflects the 
complicated evolution history of tumors. There are several aspects of interests of intra-tumor 
heterogeneity, including cellular frequencies of somatic copy number alterations (sCNAs) 
and somatic mutations, number of subclones in a tumor population, etc. Cells carrying 
somatic driver events have greater selective advantage and are likely to be maintained during 
tumor evolution. Therefore, somatic aberrations with high cellular frequencies are usually 
candidate driver events. More interestingly, if a somatic event occurred with high prevalence 
in a subclone, it is likely a subclonal driver event. Studying subclonal drivers is helpful to 
understand tumor evolution. . 
The ideal data for analyzing tumor subclones is to profile single cells or samples collected 
from multiple regions of the same tumor. However, these procedures remain expensive and 
labor intensive. Bulk tissue analysis is still a common study design and generated large 
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amounts of data. There is therefore a strong need of analytical tools to effectively infer 
intra-tumor heterogeneity using such suboptimal data. In the past five years, a number of 
algorithms have emerged that can infer tumor subclonal features using data generated from 
bulk tissue. In the following I will provide a review of six methods, and discuss their 
advantages and limitations.  
 
1.2.2.1 Review of Methods Studying Tumor Subclones 
 
Carter et al (Carter et al., 2012) introduced an algorithm, ABSOLUTE to study intra-tumor 
heterogeneity. The segmented and smoothed copy number data is first displayed on a 
histogram to examine the distribution of copy ratios (normalized copy numbers). Usually 
these values group tightly into separate peaks on the density plot, each peak representing a 
copy number configuration. Due to mixing with euploid genome, the spacing between 
adjacent peaks (b) do not reach full theoretical values and the copy ratios (δτ) of regions with 
homozygous deletions which should be zero, are usually positive. ABSOLUTE infer euploid 
mixing ratios depending on b and δτ. A subclonal segment will generate small peak between 
two major peaks of clonal events, and ABSOLUTE acknowledge it as an outlier and infer 
tumor purity using space between major peaks. In addition to inferences made via copy 
number profiles, the authors also extended ABSOLUTE to estimate average allele counts per 
cancer cell, or cell multiplicity (sq) using somatic mutation profiles with a Beta-Multinormial 
likelihood model.  
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Overall, ABSOLUTE made a contribution in the field by explicitly modeling subclonal 
events during tumor purity and ploidy estimation. Integration of somatic mutation data and 
copy number results is also a breakthrough. However, there were several existing challenges 
remained unsolved. First, ABSOLUTE lacks the capability to quantitatively estimate the 
cellular fractions of subclonal sCNA carriers. Second, despite the discussion on cellular 
multiplicity for somatic mutations, the inference is not sufficient. In their likelihood model, 
somatic mutations and CNAs always occur in the same lineage, while it is not always true 
(Nik-Zainal et al., 2012). Another limitation of this approach is that the inference of 
subclonal cell multiplicity remained categorical. The authors failed to provide any 
quantitative estimation to subclonal somatic mutations. Moreover, the inference on sq relied 
on copy number determination, and since only clonal CNA events were analyzed by 
ABSOLUTE, for any somatic mutation, clonal or subclonal, if it hit a subclonal CNA region, 
no information could be concluded from the sequencing data.  
Nik-Zainal et al (Nik-Zainal et al., 2012) studied the subclone structure for one breast tumor 
sample using whole genome sequencing (WGS) with an 188× average depth. The authors 
collected somatic mutations in euploid genomic regions and noticed that the distribution of 
somatic allele frequencies consists of four distinguishable clusters, suggesting that this tumor 
harbored multiple subclones. To further determine the lineage relationships between 
subclones, the authors phased adjacent somatic mutations that are spanned by the same read 
pair. If mutations from cluster X were always in phase with mutations from cluster Y, then X 
and Y were in the same lineage. On the other hand, if mutations from cluster X were never in 
phase with those from Y, X and Y belonged to different lineages. They used this approach to 
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determine if the cells carrying mutations from cluster X is in linear or branching relationship 
with cells carrying mutations from cluster Y. This approach has at least two contributions: 1) 
it set forward an approach to robustly identify the number of subclones in tumors using the 
distribution of somatic allele frequencies; 2) phasing somatic mutations provided rich 
information that can be used to infer lineage relationships between subclones. The major 
limitation is that, the analysis applied in this study is manually optimized for a few 
(twenty-one) samples and is not readily applied to larger cohorts. 
Landau et al (Landau et al., 2013) developed an algorithm to infer the cancer cell fraction 
(CCF) of somatic mutations and CNAs, using both SNP array and whole exome sequencing 
(WES) data. For CNAs, they modified the original ABSOLUTE algorithm to model 
subclonal events. In Landau’s method, in a subclonal region, the mixing ratio is allowed to be 
different from the global tumor purity, on the condition that the tumor CNAs only alter from 
the euploid state by one copy. This assumption, however, is unnecessary and often violated. 
Adding WES data, they were able to estimate the CCF of somatic mutations only in clonal 
CNA regions, and assuming that somatic mutation has occurred later than CNA and therefore 
affect only one allele. The second assumption is oversimplified and can be violated when 
mutation occurred before the CNA. For somatic mutations in subclonal CNA regions, they 
estimated CCF manually. This work made a contribution by explicitly modeling the 
subclonality of somatic mutations, corrected for local copy number events. . However, it is 
incomplete to assume that somatic mutations could only occur after CNAs. For example, if a 
somatic mutation occurred early in a region of subclonal copy neutral LOH, both alleles of 
the LOH-carrying cells would harbor the mutation. Using Landau’s approach, the CCF of this 
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mutation would be overestimated by a factor of two, which could wrongly assign a subclonal 
event to be clonal.  
EXPANDS (Andor et al., 2014) estimates tumor subclonal structure. It used sequencing data 
to infer the fraction of cells carrying a specific CNA or somatic mutation. The authors 
defined ‘B allele’ to be non-reference allele, which is different from the definition in SNP 
array, where B allele is arbitrarily chosen. In this definition, B allele can either be somatic 
mutations or germline polymorphic sites (will be AA if the site does not contain germline 
mutation), which is an improvement compared with previous approaches. EXPANDS 
estimated subclonality for each locus independently using the in-phase constraint, by 
enumeration of all the possible combinations of allele-specific copy numbers and screening 
of possible mixing ratios from (0,1). As mentioned above, the in-phase constraint is a very 
strong and unrealistic assumption, and using this assumption implicitly is the major limitation 
of this approach. Another limitation is, EXPANDS failed to consider all the possible 
temporal and lineage relationships between an sCNA and a somatic mutation occurred in the 
same locus. Due to this limitation, it cannot accurately estimate cellular frequencies of 
somatic mutations that have occurred in branching lineages with sCNA.  
Pyclone (Roth et al., 2014) used sequencing data to estimate CCF of somatic mutations 
(referred to as cellular prevalence) and to perform phylogenetic analysis of tumor subclones. 
Pyclone relied on other methods to infer the absolute copy numbers for each locus as a 
prerequisite. In order to estimate CCF, Pyclone introduced five possible relationships 
(denoted as priors) between a somatic CNA and a mutation occurred in it. Of these five priors, 
predictions using the Parental Copy Number (PCN) prior were the most accurate according to 
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their simulations. The PCN prior considered two lineage relationships: 1) mutation occurred 
before CNA, but with the in-phase constraint; 2) mutation occurred after sCNA, but did not 
include the scenario when mutation and sCNA occurred in different lineages. Pyclone 
considered a more complete set of lineage relationships between a somatic mutation and a 
CNA, yet was still unsatisfactory due to the in-phase assumption.  
The methods above estimate subclonality of somatic events independently. Another method, 
THeTa (Oesper et al., 2013) used an alternative approach. It jointly used all sCNAs to 
simultaenously estimate 1) the number of subclones in a tumor sample; 2) the abundance of 
each subclone and 3) the total copy number carried by each subclone in each locus. For a 
given number (K) of subclones, THeTa models the observed read counts (Yi) in the genomic 
locus i (i=1,2…n, n is the number of loci) as the linear combination of K components: 
Yi=Ni×µ, where Ni=(n1i,n2i,…,nKi) is the copy number vector for K subclones in locus i, and 
µ=(µ1,µ2,…, µK) is the vector of subclonal abundance. It then enumerates all the possible 
integer combinations of copy numbers in the K subclones and select the optimum solutions of 
µ. Combined usage of markers across the genome increases the reliability of inference in 
THeTa. However, its computational time increases exponentially with the number of markers 
analyzed. Also, THeTa could not infer the subclonality of somatic mutations.  
To conclude, current methods developed to infer tumor subclones suffer from several 
limitations. First, they usually only estimate the cellular frequencies of one type of events, 
and none of the above quantitatively infer cellular frequencies for both sCNA and somatic 
mutations. Furthermore, most of these methods implicitly applied the unrealistic ‘in-phase’ 
assumption. Finally, none of the methods above considered the scenario when a mutation 
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occurred in different lineage with an sCNA in the same locus. These methods cannot provide 
accurate estimations when their assumptions are violated. 
 
1.2.2.2 Introduction of Clonal Heterogeneity Analysis Tool 
 
In section 1.2.2.2 I have reviewed recently developed methods on intra-tumor heterogeneity. 
Applications of these methods provided insights into recognition of subclones (Carter et al., 
2012), subclonal architecture (Nik-Zainal et al., 2012, Roth et al., 2014), dynamics of 
population alterations under treatment and the discovery of subclonal driver mutations 
(Landau et al., 2013). Despite these efforts, the field lacks a systematic tool that integrates 
both sCNA and somatic mutation, and provides comprehensive estimations cellular 
frequencies of somatic mutations and sCNAs without using limiting hypothesis such as the 
‘in-phase’ assumption. In Chapter 3, I introduce Clonal Heterogeneity Analysis Tool 
(CHAT), for inferring cellular frequencies of both sCNA and somatic mutations, by jointly 
analyzing DNA SNP array data and DNA sequencing data. In CHAT, I integrated different 
types of somatic events through a systematic investigation of lineage scenarios of mutations 
in an sCNA region. Below is a brief introduction to this topic.  
For example, the task is to estimate cancer cell fraction (CCF) of a somatic mutation, which 
is the subclonality for mutations. Consider a somatic mutation that occurs in a euploid region 
and hits one chromosome: if the observed somatic allele frequency (SAF) is f, then the 
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estimated CCFis simply 2f. However, if the mutation resides in an sCNA region, the 
relationship between CCF and SAF depends on the copy number configuration: copy neutral 
loss-of-heterozygosity (CN-LOH), deletion, amplification, etc. and the cellular frequency of 
the sCNA. Further, it also depends on the chromosomal background in which the mutation 
occurs: on the parental chromosome with higher copy number (major allele) or smaller copy 
number (minor allele). Given the observed SAF of the mutation, it will be impossible to 
estimate CCF without all the information mentioned above.  
A previous research (Durinck et al., 2011) studied the temporal order of somatic mutations 
and CN-LOH event of TP53 gene in 8 cutaneous squamous cell carcinoma samples with 
whole-exome sequencing data. The authors argued that when mutation occurred earlier than 
CN-LOH, both alleles would carry the mutation, and generate homozygous genotypes; 
otherwise it generates heterozygous observations. They used heterozygosity to estimate the 
temporal orders between the TP53 somatic mutations and CN-LOH event, and found these 
mutations were early events. This method modeled the temporal order of somatic events 
explicitly. However, it did not take into consideration the possibility that a given CN-LOH 
event could be subclonal, and therefore, even though the mutation occurred early, it could 
still appear to be heterozygous due to mixing with euploid cells. Also, the estimation is 
limited to CN-LOH events and not generalized to other sCNA types.  
In CHAT, I first implemented the estimation of sCNA genotypes and sCNA subclonality.  
Then, to infer cellular frequencies of somatic mutations, I considered the following scenarios: 
A) The mutation and sCNA emerged sequentially, with the mutation occurring first, and the 
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sCNA occurring in a subset of mutation-bearing cells. Cells carrying both mutation and 
sCNA may have two configurations: A1: the duplication occurred on the mutation-bearing 
chromosome, and A2: the duplication occurred on the mutation-free chromosome.  
B) Like A, the mutation and sCNA emerged sequentially; but unlike A, the sCNA occurred 
first, with the mutation occurring in a subset of sCNA-bearing cells. Mutation may have 
occurred on one of the duplicated chromosome (B1) or the un-duplicated chromosome (B2).  
C) The mutation and sCNA emerged independently, i.e., appearing in non-overlapping 
populations of cells.  
 All previous methods only considered a subset of these scenarios. For example, Landau et 
al.’s approach only considered scenario B, while EXPANDS considered scenarios A1 and A2, 
and PyClone considered A1, A2 and B, but failed to include C. With systematic investigation 
of lineage scenarios, CHAT is able to estimate cell fractions for somatic mutations without 
limiting assumptions. 
 
1.2.3 Detection and Genotyping Short Tandem Repeats in Complex Genomes 
 
Previous cancer research extensively studied somatic CNAs and mutations, while other types 
of genomic aberrations remain poorly understood, including many kinds of structural 
variations. There is need in the field to understand the role of short tandem repeats (STR), or 
microsatellites in human diseases, including cancer. Short tandem repeats are consecutive 
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occurrence of 2-6 bases of DNA sequence many times. STR locI am very common in the 
human genome (Willems et al, 2014) and analysis of STR is useful in many fields, including 
forensic usage, paternity test (Jobling et al., 1997), phylogenetic analysis (Jarne and Lagoda, 
1996), etc. For example, germline mutations of STR locI am responsible for many 
neurodevelopmental disorders, including Huntington’s disease (Walker, 2007), Fragile X 
syndrome (Pearson et al., 2005) and multiple types of spinocerebellum ataxia (Pulst et al., 
1996, Campuzano et al., 1996, Paulson, 2012). Somatic changes in STR length are common 
in some cancers, in a phenomenon known as microsatellite instability (MSI). MSI is caused 
by impaired DNA mismatch repair (Liu et al., 1995, Ellegren, 2004), and it has been 
characterized in colorectal cancer (Popat et al., 2005) and prostate cancer (Uchida et al., 
1995). Current methods to genotype STR loci remain slow and labor-intensive. Traditional 
Sanger sequencing technology still serves as a gold standard in determining the number of 
repeats, yet cannot be efficiently applied to large sample cohorts or to genome-wide analyses. 
The development of next-generation sequencing technologies allows researchers to analyze 
many samples in genome-wide scale, but to genotype STR alleles using short-read 
sequencing data is a novel challenge because many STR alleles are longer than the read 
length. Two algorithms, lobSTR (Gymrek et al., 2012) and RepeatSeq (Highnam et al., 2013) 
have been developed to address part of this challenge. However, both methods are limited to 
genotype STR alleles that are shorter than read length, which is typically 100-nt for the 
Illumina HiSeq2000 sequencer. These methods are not suitable to detect abnormally 
expanded STR alleles beyond the read length, nor can they discover novel microsatellite 
regions due to their reliance of the locations of known STR loci. In Chapter 4, I introduce a 
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new algorithm, called STRfinder, using paired-end short read sequencing data to genotype 
STR loci. STRfinder can detect novel STR loci and genotype STR alleles that are much 
longer than a read, and out-performs lobSTR or RepeatSeq for these alleles in terms of 
variant call rates, genotyping accuracy, and length estimation precision.  
 
1.3 Summary 
 
In this Chapter, I reviewed the concepts and background related to tumor heterogeneity. 
Large amount of cancer -omics data have been accumulated in recent years, and most of 
these involve one-sample-per-tumor, bulk tissue analysis.  A number of methods have been 
developed to analyze these data to infer the features of intra-tumor heterogeneity. However, 
there are at least three challenges in the field. First, studies of inter-tumor heterogeneity 
among multiple samples usually failed to consider intra-tumor heterogeneity, and the results 
could be confounded by tumor/normal mixing ratios or tumor subclones. In Chapter 2, I 
have addressed this challenge. Second, analytical tools specifically developed for analyzing 
intra-tumor heterogeneity suffer from limiting assumptions reviewed in previous sections, 
and CHAT overcomes these limitations. Third, as an important class of genetic variation that 
can underlie the risks of both constitutional and somatic diseases, short tandem repeat has not 
received enough attention. There is need to detect and genotype STR alleles both in large 
sample cohorts and genomewide, using next generation sequencing data. In my thesis, I 
aimed to address the above challenges by developing novel bioinformatics tools.  
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Chapter 2. Inference of aneuploidy genome proportion and revised 
classification of human glioblastoma multiforme (GBM) 
 
2.1 Introduction 
 
Glioblastoma Multiforme (GBM) is an aggressive brain tumor with poor prognosis 
(Adamson et al., 2009). Recently, genomic profiling studies have provided rich new 
information for understanding molecular lesions in GBM. For example, the Cancer Genome 
Atlas (TCGA) project characterized several hundred GBM samples, of which many were 
analyzed across multiple dimensions, including single nucleotide polymorphism (SNP) 
genotyping, mRNA and microRNA (miRNA) profiling, DNA sequencing, and promoter 
methylation analysis (The Cancer Genome Atlas Research Network, 2008). These data 
highlighted the importance of ERBB2, NF1 and TP53 genes, and revealed recurrent 
aberrations in the RTK/RAS/PI(3)K, p53, and RB signaling pathways. Meanwhile, 
genomewide datasets are also useful for characterizing biological diversity in a tumor 
collection, as evidenced by numerous reports of molecular subtypes for many cancers based 
on gene expression cluster analyses (Alizadeh et al., 2000, Perou et al., 2000). In particular, 
gene expression data for TCGA's first GBM cohort were reported to reveal four subclasses 
(Verhaak et al., 2010b): Proneural (PN), Neural (NL), Classical (CL) and Mesenchymal 
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(MES).  
However, while the availability of multiple data types in TCGA provides the opportunity for 
combined analyses, the four-class model was based solely on mRNA expression data. DNA 
copy number alteration (CNA) patterns were summarized post hoc, not incorporated in the 
initial class discovery. Methylation data were analyzed subsequently (Noushmehr et al., 
2010), and revealed three clusters, which lacked a clear correspondence with the four 
transcriptome-based classes. Furthermore, the relationship of the four-class model with those 
previously reported for independent datasets (Murat et al., 2008, Phillips et al., 2006b, Sun et 
al., 2006) was not clarified. While the differences between studies could be explained by 
variations in sample selection criteria, experimental platforms, and analysis methods, the 
discrepancies among different data types within the TCGA's collection remained 
un-reconciled. My first goal was therefore to combine the CNA and expression data to 
provide a more integrated view of the molecular diversity in GBM. 
My second goal was to study within-tumor heterogeneity. Surgically obtained solid tumor 
samples (GBM included) often contain both aneuploid cells and euploid cells. I developed a 
method to leverage the allele-specific CNA data to estimate the fraction of aneuploid cells in 
each sample, and to incorporate this measure of tumor "purity" in class discovery. I also 
asked if results in GBM were seen in the ovarian (OV) cancer cohort from TCGA (The 
Cancer Genome Atlas Research Network, 2011). I emphasized between-cohort concordance 
in deciding the optimal number of clusters, and annotated the potential cell type of origin of 
different classes by comparing GBM gene expression data to reference datasets of known cell 
types. My results led to a revised framework of GBM classification, and I sought to 
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understand its biological implication and clinical relevance. I validated the between-class 
difference in survival time in an independent GBM cohort. Finally, I summarized the newly 
recognized subclasses and associated biomarkers into a hierarchical classification protocol 
for use in diagnosis and further research.  
 
2.2 Data sources 
 
2.2.1 Glioblastoma Multiforme (GBM) 
 
This study covered three cohorts of GBM samples. GBM1 is the cohort analyzed by the 
TCGA pilot study (The Cancer Genome Atlas Research Network, 2008, Verhaak et al., 
2010b). A second cohort was subsequently available and was called GBM2 (Verhaak et al., 
2010b). For validating the survival time differences I selected additional samples that became 
available by early 2012, and called it GBM3.  
 
2.2.1.1 DNA copy number data 
For GBM1-2, Allele-specific copy number data for Illumina HumanHap550K arrays were 
downloaded from the Cancer Genome Atlas (TCGA) data portal 
(http://tcga-data.nci.nih.gov/tcga/) on 4/14/2010. I queried the Data Access Matrix by 
choosing  
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Disease: GBM;  
Data Type: SNP;  
Data Level: 2 and 3;  
Platform: HAIB (HumanHap550).  
This query yielded tumor-normal logR Ratio (LRR) data for 284 paired samples, and B allele 
frequency (BAF) data for 347 tumor samples, of which 284 had matched normal samples. 
The overlapping set of 284 paired samples, 130 in GBM1 and 154 in GBM2, was selected for 
further analysis. The dataset contains 561,468 autosomal SNPs.  
Allele-specific copy number data for GBM3 came from TCGA batches 26, 38, 62, 79, 111, 
and 130. A total of 156 samples had both Affymetrix SNP 6.0 genotyping data and 
Affymetrix gene expression data available, and these were downloaded in bulk on 1/31/2012. 
The copy number data for Affymetrix SNP arrays were Birdsuite output files and were 
converted to logR and BAF. Ten samples were apparent outliers on the gene expression PCA 
plot (not shown), and were removed. Of the remaining 146 samples, two female patients 
(TCGA-12-3644 and TCGA-12-3646) had exceptionally longer survival time (62 and 44 
months respectively), and were removed before classification analysis and survival time 
comparisons. The genome coordinates for the 811 autosomal cytoband were from  
http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/cytoBand.txt.gz. 
 
2.2.1.2 Gene expression data 
Gene expression data were downloaded from 
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http://tcga-data.nci.nih.gov/docs/publications/gbm_exp/. Most of our analyses were based on 
"unifiedScaledFiltered.txt", which contains processed data for 1,740 most variable genes for 
202 GBM samples. The data processing procedure was reported previously (Verhaak et al, 
2010). I also analyzed the full dataset in "unifiedScaled.txt", containing 11,861 genes before 
filtering. In GBM1, a subset of 130 samples (out of 202) had both gene expression and DNA 
copy number data. In GBM2, all 154 samples had both gene expression and DNA copy 
number data.  
Expression data for GBM3 were downloaded on 1/9/2012, from TCGA Data Portal 
(http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm), by choosing Platform= 
BI_HT_HG-U133A. GBM3 contains 170 samples from TCGA batches 26, 38, 62, 19 and 
111. I quantile normalized these data before running downstream analysis. The 840 genes 
selected in Verhaak et al. for distinguishing the four former subtypes were provided at 
(http://tcga-data.nci.nih.gov/docs/publications/gbm_exp/ClaNC840_centroids.xls) and 
accessed on 04/12/2011. 
 
2.2.1.3 MicroRNA data 
MicroRNA data were downloaded on 1/7/2012 from TCGA portal by choosing  
Data Type: Expression miRNA;  
Batch: All;  
Level: 3;  
Platform: UNC_miRNA_8×15K, 
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This returned a dataset for 534 miRNAs in 506 samples, of which 125 overlapped with the 
202 GBM1 tumors. I quantile normalized these data before running downstream analysis.  
 
2.2.1.4 Clinical information 
Clinical data for individual patients and samples were downloaded from TCGA data-access 
site: 
http://tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/gbm/bcr/intg
en.org/minbiotab/clin/ on 1/18/2011. I extracted information regarding age of diagnosis, 
survival time, tumor cell, and tumor nuclei. An updated version, containing information for 
GBM3, was accessed on 1/5/2012. The Karnofsky performance scores were extracted from 
the clinical data accessed on 6/22/2012. 
2.2.2 Ovarian Cancer (OV) 
 
2.2.2.1 DNA copy number data 
Copy number data for Illumina 1M-Duo arrays were downloaded from TCGA Bulk 
Download site http://tcga-data.nci.nih.gov/tcga/findArchives.htm on 10/01/2010. I queried 
the Data Access Matrix by choosing  
Disease: Ovarian Cancer;  
Data Type: SNP;  
Batch number: all; 
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Data Level: 2 and 3;  
Platform: HAIB (Human1MDuo).  
The BAF files contain 1,199,189 SNP markers and 516 paired samples. The LRR files 
contained 530 samples, of which 509 were paired. The overlapping set of 509 paired samples 
was selected for further analysis. 
 
2.2.2.2 Gene expression data 
Gene expression data for OV were obtained from TCGA data analysis working group. The 
file "TCGA_batch9-15_17-19_21-22_24.UE.txt" dated 05/05/2010 contains 11,864 genes 
and 524 samples, of which 504 overlap with the DNA copy number dataset. 
 
2.2.3 Phillips et al. dataset 
 
Phillips et al. data were accessed from GEO dataset GSE4271. The processed gene 
expression data for 56 samples were obtained at 
http://tcga-data.nci.nih.gov/docs/publications/gbm_exp/.  
 
2.2.4 Cahoy et al. dataset 
 
Cahoy et al. data were accessed from GEO dataset GSE9956. 
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2.2.5 Data for microglia/macrophage 
I queried of Gene Expression Omnibus dataset (http://www.ncbi.nlm.nih.gov/gds) (Edgar et 
al., 2002b) to identify gene expression profiles for microglia/macrophage cells. During 
January 5-7th, 2012 I searched for keywords "microglia" AND "human" and found 23 
independent datasets. Among these, I selected experiments for tumor cells, and this resulted 
in 2 datasets, GSE25289 and GSE16119, which I used to infer the likely cell types 
contributing to the euploid population in MES tumors. 
 
2.3 Inferring aneuploidy genome proportion 
 
2.3.1 Introduction to SNP array data 
 
Allelic intensity data from SNP genotyping arrays provide quantitative copy number 
information of the two parental chromosomes: nA and nB. In a homogeneous cell population 
nA and nB are both integers, such that the logarithm of total intensity, logR=log(nA+nB), and 
the observed B allele frequency, BAF=nB/(nA+nB), adopt a finite combination of discrete 
values, which can be shown as "canonical positions" in the BAF-LRR plot (Figure 2.1A). In 
a tumor sample, however, the population of aneuploid cells may be mixed with euploid cells, 
consequently logR and BAF of the former "contract" towards those of the latter; and different 
mixing ratios result in different degrees of contraction (Figure 2.1B). An example of such a 
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mixed GBM sample is shown in Figure 2.2A. Based on this feature I developed an algorithm 
to quantitatively estimate genomewide mixing ratio from SNP data. In the following sections 
3.3-3.9, I will outline the procedures of this algorithm, including data preprocessing, 
theoretical models, inference and validation. 
 
2.3.2 Two-way mixing model and aneuploidy genome proportion (AGP) 
 
Before introducing the details of my algorithm, it is important to layout concepts and 
hypothesis. In this study I define Aneuploid Content, or synonymously, Aneuploid Genomic 
Proportion (AGP), as the parameter p in a mixture model consisting of two homogeneous 
populations: (1) aneuploid cells, at the fraction of p, and (2) euploid cells, at (1-p). This 
model has been routinely used in the field and hereby referred to as the two-way mixing 
model. Euploid cells carry a balanced set of parental chromosomes representing full-integer 
multiples of the haploid genome, and may include normal stromal cells surrounding the 
tumors as well as tumor cells without apparent genomic aberrations (e.g., only point 
mutations). Aneuploid cells, in contrast, carry CNAs at some chromosomes or 
subchromosomal intervals, resulting in an unbalanced set of genomic segments, each of 
which still contain an integer combination of parental DNA, e.g., nA=2, and nB=1 in a region 
of amplification. For many tumors, the two-way mixing model considered here is likely an 
over-simplification, as multiple subpopulations of tumor cells may exist, each carrying a 
different integer combination of parental segments. However, a mixture model with three or 
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more subpopulations is computationally intractable using the observed averages of the entire 
population; and realistically, many tumors may contain a dominant aneuploid population. A 
two-way mixing model is the simplest scenario that could have generated the observed data 
regarding varying levels of contraction in different samples. I therefore applied this model for 
the first-order estimation of within-tumor heterogeneity.  
 
2.3.3 Data processing, DNA segmentation, and merging 
 
Throughout this chapter, I focused on somatic events, defined by the differences between 
tumor-normal pairs, thus ignoring inherited aneuploidy.  
Seven GBM samples, TCGA-06-0139, TCGA-06-0160, TCGA-06-0165, TCGA-06-0167, 
TCGA-06-0189, TCGA-06-0240, and TCGA-06-0881 bear few copy number alterations 
(CNAs), and were excluded from further analysis. 
As homozygous locus is uninformative for detecting changes in BAF patterns I focused on 
BAF data at heterozygous loci. For each tumor-normal pair, loci with BAF value >=0.9 or 
<=0.1 in the normal sample were designated as homozygous. Altering the stringency of this 
definition did not make a major impact on AGP inference, as AGP will be driven by large 
aneuploid events, for which having more or fewer heterozygous loci would not substantially 
change the estimate of "contraction" (see below). For the heterozygous loci thus defined, I 
extracted tumor BAF data and generated the "folded BAF", defined as the absolute value of 
(BAF-0.5), for segmentation. For both GBM and OV, I performed segmentation on folded 
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BAF using the Circular Binary Segmentation (CBS) algorithm, implemented in the R 
package DNAcopy with default parameters, except that "minimal markers required" was set 
to 5. The series of BAF change points were merged with the corresponding LRR change 
points, which were generated by Dr. Devin Absher at the HudsonAlpha Institute of 
Biotechnology using CBS (Olshen et al., 2004), and were made publicly accessible as TCGA 
Level 3 data. As the BAF segments and LRR segments sometimes captured the same event, I 
merged the combined change points as follows: if a BAF change point was within 5 markers 
of a LRR change point, either upstream or downstream, it was removed, i.e. only the LRR 
breakpoint was kept, under the assumption that the two change points captured the same 
event, but the BAF change point was less accurately placed due to the constraint of using 
only heterozygous markers. After merging, small segments, defined as containing fewer than 
10 BAF markers were merged with adjacent segments by removing the flanking change 
points. These steps resulted in a final set of CNA segments for each tumor sample. 
 
2.3.4 Per-segment summary of LRR and BAF 
 
For each segment in the final CNA call set, I re-calculated the median LRR and mean folded 
BAF to update these values within each merged segment. For segments with balanced 
parental chromosomes, BAF values at heterozygous locI am distributed as one track near 0.5, 
but it may not be centered exactly at 0.5. Likewise for segments with unbalanced parental 
chromosomes, BAF values split to two tracks, which may not fall symmetrically around 0.5. 
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To increase the accuracy of BAF estimation I fit each segment's distribution of heterozygous 
BAF values as either one Gaussian distribution or the summation of two Gaussian 
distributions. When there were in fact two tracks but the separation between tracks was small, 
the summed distribution might resemble a single Gaussian distribution. I used the baseline 
variance of BAF as the criterion to distinguish the two cases: segments with folded BAF 
standard variation >=0.1 were considered as two-track segments, and fit with two Gaussians. 
For segments with one track, I obtained the best fitting distribution as N(µ,σ), and defined the 
folded BAF value as 0. For segments with two tracks, the best fitting distribution is N(µ1,σ1) 
and N(µ2,σ2), and the folded BAF value is |µ1 -µ2|/2. If the distribution cannot be fit in R or if 
the segment had fewer than 100 markers, the folded BAF value is taken as the mean absolute 
deviation around the mean: mean(|xi-mean(xi)|), where xi is the BAF value at the i-th marker. 
 
2.3.5 LRR scale-normalization 
 
The primary goal of Illumina's data processing algorithm is to find clusters that represent 
discrete genotypes. As a result the LRR values are not linearly scaled with the true copy 
number changes, e.g., when the true DNA copy number drops from 2 to 1, LRR drops less 
than 1 unit (2-fold). Moreover, the severity of this "saturation effect" is different between 
amplifications and deletions. For Illumina 550K arrays, the correction factors are 0.572 for 
deletions and 0.553 for amplifications (Peiffer et al., 2006). I re-scaled LRR segmental means 
by these ratios before downstream analysis. 
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2.3.6 BAF-LRR plot: canonical points and tracks 
 
I used the BAF-LRR plot to depict the bivariate data of allele-specific copy numbers. In this 
plot, the folded BAF values are shown on the x-axis, and the normalized LRR values are 
shown on the y-axis. Each segment is plotted as a point in the BAF-LRR space, with the 
symbol size indicating segment length. Amplifications, deletions, and copy-neutral LOH 
segments are uniquely placed in the plot.  
Canonical points, representing integer combinations of A and B alleles, were placed as 
follows. For a pair of integers (nB, nT), where nT denotes the copy number for the B allele, 
and nT denotes the total copy number of both alleles, its x and y coordinates are: 
|5.0| −=
T
B
n
nx
 
0
pl2 y2
log −= Tny
                       (1) 
where y0pl is an adjustable offset of LRR level to reflect (1) the average ploidy of the 
aneuploid population, which can be a non-integer, and (2) potential alternative ploidy of the 
euploid population. In some tumors, the euploid portion might be nT=4 (or nT=6) rather than 
nT=2, yet the normalization procedure of each sample tended to center its genomic average 
LRR to 0, thus an offset is needed to adjust the y-positions of the canonical points to achieve 
a maximal fit. I will separately fit nT=2, 4, and 6 for the euploid population when searching 
for the optimal AGP (see below).  
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Tumor samples that contain a mixture of euploid cells and aneuploid cells will show a 
contraction of canonical points from its original position toward the origin, where the euploid 
segments reside. The paths of the contraction when AGP decreases from 1 to 0 are called 
canonical tracks (Figure 2.1A and 2.1B). For a given p, canonical points on the BAF-LRR 
plot can be organized into a 2D lattice, in which the near-vertical gridlines connect points of 
equal nB. The first line, located at the right, contains all LOH points with (nB, nT) =(0,1), (0,2), 
(0,3), etc. The second line, to the left, contains (nB, nT) =(1,2), (1,3), (1,4), etc. And the third 
line contains (nB, nT) = (2,4), (2,5), (2,6),etc. They are orthogonal to the canonical tracks, 
which describe the movement of canonical points toward the origin ((nB, nT) = (1,2)) under 
shrinking values of AGP. The relative positions of the canonical points contain information 
for distinguishing the alternative ploidy of the euploid genome, which define the origin of 
contraction for the aneuploid segments. 
 
2.3.7 Inference of Aneuploid Genome Proportion 
 
A. Definition of Euploid Segments: On a BAF-LRR plot, euploid regions tend to land near the 
point (x,y) = (0,0). But due to random noise and various technical artifacts some segments 
may lie slightly off (0,0). Precise assignment of the near (0,0) segments into the euploid 
cluster is important because it affects the relative distances to other canonical points and the 
AGP estimates. To anchor its position, I first ran k-means clustering 10 times on the observed 
BAF-LRR values for all segments. For each run, I identified the segments that belong to the 
! 39!
cluster nearest to (0,0), and tagged them as euploid. Segments that were tagged more than 6 
times out of 10 were used to define the seed position, located at the cluster mean (xs, ys) of 
the tagged segments, weighted by segment size. Second, I examined each non-seed segment 
to see if its coordinates (x, y) were sufficiently close to the seed location. If BAFsxx σ<=− ||  
and LRRsyy σ<=− || , this segment was "pulled" into the euploid cluster, where ,04.0=BAFσ  
the empirically estimated standard variation of BAF, and ,16.0=LRRσ  the empirical standard 
variation of LRR. This step was iterated, with more segments joining the euploid cluster until 
the cluster was no longer updated. The final coordinate of the weighted center of the euploid 
cluster is denoted as (
ff yx 00 , ).  
B. Canonical Points under admixture: Consider the mixture containing a population of cells 
carrying an aneuploid segment (nB, nT), and a second population of cells carrying an euploid 
segment (npl, 2npl), npl=1,2, or 3, and that the euploid portion makes up 1-p of the total (i.e., 
AGP = p). The coordinates for the mixed population are given by: 
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C. Aneuploid genome Proportion: For each sample, after the euploid cluster was defined, I 
searched for the best fitting p and npl by screening the parameter space of p   (0,1), and npl   
(1,2,3,4). I did not include the canonical point for homozygous deletions because their BAF 
or LRR values are not determined. 
For each (p, npl ) combination being considered, the canonical points were calculated and the 
penalized sum of squared distance ( )(' pSSD pl ) was calculated as: 
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where i is the segment index and Ω represents all segments in this sample (excluding those in 
the euploid cluster), pl stands for ploidy npl, 
i
pldmin, is the squared distance of the segment to 
the nearest canonical point. )( pDpl is the penalty score for applying a larger npl, as 
increasing npl results in a larger number of available canonical points to fit with, and 
consequently a smaller sum of squared distances. Applying this penalty will avoid making 
excessively high euploid baseline assignments. )( pDpl is linearly correlated with the 
approximate distance between adjacent canonical points such as (2.4) and (1,4). I defined  
)( pDpl = pn × (npl-1) × distance between canonical points (2,4) and (1,4) 
Penalty Pn was manually chosen as pn=200 as it generated the most reasonable assignments.  
Best fitting AGP value was determined by the smallest SSD'pl(p). The scanning of the 
parameters was carried out in two steps to increase computation speed: a coarse scan of p   
(0.05,0.95) at an interval of 0.05 was performed, with a best fitting value p* determined. 
Then, in the second step, a finer scan of p   (p*-0.1,p*+0.1) at an interval of 0.02 was 
performed to refine the final score. The model also yielded the optimal ploidy value, resulting 
in 135 diploid, 127 tetraploid and 22 hexaploid samples for GBM1 and GBM2. For OV, I 
identified 23 diploid, 64 triploid, 273 tetraploid, 127 hexaploid and 22 octoploid samples. 
 
2.3.8 Genomic features and QC measures 
 
I extracted multiple genomic measures for each tumor sample, including percent of genome 
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changed (PC) and percent of genome on canonical points (PoP). Let P1 denote the proportion 
of genome in the euploid cluster, thus 1-P1 of genome has been alerted either in copy number 
or in the B allele frequency. I define: 
PC = 1 – P1 
Extremely low PC indicates that there is insufficient amount of CNAs to inform model 
parameters and should be considered as having yielded low-quality AGP estimates. 
Actual segments on the BAF-LRR plot may fall near or far from a canonical point for a given 
AGP. I quantify these deviations as measures of goodness-of-fit by the two-way mixing 
model with optimal AGP. If there is more than one dominant aneuploid population mixed 
with the euploid population, some segments would have a different mixing ratio than some 
other segments, and as a consequence, the fit at a single AGP would not be suitable for all 
segments, and this can be reflected by a low rate of "Percent-on-Point", defined as the 
proportion of segments falling within sBAF = 0.04 and sLRR = 0.16 of a canonical point. If this 
proportion is P2 of the genome, I define 
1
2
P
P
PoP
−
=
1  
As aneuploid cells carry variable copy numbers at different segments, it is no longer 
sufficient to define an integer ploidy as a genomewide attribute of a tumor. However I define 
average aneuploid ploidy as the genomewide mean copy number for the aneuploid cells of 
the tumor, and average overall ploidy as the weighted average of euploid and aneuploid 
populations. Specifically, as I assign ploidy status for every segment in the aneuploid genome, 
the average aneuploid ploidy, Ψtumor, can be defined as the length-weighted means of 
segmental ploidy. The average overall ploidy of the sample, containing p of aneuploid 
! 42!
genome and 1-p of euploid genome, is  
)1(2 pnp pltumoroverall −××+×Ψ=Ψ           
Other tumor genomic features, including percentage of genome amplified (%amp), deleted 
(%del), percentage of hemizygous deletion (%del.loh), and percent of genome underwent 
loss of heterozygosity (%LOH), were also extracted.  
I use a bootstrap method to estimate the confidence intervals of AGP. A weighted resampling 
was performed for each sample, such that each segment was chosen with the probability 
proportional to its size. Permutation was done 100 times for each sample, and for each run, 
80% segments were resampled and AGP recalculated. The standard deviation, and the 2.5%, 
50%, and 97.5% quantiles of AGP, were extracted and included in Table 2.1. The 2.5-97.5% 
confidence interval (CI) can be calculated from these results. I also calculated the relative 
confidence interval (rCI) as the ratio of CI to the median of AGP. Eighty-eight percent of 
samples had rCI less than 100%. 
PoPs were negatively correlated with AGPs (Figure 2.1C, Spearman's r = -0.40, P = 3,3 × 
10-12), suggesting that samples better accounted for by the model (i.e., higher PoP) tend to 
have lower AGP estimates, thus our method may have over-estimated AGP for poorly fit 
samples. The CIs, however, were positively correlated with AGPs (Figure 2.1D, r = 0.13, P = 
0.03).  
 
2.3.9 Validation of AGP algorithm 
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The validation dataset, GSE11976, was downloaded from the Gene Expression Omnibus 
(GEO) (Edgar et al., 2002a). It contained 11 samples of DNA from the human breast 
carcinoma cell line CRL2324 mixed with DNA from the lymphoblastoid cell line 
HCC1395BL with known mixing ratios. Samples were measured across 370,404 SNP loci by 
using the Illumina HumanCNV370-Duov1 BeadChips. Known CNVs in HCC1395BL were 
removed so that HCC1395BL DNA represents the euploid portion of the mixture. AGP value 
for each sample was calculated using our algorithm, and compared with the mixing 
percentage. Pearson’s correlation coefficient r = 0.979, confirming that our method 
accurately estimated aneuploid content.  
 
2.4 GBM samples AGP estimation 
 
As mentioned above, in the first batch (GBM1), seven of 284 tumors had too few CNAs 
(including copy-neutral loss-of-heterozygosity events) for AGP estimation, and were 
removed. The remaining 277 tumors had > 0.5% of the genome affected by CNAs, with an 
average Percent Changed (PC) of 37.3%, i.e., > 1/3 of the genome was altered in an 
"average" GBM. Across the 277 samples, the estimated AGPs ranged from 23% to 99% 
(mean ± SD: 76% ±17%), indicating significant admixture of euploid cells (average euploid 
content of 24%). To assess the goodness-of-fit for each sample I quantified the confidence 
interval (CI, 2.5-97.5%) of AGP and the fraction of CNAs that fall on canonical positions 
(PoP, Percent-on-Point) in the optimal two-way mixing model (Figure 2.1C-D). PoP values 
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had a median of 92% among 277 GBMs, suggesting that it is indeed adequate to model a 
single dominant aneuploid cell population in most GBM samples.  
 
2.5 Comparison of genomic estimated aneuploidy contents with histologic reports 
 
Histopathologic assessment of tumor purity provides basic information for clinical diagnosis, 
and is a key criterion in sample selection for research. In TCGA, for example, only GBM 
with >80% "tumor nuclei" were studied. I found, however, that aneuploid estimates based on 
SNP data were only moderately correlated with pathologists' report of "percent tumor cells" 
(Spearman's r = 0.14, P = 0.02, n=275), not correlated with "percent tumor nuclei" (r = 0.076, 
P = 0.21, n=275), and were lower than AGP by an average of 7% and 18%, respectively 
(Figure 2.3). The difference was not explained by tumors with worse fit in our model, or 
greater estimation uncertainty. Our inferred AGP is therefore a novel feature extracted from 
molecular measurements, and can be complementary to the traditionally observed tumor 
purity. 
 
2.6 Impact of aneuploid content on gene expression patterns 
 
I examined 128 GBM1 samples with both gene expression and CNA data. First, samples of 
low AGP tend to cluster together in PCA of gene expression data, driving a strong correlation 
between the first principal component scores (PC1) and AGP (Pearson’s r = 0.62, P = 
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7.3×10-15, n = 128) (Figure 2.2C). PC2 was also correlated with AGP (r = 0.48, P = 1.1×10-8). 
This pattern suggests that within-tumor heterogeneity is a major driver of gene expression 
variation, and a factor overlooked in most previous studies. To see if the results for GBM 
extend to other tumor types, I applied a similar analysis to SNP and expression data for 509 
ovarian (OV) tumors from TCGA (The Cancer Genome Atlas Research Network, 2011), and 
observed a similar pattern (Figure 2.4), with a strong correlation between AGP and PC1 (r = 
0.56, P < 2.2×10-16, n = 504). In contrast to AGP, clinically recorded purity values showed 
little correlation with PC1, r was 0.004 (P = 0.96) for "tumor nuclei", and 0.14 (P = 0.10) for 
"tumor cells", thus underscoring a key advantage of empirical measures of intra-tumor 
heterogeneity (Shirahata et al., 2007). Similar to mRNA, expression patterns of 504 
microRNAs were also correlated with AGP (r = -0.26, P = 3.0×10-3 for PC1; r = -0.56, P = 
1.7×10-11 for PC2, n=125).  
 
2.7 Combined use of DNA and mRNA patterns in class discovery 
 
The results above raised the question of whether varying levels of euploid-aneuploid mixing 
could affect the detection of tumor subtypes. To answer this, I performed a joint classification 
analysis of DNA and mRNA data. In PCA of DNA copy number data, high-AGP samples 
had high and low PC1s, flanking low-AGP samples (Figure 2.5A), and this was mostly due 
to a split of Proneural samples (colored purple). Interestingly, PC1 for copy number and PC1 
for expression data, when plotted together, showed a clear separation of two groups (Figure 
! 46!
2.2D), which, due to annotation efforts described below, I will call Non-Proneural and 
Proneural samples (even though the Proneural group defined here only partially overlaps with 
the previously defined Proneural group (Verhaak et al., 2010b)). The two groups were not 
readily separable when either dataset was analyzed by itself. MicroRNA PC2 was highly 
correlated with PC1 of mRNA data (not shown); thus the joint use of this quantity with copy 
number PC1 also separated the two groups (Figure 2.5B). The Proneural class consisted of 
20 high-AGP samples (AGP = 0.86 ± 0.11), of which all but one belonged to the Proneural 
group defined previously (Verhaak et al., 2010b). Conversely, only 19 out of 38 previously 
defined Proneural samples (among the 128 analyzed) were Proneural here. Thus, our first 
revision of GBM classification is that the previously recognized Proneural group splits into 
two, about half becoming the newly recognized Proneural GBM, another half joining the 
Non-Proneural class. The Non-Proneural GBMs fell on a continuous distribution that 
parallels a gradient of AGP (range: 0.23-0.99), and span from the former Mesenchymal 
samples toward the Classical, Neural, and the rest of the former Proneural samples (Figure 
2.2D). 
I sought to validate these findings in the second batch of GBM (GBM2), using 154 samples 
having both DNA and mRNA data. AGP estimates were generated as above, showing a 
similar distribution of AGP in PCA plots of CNA and gene expression data (Figure 2.6A-B). 
Just as in GBM1, combined analysis revealed two well separated classes (Figure 2.6C), with 
15 Proneural samples. 
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2.8 Molecular and clinical features of Proneural GBMs (Proneural/G-CIMP+) 
 
To provide biological annotation of Non-Proneural and Proneural samples, I first note that 
they carried distinct CNA patterns. Non-Proneural GBMs carried recurrent gains in 
chromosomes 7, 19, 20, recurrent losses in chromosomes 9p and 10, and a gradient of CNA 
intensities due to varying AGP (Figure 2.7A). Proneural tumors, in contrast, lacked most of 
the Non-Proneural features described above and had high AGP values. They carried a more 
diverse set of CNAs, including 11p15.2 deletions (n=12 out of 20), 8q24.21 amplification 
(n=7), and 10p11.23 amplifications (n=14). Two of the Proneural samples showed 
co-occurrence of chr1p loss and chr19q loss (bottom of Figure 2.7A), each of which was 
rarely seen in other samples, yet this co-deletion has been reported as a key feature in 
anaplastic oligodendrogliomas (Cairncross et al., 1998, Ducray et al., 2008). Proneural GBMs 
had more IDH1 mutation, a hallmark of secondary GBM (Cooper et al., 2010, Kleihues and 
Ohgaki, 1999, Nobusawa et al., 2009). They showed higher frequencies of mutations in TP53, 
lower frequencies of mutations in PTEN, fewer deletions of CDKN2A - these are also 
signatures of secondary GBM reported previously (Kleihues and Ohgaki, 1999, Ohgaki and 
Kleihues, 2007). They also showed fewer amplifications and over-expression of EGFR, high 
expression of PDGFRA, and lower expression of FAS and MDM2 (Figure 2.7B and Table 
2.2). 
I also compared clinical outcome between the two groups. Compared to Non-Proneural GBM, 
patients with Proneural GBM were younger at diagnosis (Figure 2.7C) and had longer 
survival time (Figure 2.7D). Notably, while the Proneural group defined here has a better 
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outcome, the other half of the former Proneural group (which I assigned to non-Proneural), is 
significantly worse than the rest of the Non-Proneural group (P=0.0059). Thus, lumping the 
two dissimilar types of GBM in the previously defined Proneural class would have missed a 
clinically relevant distinction. 
A recent study of methylation patterns in TCGA samples revealed a subclass of GBM with 
glioma-CpG island methylator phenotype (G-CIMP+), an epigenetic signature associated 
with secondary or recurrent GBM and with IDH1 mutations (Noushmehr et al., 2010). Of the 
20 Proneural samples I identified, 15 were G-CIMP+ (Figure 2.7B); whereas of the 108 
Non-Proneural samples none was G-CIMP+, strongly supporting Proneural GBM as a 
biologically distinct subtype. Indeed, 3-way analysis of CNA, gene expression, and DNA 
methylation data revealed consistent separation between Proneural and Non-Proneural GBMs 
(Figure 2.8). Proneural samples also match the Proneural GBMs defined in Phillips et al. 
(Phillips et al., 2006b) (Table 2.3). As the term "Proneural" was applied differently in 
Verhaak et al. and Phillips et al. I renamed the Proneural group as Proneural/G-CIMP+ (or 
PN/G-CIMP+). PN/G-CIMP+ samples carry signatures resembling those of secondary GBM 
or low-grade gliomas (Cooper et al., 2010), despite the fact that all but four samples in TCGA 
have been designated as primary (three of these were PN/G-CIMP+). These results suggest 
that a fraction (20 of 128 analyzed, ~16%) of the apparently primary GBM cases recruited in 
TCGA may in fact be latent secondary cases. 
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2.9 Three subclasses within Non-Proneural GBMs: Molecular and clinical signatures 
 
After Proneural/G-CIMP+ GBMs were recognized, I sought to identify subclasses within the 
remaining, Non-Proneural GBMs. The reason for removing an already recognized group (i.e., 
Proneural/G-CIMP+) when studying the fine structure inside another (Non-Proneural) is that 
the markers distinguishing the two main groups may not be most informative for the 
within-group analyses, and could confound the latter. 
 
2.9.1 A two-step procedure that relies on GBM1-GBM2 mutual validation 
 
In PCA, Non-Proneural GBMs described a nearly continuous distribution (Figure 2.2C), in 
which the low-AGP samples aggregated to the left, and there were no clearly separated 
sub-groups in this type of plot. For practical reasons it is often useful to partition seemingly 
continuously varying samples into discrete classes in order to draw broad biological 
conclusions, and to aid clinical decision-making. With high-dimension data, however, even 
samples from a homogeneous distribution can be divided into pre-specified numbers of 
clusters; but the result can be unstable, and be sensitive to samples included, or the statistical 
algorithms applied. Self-aggregating algorithms such as hierarchical clustering or k-means 
clustering will always produce a desired number of clusters; and Consensus Clustering is 
prone to exaggerate cluster stability (Senbabaoglu et al., manuscript under preparation). In 
CC, class assignment can be sensitive to outlier samples, chance occurrence of tightly 
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clustered samples, and the markers used. In addition, as gene-gene correlation is ubiquitously 
observed, and if groups of highly correlated genes appeared in both the test cohort and 
validation cohort, it is easy to find that the most discriminating genes in one cohort are 
"validated" in the second cohort by observing similar clustering patterns.  
To address these methodological challenges, I placed major emphases on mutual validation 
between the GBM1 and GBM2 cohorts rather than first selecting the most informative genes 
in one and testing them in another. I also focused on the Non-Proneural samples. I ran 
K-means-based CC on quantile-normalized gene expression data for GBM1, and separately 
for GBM2, recording the class assignments for K = 2, 3, 4 (K is the number of clusters) for 
both cohorts. To assess classification concordance between GBM1 and GBM2, I calculated 
the cross-correlation matrix between every sample in GBM1 and every sample in GBM2, and 
displayed the resulting matrix where samples were grouped by class assignments 
independently obtained for the two cohorts (Figure 2.9A-B). If samples of a given class in 
GBM1 showed high correlation coefficients (r) with those of a particular class in GBM2, and 
showed low r values with other GBM2 classes, the class discovery was considered mutually 
validated. Conversely, if the classes did not show a one-to-one correspondence between the 
two independent cohorts, I considered the class definition poorly replicated. Figure 2.9A 
showed the GBM1-GBM2 cross-correlation matrix for K=2, where the two classes defined in 
GBM1 could be matched, one-to-one, to the two classes independently defined in GBM2. In 
comparison, K=3 or 4 yielded substantially worse matching (Figure 2.10A-B). 
At K=2, one of the two classes for GBM1 contained all the 37 samples in the Mesenchymal 
group defined previously (Figure 2.9A). I therefore named it the Mesenchymal (MES) group 
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even though it now also contained 4 former Neural/Proneural samples and 11 former 
Classical samples. The other class showed hints of finer structure in Figure 2.9A; and this 
was explored by repeating the analysis described above within this class. This led to a further 
split into 2 subclasses (n=27 and 29, Figure 2.9B), with K=2 being better than k=3 or 4 
(Figure 2.10C-D). One of the subclasses was dominated by the previously defined Classical 
samples, and was thus named the Classical group even though it also contained 5 Neural and 
1 Proneural samples. The other subclass, with a mixture of Non-Proneural-Proneural and 
Neural tumors, was named Proliferative for its similarity with the Proliferative samples 
identified by Phillips et al. (Phillips et al., 2006b). Attempts to identify further subtypes 
within the Proliferative group were not supported by mutual validation between GBM1 and 
GBM2 (not shown). This led us to conclude that the G-CIMP-minus (G-CIMP-) subset of 
previously defined Proneural samples did not form a distinct group. In other words, there 
wasn't a second, self-contained Proneural group in the current GBM dataset, although it is 
possible that a larger sample size in future studies could have the power to reveal finer splits. 
In all, I identified three subclasses for Non-Proneural GBM through a two-stage, stepwise 
clustering procedure, with optimal K=2 at both stages, and supported by concordance 
between GBM1 and GBM2. The resulting assignments were different (by 12% of samples) 
from those assigned by a one-stage, K=3 approach. I consider the two-stage approach more 
appropriate because the finer division in the second stage is not affected by the more 
divergent profiles of the two main classes identified in the first stage. The three newly 
identified Non-Proneural GBM classes are visually coherent on the gene expression PCA plot, 
for both GBM1 (Figure 2.9C) and GBM2 (Figure 2.9D). 
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2.9.2 Comparison with previous studies 
 
Phillips et al. (Phillips et al., 2006b) proposed a three-class system for GBM: Proneural, 
Proliferative and Mesenchymal. Verhaak et al. (Verhaak et al., 2010b) reported four classes 
for TCGA samples: Proneural, Neural, Classical, and Mesenchymal; and in this work I 
described a revised four-class system for the same dataset as in Verhaak et al. Based on 
molecular signatures and comparisons with Phillips et al and Verhaak et al’s work discussed 
below, I name the three revised Non-Proneural GBM classes: Classical, Proliferative and 
Mesenchymal. In order to summarize how these systems have evolved (i.e., how different 
classes correspond to each other), I first reanalyzed the Phillips' data, which were made 
publicly available and a subset of 56 samples were subsequently processed to combine two 
technical platforms (Verhaak et al., 2010b). Among the 56 samples I first observed that the 
Proneural samples in Phillips' study showed high similarities to our PN/G-CIMP+ GBMs in 
terms of patient age, survival time, and patterns of CNAs (not shown). For the remaining 46 
samples, which were designated Non-Proneural GBMs here, I followed the procedure of 
Phillips et al. to select 584 genes most highly correlated with patients’ survival time (out of 
1,740 most variable genes) and performed k-means clustering, using cross-correlation with 
TCGA’s GBM1 to find the optimal number of classes. Again, K=2 yielded the best match for 
both steps in a two-step procedure (Figure 2.11), leading to the recognition of 19 
Mesenchymal, 14 Proliferative and 13 Classical samples. This new three-way classification 
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of 46 Non-Proneural samples showed better cohesion on the PCA plot (Figure 2.12) than the 
original classification, and this could be explained by noting that the latter was based on a 
different set of (and much fewer) genes.  
By tracking the class reassignments between the two datasets and between the original 
classification and our revised classification (Figure 2.13A-B), I documented the 
commonalities and differences among different classification systems (Figure 2.13C, Table 
2.3). Of the 108 samples, 70 (65%) had one-to-one mapping to the previous NL, CL, and 
MES classes (Figure 2.13); thus 35% of GBM1 samples received revised assignments. I 
similarly analyzed the 46 Non-Proneural samples in Phillips et al. (Figure 2.11-12), and 
found that the former Proliferative group was split into the new Proliferative and Classical 
groups, and 11 (24%) were reassigned into or out of the MES group. The MES class was 
reproducibly identified in both datasets and in both the original and the revised schemes. The 
original Proneural group for TCGA was split into (1) the PN/G-CIMP+ group, which is 
equivalent to Phillips' Proneural group, and (2) Non-Proneural-Proneural (N-P-P), which was 
merged with the original Neural samples to form the revised Proliferative group, which 
closely resembles Phillips' Proliferative group. However, some of Phillips' Proliferative 
samples split and formed the revised Classical group, which closely resembles the original 
Classical group for TCGA samples. In sum, a major revision of the Verhaak et al. 
classification is in recognizing that the Proneural group contains two distinct subgroups, one 
of which, PN/G-CIMP+, is well separated from the other three classes by CNA patterns, 
IDH1 mutations, patient age, and outcome. For the Philipps' dataset, a major revision is in 
separating the original Proliferative group into the revised Proliferative and Classical groups. 
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The primary reason that the Proneural/G-CIMP+ class was previously mis-grouped with 
some Neural samples is that their gene expression signatures, when viewed without other 
genomic data, were not sufficiently distinctive, because Proneural samples share a cell 
type-specific signature with the Neural samples (renamed as the Proliferative samples in our 
system). It was only by integrating the CNA data (this work) or by using the methylation data 
(Noushmehr et al., 2010) that the Proneural/G-CIMP+ group became evident. The Phillips' 
study did not miss this group because the authors selected genes strongly correlated with 
survival time rather than those showing the largest variation. Since patients in the 
Proneural/G-CIMP+ group survived longer, genes that were most informative for recognizing 
this group were used in that study.  
 
2.9.3 Clinical relevance of revised Non-Proneural GBM classes 
 
Since any new method could lead to a different classification, I pursued an important 
question: are the biological features of the new classes more robust than in the old system? 
Many marker genes highlighted in previous studies were consistently observed (Table 2.4). 
In CNA patterns (Figure 2.14A), while Non-Proneural samples shared the chr7 gains and 
chr10 losses, Proliferative samples carried additional deletions in chr14 and chr15 rarely seen 
in Classical samples (Student t test for chromosome-wide averaged copy number: P=2.6×10-3 
and 3.1×10-4, for chr14 and chr15, respectively), whereas Classical samples carried more 
amplifications in chr19 (P=1.1×10-6) and chr20 (P=3.6×10-6) than in Proliferative samples. 
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Interestingly, many MES samples carried both the chr14-15 deletions and the chr19-20 gains, 
although with varying intensities due to lower aneuploid content, and with significantly more 
chr13 deletions compared with non-MES tumors (P=9.6×10-3). For Proliferative and MES 
samples, chr14q and 15 deletions tended to be mutually exclusive (mean Pearson’s r = -0.23 
for Prolif and -0.26 for MES); whereas for Classical samples, chr19 gains tended to co-occur 
with chr20 gains (mean Pearson’s r = 0.46). These results showed that in addition to the CNA 
differences between Non-Proneural and PN/G-CIMP+ (Figure 2.7A), the three 
Non-Proneural classes carried different patterns of genomic aberration, possibly reflecting 
their differences in cell lineage, transcriptome patterns, and patient outcome. 
The three Non-Proneural classes also showed significant differences in survival time in a 
three-way comparison in GBM1 (Figure 2.14B, log-rank test P=0.011). This is in contrast to 
the previous class assignments (Verhaak et al., 2010b), for which the three-way comparison 
was not significant (Figure 2.14C). For individual pairs of classes, five out of six pairwise 
comparisons were significant in the revised system, while only one of six was significant in 
the previous system (Figure 2.15). The revised classes for Phillips' dataset also had 
significant survival differences in the three-way comparison (P = 0.033, log-rank test) and in 
the four-way comparison that included the PN/G-CIMP+ group (P = 0.014).  
To directly compare the relative hazard across the four GBM subtypes and incorporate 
relevant patient characteristics, I performed a Cox proportional hazard regression analysis 
using our four-class assignments as explanatory covariates, and including patient age and the 
Karnofsky Performance Status (KPS) scores. First, for the entire set of 128 GBM1 samples, 
with the PN/G-CIMP+ subtype used as the reference category, the three non-Proneural 
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subtypes had higher hazard ratios in the revised system (Figure 2.16A) than in the previous 
system (Figure 2.16B). Second, when I focused only on the three non-Proneural subtypes, 
using Classical as the reference, the 108 samples in the revised system (Figure 2.16C) 
showed higher hazard ratios than the 98 samples in the previous system (Figure 2.16D). To 
compare concordance between tumor classification and patient outcomes, I computed the 
C-statistics (Harrell et al., 1996) for the 128 GBM1 dataset using the Cox regression model 
with age, KPS and subtypes as covariates. Revised classification had a concordance score of 
0.668, higher than using age and KPS alone (0.643) by 2.5%, whereas the previous system 
had a concordance of 0.651, higher than using age and KPS alone (0.643) by only 0.8%, 
indicating that the revised system had improved predictive power for patient outcome. 
 
2.9.4 Validation of survival time differences in an independent cohort 
 
The Non-Proneural classes described above were defined by mutual validation of GBM1 and 
GBM2, thus having used information from both cohorts. To validate the survival time 
differences in a new, independent dataset, I analyzed a third batch of 144 TCGA samples 
(GBM3). As before, I identified 26 PN/G-CIMP+ samples using expression data and CNA 
data. Survival time differences were indeed validated in GBM3, with five out of six pairwise 
comparisons showing significant differences (Table 2.5A). To compare with the previous 
system, I used the 840 markers suggested by Verhaak et al. to classify the GBM3 samples 
and found that only one of six pairwise comparisons was significant (Table 2.5B).  
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2.10 Inference of cell type composition of GBM classes 
 
I attempted to deduce the possible cell type composition of the four GBM classes to shed 
light on the cellular origins of this heterogeneous cancer. To do so, I compared GBM 
expression data with a reference dataset, GSE9566 (Cahoy et al., 2008), for 38 samples that 
represent four main cell types in the central nervous system: acutely isolated astrocytes, 
neurons, oligodendrocytes, and cultured astroglia. The 38 samples formed four 
well-separated clusters, in agreement with their known identity (Figure 2.16). 
Cross-correlations of Non-Proneural GBM samples with the 38 reference samples, when 
grouped by class (for GBM) and cell type (for reference samples), showed recognizable 
mapping of GBM classes to known neural cell types, for GBM1 (N=128), GBM2 (N=154), 
and Phillips’ dataset (N=56) (Figure 2.17A-C). Both PN/G-CIMP+ and Proliferative samples 
showed high correlations with neurons and oligodendrocytes, suggesting that they both 
resemble oligodendrogliomas. The Classical samples were similar to the astrocytes, 
suggesting that they may be related to astrocytomas. Lastly, the Mesenchymal samples 
showed high similarities with the cultured astroglia samples, which had an "immature or 
reactive phenotype" (Cahoy et al., 2008), consistent with the MES signatures of angiogenesis 
and inflammatory infiltration (Phillips et al., 2006b, Verhaak et al., 2010b, Murat et al., 2009). 
The observed resemblance to known cell types was generally consistent with what was 
reported previously (Verhaak et al., 2010b), but with important differences. First, the former 
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Neural group did not show clear mapping to any cell type. Second, the mapping to reference 
cell types is much stronger with the new system: the difference (D) of the mean correlation 
coefficients between the mapped diagonal blocks and the off-diagonal blocks of the 
correlation matrix (Figure 2.17A-C) was 0.562 for the new classes, much higher than in the 
previously reported classes (D = 0.247) even when I counted the best mapped blocks for the 
latter. 
As most of the low-AGP samples fell in the Mesenchymal group, I attempted to clarify the 
cell lineage of the aneuploid and euploid populations. If the aneuploid cells were derived 
from one of the reference cell types, there should be a positive correlation between (1) the 
correlation between samples of that particular cell type and individual MES tumors and (2) 
the MES tumors' AGP values, which measure how much aneuploid cells they contain. I 
calculated the correlation coefficients r, for each of the 38 reference samples, between its 
correlation coefficients with the MES samples and the AGP values of the MES samples, and 
found consistent and positive r values for Cultured Astrocytes (Figure 2.17D), suggesting 
that the aneuploid cells in MES share gene expression features, and possible common lineage, 
with reactive astrocytes (Cahoy et al., 2008).  
As no other cell type in the reference set showed negative correlations, the identity of the 
euploid cells in MES remained unexplained. MES tumors carry angiogenic and inflammatory 
signatures, and some microglia markers are highly expressed in MES samples (Verhaak et al., 
2010b). I therefore hypothesize that the euploid fraction may be related to 
microglia/macrophage infiltration. To test this hypothesis, I searched public databases for 
gene expression data for microglia samples, and found data for tumor-infiltrating 
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microglia/macrophage isolated from freshly excised brain tumors ("TI. microglia", in 
GSE25289) (Mora et al., 2010) and for microglia fraction from postoperative GBM tissue 
("G. microglia", in GSE16119) (Murat et al., 2009). The correlation of these cells with MES 
tumors showed negative correlations with AGP (Figure 2.4D), suggesting that expression 
signatures of MES euploid cells are similar to microglia/macrophage. Moreover, two 
microglia/macrophage-specific transcripts, integrin alpha M (ITGAM) (Guillemin and Brew, 
2004) and allograft inflammatory factor-1 (AIF1) (Schwab et al., 2001), were negatively 
correlated with AGP (r = -0.58, P = 6.3×10-6 for ITGAM; r = -0.53, P = 5.3×10-5 for AIF1), 
further supporting microglia/macrophage as the probable source of euploid population in 
MES.  
 
2.11 Hierarchical classification of GBM 
 
The new understanding of GBM genomic landscape led to our proposal of a cohesive 
stepwise classification procedure (Figure 2.18). First, Proneural/G-CIMP+ GBMs can be 
identified with joint analyses of copy number and mRNA profiles, along with clinical data 
such as patient age. Even if a case was recorded as primary GBM due to the apparent lack of 
antecedent tumors, it could be recognized as Proneural/G-CIMP+ by features such as younger 
age, IDH1 mutations, lack of PTEN mutations, hyper-methylation patterns, and lack of chr7 
gains and chr10 losses. Among the remaining, Non-Proneural samples, MES samples can be 
separated from the Classical and Proliferative samples by lower AGP values, necrosis 
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signatures, higher expression of FAS and CHI3L1, etc. These tumors experienced more 
infiltration of non-cancerous cells, containing aneuploid reactive astrocyte-like cells 
intermingled with cells such as microglia/macrophage that lack CNAs. Lastly, Classical and 
Proliferative samples can be distinguished by gene expression patterns that resemble different 
neural cell types. Known markers highlighted by previous studies (Table S4), such as PCNA 
and TOPA2A overexpression in Proliferative samples, can also be incorporated in this step.  
 
2.12 Summary 
 
The practice in this work covered inter-tumor level and sample level heterogeneity. I have 
developed an algorithm to estimate the euploid cell mixing ratios in surgically removed bulk 
tumor tissues. My algorithm falls in the lineage of pattern recognition discussed in Chapter 1, 
4.2, which was first introduced by Popova et al (ref). However, AGP inference algorithm 
differentiates from the original GAP method in several ways: first, it used folded BAF as 
x-axis, which allowed me to introduce contraction tracks for each possible CNA 
configuration. This feature will later be used to develop a more capable tool, segmental AGP 
inference algorithm, which estimates   
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estimation. Second, AGP inference algorithm does not rely on external input of tumor DNA 
content to genotype the somatic CNAs. It is able to estimate tumor and sample ploidy based 
on the distribution of observed data points on the BAF-LRR plot.  
Discoveries of GBM subtypes have so far relied on single data types. The work reported here 
combined DNA genotyping data and gene expression data, and revealed a novel GBM 
subtype (Proneural/G-CIMP+) that carried distinct molecular, clinical, and demographic 
features. While this subtype was described separately in a study of methylation data 
(Noushmehr et al., 2010), our approach reached the conclusions from two other, independent 
data types, and suggests that such a combined approach will be useful in genomic analysis of 
other cancers.  
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0.99 
0.166 
0.853 
0.116 
2 
1.99 
1.99 
0.363 
0.49 
0.00605 
0 
0.14475 
0.99 
0.99 
95 
95 
T
C
G
A
-26-1438 
0.42 
0.0917 
0.227 
0.996 
4 
6.68 
3.97 
0.056 
0.171 
0 
0 
0.23 
0.415 
0.44 
90 
90 
T
C
G
A
-26-1440 
0.85 
0.191 
0.323 
0.623 
4 
4.44 
4.07 
0.186 
0.137 
0 
0 
0.25 
0.75 
0.84 
90 
90 
T
C
G
A
-26-1443 
0.98 
0.0937 
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3.85 
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0.139 
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0.232 
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-28-1749 
0.99 
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0.598 
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2.02 
2.02 
0.0985 
0.0657 
0 
0 
0.16 
0.99 
0.99 
80 
90 
T
C
G
A
-28-1750 
0.67 
0.0864 
0.854 
1 
4 
5.9 
4.61 
0.624 
0.23 
0 
0 
0.46475 
0.55 
0.67 
80 
90 
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C
G
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-28-1751 
0.43 
0 
0.198 
1 
2 
2.05 
2.02 
0.127 
0.0708 
0.0708 
0 
0.05 
0.05 
0.05 
75 
90 
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C
G
A
-28-1752 
0.62 
0.137 
0.285 
0.999 
4 
5.1 
3.92 
0.0725 
0.212 
0 
0 
0.14 
0.305 
0.57 
80 
80 
T
C
G
A
-28-1755 
0.95 
0.296 
0.366 
0.3 
2 
1.97 
1.97 
0.153 
0.213 
0.00653 
0.0489 
0.13 
0.95 
0.96 
70 
95 
T
C
G
A
-28-1757 
0.85 
0.00601 
0.165 
0.342 
2 
2 
2 
0.0561 
0.109 
0.00136 
0 
0.83 
0.84 
0.85 
85 
90 
1: Standard deviation of A
G
P values (std), obtained from
 100 bootstrap runs. 
2:Percent of genom
e changed (PC
): the fraction of the genom
e w
ith C
N
A
s.   
3:Percent of genom
e on-Point (PoP): the fraction of genom
e w
ith C
N
A
s near a canonical point at the optim
al A
G
P. 
4:Ploidy of the euploid population (2n/4n/6n). 
5:G
enom
ew
ide average ploidy of the aneuploid population (pl.tum
or). 
6:A
verage overall ploidy (pl.overall): the w
eighted average ploidy of the aneuploid and euploid portions.  
7:Percent of genom
e am
plified (%
am
p), the fraction of genom
e w
ith copy num
ber gains. 
8:Percent of genom
e deleted (%
del), the fraction of genom
e w
ith copy num
ber losses. 
9:Percent of hem
izygous deletion (%
del.loh), the fraction of loss-of-heterozygosity segm
ents due to single-copy loss. 
10:Percent of copy neutral loss of heterozygosity (%
cn.loh). 
11-13:2.5%
, 50%
 and 97.5%
 quantiles of the bootstrapped distribution of A
G
P. 
14-15:H
istopathologic report of tum
or contents: percent of tum
or cells and nuclei.  These w
ere obtained from
 
TC
G
A
, not derived from
 A
G
P inference. 
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Table 2.2: Selected molecular signatures distinguishing Typical (T) and Atypical (AT) 
GBMs 
  Signatures* N(AT)1 N(T)1 N(T-PN)1 
Fold change 
(T/AT) 
Change(T/AT)3 
P value2 Reference 
Molecular 
IDH1 mut 10 0 0     
Nobusawa 
et al, 2009 
EGFR amp 1 106 18 
 
<2.2e-16 
Kleihues et 
al, 1999 
EGFR OE 1 50 5 3.44 3.99E-07 
Kleihues et 
al, 1999 
MDM2 OE 1 18 3 1.65 3.11E-04 
Kleihues et 
al, 1999 
CDKN2A 
del 
8 79 12   0.13 
Kleihues et 
al, 1999 
PTEN mut 3 32 6 
  
Kleihues et 
al, 1999 
FAS OE 2 44 3 2.4 2.86E-05 
Tohma et 
al, 1998 
TP53 mut 12 33 8 
  
Kleihues et 
al, 1999 
PDGFRA 
OE 
12 27 10 0.29 2.85E-04 
Kleihues et 
al, 2007 
G-CIMP+ 15 0 0     
Cooper et 
al, 2010 
Clinical 
Mean Age 
(Onset) 
38 58 58   4.63E-05 
Kleihues et 
al, 1999 
Sex Ratio 
(M/F) 
1.5 1.56 2.16 
  
Kleihues et 
al, 1999 
Survival 
(days) 
1,024 370 232   7.48E-07 
Kleihues et 
al, 2007 
Necrosis 
(%) 
6.75% 12.80% 15.7   9.28E-03 
Kleihues et 
al, 2007 
1:Counts of Atypical (AT), Typical (T) and Typical-Proneural (T-PN) samples with corresponding signatures 
passing a certain threshold. For CNA, the threshold is LRR ratio (base 2) greater than 0.2 or less than -0.2. For 
mutation, the counts are for the presence of validated non-silent mutations. For gene expression it is ±0.5 for 
logged (base 2) gene expression level when the median across the entire cohort is centered at 0 (therefore >0.5 
is counted as OE). 
2:P-values for comparing between Typical and Atypical samples, using the student T-test for expression and 
CNA, Age of Onset, and Necrosis, and the log-rank test for survival time. 
3:Fold change (transformed to linear scale) of gene expression between T and AT groups. 
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*Abbreviations: mutation (mut), amplification (amp), deletion(del), overexpression (OE).
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Table 2.3: Revised class assignment obtained in this work 
GBM1 Classes GBM2 Classes 
Phillips 
et al. 
Classes 
TCGA-02-0001 Mes* TCGA-02-0116 Mes GSM96954 Classical 
TCGA-02-0003 Prolif TCGA-06-0137 Classical GSM96963 Atypical 
TCGA-02-0006 Mes TCGA-06-0138 Prolif GSM96984 Classical 
TCGA-02-0007 Prolif TCGA-06-0145 Classical GSM96991 Atypical 
TCGA-02-0009 Classical TCGA-06-0148 Classical GSM97014 Atypical 
TCGA-02-0010 Atypical TCGA-06-0154 Mes GSM97048 Atypical 
TCGA-02-0011 Atypical TCGA-06-0155 Mes GSM96965 Prolif 
TCGA-02-0014 Atypical TCGA-06-0156 Mes GSM96973 Classical 
TCGA-02-0015 Mes TCGA-06-0169 Mes GSM96972 Mes 
TCGA-02-0016 Classical TCGA-06-0176 Atypical GSM96970 Prolif 
TCGA-02-0021 Classical TCGA-06-0192 Mes GSM96969 Mes 
TCGA-02-0023 Classical TCGA-06-0201 Mes GSM96966 Mes 
TCGA-02-0024 Atypical TCGA-06-0206 Mes GSM96967 Mes 
TCGA-02-0025 Mes TCGA-06-0208 Classical GSM97041 Prolif 
TCGA-02-0026 Atypical TCGA-06-0211 Classical GSM97004 Mes 
TCGA-02-0027 Classical TCGA-06-0213 Mes GSM97002 Mes 
TCGA-02-0028 Atypical TCGA-06-0216 Prolif GSM96996 Prolif 
TCGA-02-0033 Mes TCGA-06-0649 Mes GSM96992 Mes 
TCGA-02-0034 Mes TCGA-06-0686 Prolif GSM96989 Mes 
TCGA-02-0037 Mes TCGA-06-0743 Classical GSM96987 Mes 
TCGA-02-0038 Classical TCGA-06-0744 Classical GSM96982 Mes 
TCGA-02-0039 Mes TCGA-06-0745 Prolif GSM96981 Mes 
TCGA-02-0043 Classical TCGA-06-0747 Classical GSM96980 Mes 
TCGA-02-0046 Prolif TCGA-06-0749 Prolif GSM96964 Mes 
TCGA-02-0047 Atypical TCGA-06-0750 Mes GSM96961 Mes 
TCGA-02-0048 Prolif TCGA-06-0875 Prolif GSM96958 Mes 
TCGA-02-0051 Mes TCGA-06-0876 Classical GSM96951 Mes 
TCGA-02-0052 Prolif TCGA-06-0877 Mes GSM96952 Mes 
TCGA-02-0054 Mes TCGA-06-0878 Mes GSM96955 Atypical 
TCGA-02-0055 Mes TCGA-06-0881 Mes GSM96959 Prolif 
TCGA-02-0057 Mes TCGA-06-1084 Mes GSM96995 Prolif 
TCGA-02-0058 Atypical TCGA-06-1086 Mes GSM97009 Prolif 
TCGA-02-0059 Mes TCGA-06-1087 Prolif GSM97008 Prolif 
TCGA-02-0060 Atypical TCGA-06-1800 Mes GSM97000 Prolif 
TCGA-02-0064 Mes TCGA-06-1801 Prolif GSM97011 Prolif 
TCGA-02-0068 Mes TCGA-06-1802 Mes GSM97010 Prolif 
TCGA-02-0069 Atypical TCGA-06-1805 Atypical GSM96977 Prolif 
TCGA-02-0070 Mes TCGA-12-0654 Mes GSM97040 Prolif 
TCGA-02-0071 Mes TCGA-12-0656 Classical GSM96953 Atypical 
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TCGA-02-0074 Prolif TCGA-12-0657 Mes GSM96962 Classical 
TCGA-02-0075 Mes TCGA-12-0670 Classical GSM96978 Classical 
TCGA-02-0079 Mes TCGA-12-0688 Classical GSM96979 Classical 
TCGA-02-0080 Atypical TCGA-12-0692 Classical GSM96983 Classical 
TCGA-02-0083 Classical TCGA-12-0703 Classical GSM96985 Classical 
TCGA-02-0084 Atypical TCGA-12-0707 Classical GSM96988 Classical 
TCGA-02-0085 Mes TCGA-12-0772 Mes GSM96990 Atypical 
TCGA-02-0086 Mes TCGA-12-0773 Atypical GSM96994 Classical 
TCGA-02-0089 Mes TCGA-12-0775 Mes GSM97007 Classical 
TCGA-02-0099 Mes TCGA-12-0776 Mes GSM97018 Atypical 
TCGA-02-0102 Classical TCGA-12-0778 Mes GSM97037 Atypical 
TCGA-02-0104 Atypical TCGA-12-0780 Classical GSM97042 Atypical 
TCGA-02-0107 Mes TCGA-12-0820 Prolif GSM96976 Classical 
TCGA-02-0113 Classical TCGA-12-0821 Prolif GSM96974 Classical 
TCGA-02-0114 Atypical TCGA-12-0822 Mes GSM96950 Mes 
TCGA-02-0115 Classical TCGA-12-0826 Classical GSM96997 Classical 
TCGA-06-0122 Mes TCGA-12-0827 Atypical GSM96993 Mes 
TCGA-06-0124 Mes TCGA-12-0828 Classical     
TCGA-06-0125 Classical TCGA-12-0829 Mes 
  
TCGA-06-0126 Classical TCGA-12-1088 Mes     
TCGA-06-0127 Classical TCGA-12-1089 Classical 
  
TCGA-06-0128 Atypical TCGA-12-1091 Classical     
TCGA-06-0129 Atypical TCGA-12-1092 Mes 
  
TCGA-06-0130 Mes TCGA-12-1093 Mes     
TCGA-06-0132 Mes TCGA-12-1094 Mes 
  
TCGA-06-0137 Classical TCGA-12-1095 Mes     
TCGA-06-0138 Prolif TCGA-12-1096 Mes 
  
TCGA-06-0143 Mes TCGA-12-1097 Prolif     
TCGA-06-0145 Classical TCGA-12-1098 Classical 
  
TCGA-06-0147 Mes TCGA-12-1099 Atypical     
TCGA-06-0148 Mes TCGA-12-1598 Prolif 
  
TCGA-06-0152 Mes TCGA-12-1599 Mes     
TCGA-06-0154 Mes TCGA-12-1600 Classical 
  
TCGA-06-0156 Prolif TCGA-12-1601 Mes     
TCGA-06-0157 Classical TCGA-12-1602 Prolif 
  
TCGA-06-0158 Classical TCGA-14-0736 Mes     
TCGA-06-0166 Prolif TCGA-14-0783 Mes 
  
TCGA-06-0168 Mes TCGA-14-0786 Classical     
TCGA-06-0171 Prolif TCGA-14-0787 Classical 
  
TCGA-06-0173 Prolif TCGA-14-0789 Mes     
TCGA-06-0174 Prolif TCGA-14-0812 Mes 
  
TCGA-06-0176 Mes TCGA-14-0813 Prolif     
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TCGA-06-0184 Mes TCGA-14-0817 Mes 
  
TCGA-06-0185 Classical TCGA-14-0865 Prolif     
TCGA-06-0187 Mes TCGA-14-0866 Classical 
  
TCGA-06-0188 Prolif TCGA-14-0867 Atypical     
TCGA-06-0195 Prolif TCGA-14-0871 Prolif 
  
TCGA-06-0197 Mes TCGA-14-1034 Mes     
TCGA-06-0208 Classical TCGA-14-1037 Mes 
  
TCGA-06-0210 Mes TCGA-14-1396 Mes     
TCGA-06-0211 Classical TCGA-14-1401 Prolif 
  
TCGA-06-0214 Prolif TCGA-14-1402 Classical     
TCGA-06-0219 Prolif TCGA-14-1451 Prolif 
  
TCGA-06-0221 Atypical TCGA-14-1452 Mes     
TCGA-06-0237 Prolif TCGA-14-1453 Classical 
  
TCGA-06-0238 Prolif TCGA-14-1454 Prolif     
TCGA-06-0241 Prolif TCGA-14-1455 Prolif 
  
TCGA-06-0644 Mes TCGA-14-1458 Atypical     
TCGA-06-0645 Mes TCGA-14-1459 Classical 
  
TCGA-06-0646 Prolif TCGA-14-1794 Prolif     
TCGA-06-0648 Prolif TCGA-14-1795 Prolif 
  
TCGA-08-0244 Classical TCGA-14-1821 Atypical     
TCGA-08-0246 Mes TCGA-14-1823 Mes 
  
TCGA-08-0344 Atypical TCGA-14-1825 Prolif     
TCGA-08-0345 Mes TCGA-14-1827 Classical 
  
TCGA-08-0346 Mes TCGA-14-1829 Mes     
TCGA-08-0347 Prolif TCGA-15-0742 Classical 
  
TCGA-08-0348 Prolif TCGA-15-1446 Classical     
TCGA-08-0349 Prolif TCGA-15-1447 Atypical 
  
TCGA-08-0350 Atypical TCGA-15-1449 Prolif     
TCGA-08-0351 Atypical TCGA-16-0846 Atypical 
  
TCGA-08-0352 Mes TCGA-16-0848 Prolif     
TCGA-08-0353 Classical TCGA-16-0849 Atypical 
  
TCGA-08-0354 Mes TCGA-16-0850 Atypical     
TCGA-08-0355 Classical TCGA-16-0861 Prolif 
  
TCGA-08-0356 Mes TCGA-16-1045 Mes     
TCGA-08-0357 Classical TCGA-16-1047 Classical 
  
TCGA-08-0358 Classical TCGA-16-1055 Mes     
TCGA-08-0359 Prolif TCGA-16-1056 Classical 
  
TCGA-08-0360 Mes TCGA-16-1060 Mes     
TCGA-08-0375 Classical TCGA-16-1062 Classical 
  
TCGA-08-0380 Prolif TCGA-16-1063 Classical     
TCGA-08-0389 Prolif TCGA-16-1460 Atypical 
  
TCGA-08-0390 Mes TCGA-19-0955 Mes     
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TCGA-08-0392 Mes TCGA-19-0957 Prolif 
  
TCGA-12-0616 Prolif TCGA-19-0960 Atypical     
TCGA-12-0618 Prolif TCGA-19-0962 Mes 
  
TCGA-12-0619 Mes TCGA-19-0963 Prolif     
TCGA-12-0620 Mes TCGA-19-0964 Classical 
  
    TCGA-19-1385 Mes     
  
TCGA-19-1386 Classical 
  
    TCGA-19-1387 Prolif     
  
TCGA-19-1388 Mes 
  
    TCGA-19-1389 Mes     
  
TCGA-19-1392 Prolif 
  
    TCGA-19-1786 Classical     
  
TCGA-19-1788 Atypical 
  
    TCGA-19-1789 Classical     
  
TCGA-19-1791 Classical 
  
    TCGA-26-1438 Mes     
  
TCGA-26-1440 Classical 
  
    TCGA-26-1443 Classical     
  
TCGA-26-1799 Prolif 
  
    TCGA-27-1830 Mes     
  
TCGA-27-1832 Mes 
  
    TCGA-27-1833 Classical     
  
TCGA-27-1834 Mes 
  
    TCGA-28-1745 Mes     
  
TCGA-28-1746 Prolif 
  
    TCGA-28-1749 Classical     
  
TCGA-28-1750 Mes 
  
    TCGA-28-1751 Mes     
  
TCGA-28-1752 Mes 
  
    TCGA-28-1755 Classical     
    TCGA-28-1757 Classical     
1:GBM sample assignments based on the revised classification system.  Sample from the three cohorts were 
combined in the same table, where each row is not intended to show any sample matching between studies. 
*Abbreviations: Proliferative (Prolif), Mesenchymal (Mes).
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Table 2.4: Selected gene expression features distinguishing Typical GBM classes 
  TCGA Phillips 
Classes Genes Classical Prolif Mes Classical Prolif Mes 
Classical 
EGFR 2.6 -0.35 -0.05 1.17 -1.97 -0.6 
CDKN2A -0.9 0.35 -0.027 -0.38 1.5 0.32 
Proliferative 
PCNA 0.24 0.4 -0.17 0.45 0.82 -0.2 
TOP2A -0.06 0.99 -0.64 0.27 1.77 -0.32 
Mesenchymal 
CHI3L1 0.52 -0.42 1.2 -0.052 -1.57 1.36 
TRADD -0.047 -0.19 0.26 -0.029 -0.12 0.22 
RELB -0.034 -0.26 0.31 -0.043 -0.16 0.39 
TNFRSF1A 0.14 -0.37 0.57 0.093 -0.57 0.92 
Number in each entry is the average expression value (log 2 scale) for a given class for the 
gene indicated in the column Genes.
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Table 2.5: Pairwise comparisons between GBM subtypes. 
 
PN/G-CIMP+ Prolif Classical MES 
PN/G-CIMP+ - 1.5e-4 0.018 0.0015 
Prolif 
 
- 0.010 0.040 
Classical 
  
- 0.33 
MES 
   
- 
 
 
PN NL CL MES 
PN - 0.059 0.046 0.091 
NL 
 
- 0.60 0.85 
CL 
  
- 0.92 
MES 
   
- 
Log rank test was performed for each pair of subtypes compared. Upper table shows the results for 
revised GBM subtypes in this work, and lower table is for Verhaak’s four subtypes. 
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Figure 2.1: Inference of Aneuploid Genome Proportion and its goodness-of-fit 
measures. 
 
A. BAF-LRR plot for an idealized sample with 100% aneuploid cells. Canonical positions 
representing integer combinations of (NB, NA+NB) are marked with red stars, with red dashed lines 
indicating the contraction paths when AGP is less than 100%.  B. A hypothetic sample with 
AGP=0.6, with canonical points showing concerted contraction toward (1,2), the position of a normal 
diploid segment.  C. AGP versus the PoP (Percent-on-Point), i.e., the fraction of CNA segments 
accounted for by canonical positions in the optimal mixing model.  D. AGP versus the CI 
(Confidence Interval), defined as the range between the 2.5- and 97.5- percentiles in repeated runs of 
AGP estimates. Values were for GBM1 samples. 
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Figure 2.2: AGP and relationship to gene expression patterns A.  
 
BAF-LRR plot of sample TCGA-02-0038 as an example of using allelic intensity data to estimate 
AGP. The x axis shows |BAF-0.5|, the absolute deviation of B allele frequency (BAF) between tumor 
and matched normal samples, at heterozygous SNP loci in the normal sample; y axis is the LRR, logR 
Ratio between tumor and normal samples. Canonical positions representing integer combinations of 
(NB, NA+NB) are marked with red stars, with red dashed lines indicating the contraction paths when 
AGP < 1 (see also Figure S1). Most CNAs, shown as "bubbles", fell on canonical positions. The size 
of the bubble shows CNA length. PC (percent of genome changed) = 0.20 for this sample. Inferred 
AGP is 0.82. PoP (percent of changed genome on canonical points) = 0.99. B. Validation of AGP 
inference algorithm, using reference dataset GSE11976, for DNA pools of a breast cancer cell line 
mixed with a lymphoblastoid cell line at known ratios. Error bars show the 95% confidence intervals 
from the experimental procedures (horizontal) and from our bootstrap method (vertical). The red line 
has a slope of 1 and intercept of 0. C. Scatter plot of PC1-PC2 (the first two principal component 
scores) of GBM1 gene expression data. Symbol size is proportional to AGP as indicated in the legend. 
D. Scatter plot of PC1 of CNA (also shown on the x-axis in S4A) versus PC1 of gene expression data 
(shown on the x-axis in 1C); Non- Proneural and Proneural/G-CIMP+ GBM samples were indicated 
by filled and open symbols, respectively. 
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Figure 2.3: Histolopathological estimates of tumor purities versus AGP. 
 
Comparison of AGP and clinically recorded "percent tumor cell"(upper panel) and "percent tumor 
nuclei" (lower panel), showing large deviations in many samples and generally higher estimates of 
tumor content in clinical records.  
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Figure 2.4: Relationship between AGP and gene expression pattern in ovarian cancer 
(OV). 
  
TCGA OV samples (n=504) were analyzed, and the gene expression PC1-PC2 plot showed an AGP 
gradient similar to that in Figure 1C.  
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Figure 2.5: PCA plots for CNA and MicroRNA joint analysis.
 
A. PC1-PC2 plot of average DNA copy number in each of 811 cytobands, with AGP indicated by 
bubble size and samples colored by the four-class assignment in Verhaak et al., showing the split of 
the Proneural subtype (purple). B. Scatter plot of PC1 of CNA (y) and PC2 of microRNA expression 
data (x). 
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Figure 2.6: Principal component analyses of gene expression and CNA data for GBM2.
 
A. PC1-PC2 plot for total DNA copy number data of 154 samples in GBM2, averaged in each of 811 
cytobands, with AGP indicated by bubble size. B. PC1-PC2 plot for expression profiles in 1740 genes 
for the same samples in A. Patterns for both CNA and gene expression data were similar to the 
corresponding plots for GBM1 as shown in Figure 1C and Figure 2C. C. Joint use of DNA and gene 
expression data identified 15 PN/G-CIMP+ tumors in the GBM2 cohort, similar to the results for 
GBM1 as shown in Figure 2C-D. 
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Figure 2.7: Molecular and clinical features of Proneural/G-CIMP+ GBM A. 
 
Heatmap of per-cytoband total copy number in Non-Proneural and Proneural/G-CIMP+ samples, with 
Chr1–22 arranged from bottom to top. Non-Proneural samples were ordered from left to right by 
decreasing AGP, and showed characteristic features, such as chr7 amplifications (shown in red) and 
chr10 deletions (in blue), across most samples, albeit with a gradient of magnitude. B. Selected 
molecular features, including, from top to bottom, presence or absence of non-silent mutations in 
IDH1, TP53 and PTEN as reported by (2); G- CIMP+, a methylation signature described in (6); total 
copy number in CDKN2A and EGFR; expression levels of NF1, PDGRFA, FAS, MDM2 and EGFR, 
as described in (2). The four classes defined in Verhaak et al., and the three classes defined in this 
work, are indicated as colored symbols in the bottom row. C. Distribution of age-of-diagnosis in 
Non-Proneural (n=110) and Proneural/G-CIMP+ (n=20) samples. Also shown are two subgroups of 
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Non- Proneural GBM: Proneural (N-P-P) and non-Proneural (N-P-N). D. Kaplan-Meier survival 
curves for Non-Proneural and Proneural/G-CIMP+ groups, with the latter showing better outcome 
(log rank test p-value=7.5E-7). The Non-Proneural group was further split into the former Proneural 
(N-P-P) and non-Proneural (N-P-N) samples. 
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Figure 2.8: Clustering pattern of three data types: PC1 of copy number data, PC1 of 
expression data, and PC2 of methylation data. 
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Figure 2.9: Classification of Non-Proneural GBM tumors. 
 
A-B. Heatmaps of the cross-correlation matrices between samples in GBM1 (left to right) and 
samples in GBM2 (top to bottom), for all Non-Proneural GBM tumors used in the first stage (A), and 
for one of the two subclasses discovered in the first stage (B). Consensus clustering was separately 
performed on both datasets with K = 2, with K = 3, 4 shown in Figure S8.  Samples were ordered by 
the two-class assignment, as indicated by the two-color segments in the sidebar: vertical bar for 
GBM2, and horizontal bar for GBM1.  The original four-class assignment from Verhaak et at. (2) 
was indicated in the four-color sidebar at the bottom. C-D. Three-dimensional PC1-3 plots of gene 
expression data for Non-Proneural samples in GBM1 (C) and GBM2 (D), showing coherent grouping 
of the three classes defined in A and B. 
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Figure 2.10: Cross-correlation analysis of GBM1-GBM2 at K=3 and 4. These plots 
complement Figure S5A-B, which showed k=2.   
 
Shown are heatmaps of the cross-correlation matrices between samples in GBM1 (left to right) and 
samples in GBM2 (top to bottom), for all Non-Proneural GBM tumors used in the first stage at k=3 
(A) and k=4 (B), and for the non-Mesenchymal class discovered in the k=2 first stage analysis, at k=3 
(C) and k=4 (D). Samples were ordered by the three-class or four-class assignment, as indicated by 
the colored segments in the vertical bar for GBM2, and horizontal bar for GBM1.  The original 
four-class assignment from Verhaak et at. was indicated in the four-color sidebar at the bottom.  
These plots revealed no clear one-to-one mapping between GBM1and GBM2 for either K=3 or K=4. 
C-D). The quality of mapping between batches can be quantified by the difference of average 
Pearson’s r for diagonal and off-diagonal sample pairs, which are 0.428, 0.362 and 0.242 for K=2, 3, 
4, respectively, for the first step analysis of all Non-Proneural tumors, and 0.442, 0.313 and 0.256 for 
K=2, 3, 4, respectively, for the second step analysis of Non-Mesenchymal samples. 
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Figure 2.11: Cross-correlation analysis between GBM1 and Phillips' dataset at K=2, 3 
and 4 
 
Correlation matrices for the first stage classification (A, B, and C, for k=2, 3, 4 respectively) and 
second stage (D, E, and F, for k=2, 3, 4 respectively), with procedures and sidebar labels similar to 
those shown in Figure 10 
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Figure 2.12: PCA plots for 46 Non-Proneural GBM samples in Phillips' dataset. 
 
The same PC1-PC2 scatter plot, generated using 584 genes highly correlated with survival time, was 
shown in both A and B, and colored by the three-class assignment defined in this work (A) or the 
original Proliferative-Mesenchymal assignment by Philipps et al. (B), showing more coherent 
separation in A. 
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Figure 2.13: Comparison between the revised and the previous GBM classification 
systems. 
 
A. Cross-tabulation ("Confusion matrix") of samples between the current four-class assignment and 
that reported in Verhaak et al. (2) for TCGA samples.  B. Cross-tabulation between the current 
four-class assignment and that reported in Phillips et al.(7). C. Correspondence of different classes 
across two datasets and the revised and previous classifications.  Arrow width is proportional to the 
number of samples matched. 
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Figure 2.14: Molecular and clinical signatures for Non-Proneural GBM classes. A, 
Chr13–22 CNA patterns in the revised Non-Proneural GBM classes. 
 
Class assignments were indicated by the stars at the bottom, with size proportional to AGP. B and C, 
Kaplan–Meier curves for GBM1 according to the revised classes (B) and the previous classes (C). 
The overall log-rank test for the 3 classes was significant in (B; P 1⁄4 0.011) but not in (C). 
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Figure 2.15: Survival time differences between GBM subtypes, compared between the 
current and previous classification systems. 
Revised Classification 
 
PN/G-CIMP+ Classical Proliferative MES 
PN/G-CIMP+ - 9.5E-04 6.0E-07 4.7E-06 
Classical 
 
- 0.012 0.23 
Prolif. 
  
- 0.035 
MES 
   
- 
Verhaak et al. Subtypes 
 
PN NL CL ME 
PN - 0.12 0.0044 0.065 
NL 
 
- 0.12 0.94 
CL 
  
- 0.18 
ME 
   
- 
P values of pairwise survival time comparisons among the four classes defined in this work (upper 
table) and those defined in Verhaak et al. (lower table) were calculated from the log-rank test, 
showing greater differences in outcome among the revised classes. 
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Figure 2.16: Cox proportional hazard regression analysis with GBM subtypes as covariates, 
after adjusting age and Karnofsky performance scores (KPS). 
 
A) Hazard ratios (HR) and P-values (P) reported for Cox regression on 4 revised subtypes, 128 
GBM1 samples, with Proneural/G-CIMP+ as reference category. B) Same analysis on 4 TCGA 
subtypes, with Proneural as reference. C) Cox regression performed on 3 revised subtypes, 108 
GBM1 samples, excluding Proneural/G-CIMP+ and with Classical subtype as baseline. D) Same 
analysis on 3 TCGA subtypes, 98 GBM1 samples, excluding Proneural and with Classical as 
reference. 
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Figure 2.17: Inference of cell type composition of revised Non- Proneural classes.  
 
 
A–C, heatmaps of the cross-correlation coefficients between the reference dataset of 38 
samples of known neural cell types and samples in GBM1 (A), GBM2 (B), and Phillips' 
study (C). Colored segments in sidebars indicate sample assignments for 4 GBM classes or 
for the 4 neural cell types. D, distribution of the correlation coefficients between (1) AGP 
values of MES samples and (2) correlations with individual reference samples, for the 4 
neuronal cell types in Cahoy and colleagues (GEO accession GSE9956) and 2 datasets for 
microglia (GSE25289 and GSE16119).
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Figure 2.18: A proposed hierarchical classification scheme for GBM. 
 
Joint use of DNA and mRNA data, along with patient age and outcome data, separates 
Proneural/G-CIMPþ GBMs from Non-Proneural GBMs in the first step of the decision tree. The 2 
subsequent 2-way decisions define the 3 Non-Proneural classes, using features indicated in the 
diagram and the most informative transcripts in Supplementary Table 4. 
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Chapter 3. A general framework for analyzing tumor subclonality using 
DNA sequencing and SNP profiling data 
 
3.1 Introduction 
 
It have been recognized for nearly 40 years that cancer is a dynamic disease and its evolution 
follows a classical Darwinian process (Nowell, 1976, Fidler, 1978). After the proposal of the 
two-hit model of oncogenesis (Knudson, 1971), and especially after the discovery of multiple 
mutational milestones marking the linear progression from benign polyps to colorectal cancer 
(Fearon and Vogelstein, 1990, Vogelstein and Kinzler, 1993), it was briefly envisioned that 
cancer could be understood by simply finding the small number of events that act 
sequentially to drive step-wise clonal selection in most cancer cases. However, initial efforts 
to sequence most coding genes in tumor DNA revealed remarkable heterogeneity between 
tumors in each cancer type examined (Sjoblom et al., 2006, Wood et al., 2007, Jones et al., 
2008): typically, very few (< 10) genes are mutated in >10% of tumors, but many (40-80) are 
mutated in 1-5% of tumors. Further, heterogeneity in cancer could manifest on other levels: 
not just among different patients, but also among tumors of different grades or organ sites in 
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the same patient, as well as among different cells within a tumor (Greaves and Maley, 2012, 
Yates and Campbell, 2012). Heterogeneity at any of these levels could confound diagnosis 
and treatment, and underlie the inherent evasiveness of this disease. Most genomic analyses 
to date, notably those led by the Cancer Genome Atlas (TCGA) Research Network (The 
Cancer Genome Atlas Research Network, 2008, The Cancer Genome Atlas Research 
Network, 2011, The Cancer Genome Atlas Research Network, 2012b, The Cancer Genome 
Atlas Research Network, 2012a) and the International Cancer Genome Consortium (ICGC) 
(Alexandrov et al., 2013) have focused on inter-tumor heterogeneity. These studies analyze 
hundreds of tumors per cancer type, relying on bulk tissue samples, usually from one tumor 
per patient. The data were primarily interpreted by regarding each tumor as a single 
population of cells with uniform character. Despite the inherent limitation of this assumption, 
as shown by the widely reported tumor-normal mixing (Van Loo et al., 2010, Li et al., 2012, 
Popova et al., 2009), large-scale inter-tumor comparisons have led to important new insights 
into significantly mutated genes (The Cancer Genome Atlas Research Network, 2008, The 
Cancer Genome Atlas Research Network, 2011), recurrently perturbed pathways, mutation 
signatures (Lawrence et al., 2013, Alexandrov et al., 2013), tumor subtypes (Verhaak et al., 
2010a, Curtis et al., 2012), molecular predictors of outcome, and commonalities or 
distinctions among different cancer types (Garraway and Lander, 2013). However, these 
studies are not designed to adequately investigate intra-tumor heterogeneity. Ultimately, 
cancer genome evolution takes place at the single-cell level, and it is the cellular complexity 
and its dynamics that give rise to both intra- and inter-tumor heterogeneity. Currently, 
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cytogenetic methods are of low throughput and often cannot assure representative sampling. 
And the cost of single-cell sequencing (Navin et al., 2011, Shalek et al., 2013, Hou et al., 
2012, Xu et al., 2012) remains prohibitively expensive for all but the proof-of-concept studies. 
Under such constraints, many groups have surveyed intra-tumor heterogeneity by comparing 
multiple specimens from the same patient by longitudinal sampling or spatial sampling 
(mainly for solid tumors). Almost invariably, analyses of longitudinal samples have 
uncovered dramatic temporal changes of the cancer cell population that often correlate with 
disease progression, severity, and treatment resistance (Keats et al., 2012, Ley et al., 2010, 
Durinck et al., 2011, Landau et al., 2013). Similarly, multi-region comparisons revealed 
extensive genomic variability across different geographic sectors of the tumor (Gerlinger et 
al., 2012, Sottoriva et al., 2013), or between the primary and metastatic tumors (Yachida et 
al., 2010). These studies, while using samples collected with a higher spatial or temporal 
resolution than those in TCGA and ICGC, often still contain heterogeneous populations of 
cells (Yachida et al., 2010, Campbell et al., 2010, McFadden et al., 2014).  
Fortunately, when bulk tissue data describe the global average of multiple subpopulations of 
cells, it remains possible to statistically infer the number and genomic profile of such 
subpopulations. For example, when a sample is sequenced deeply, the somatic mutation 
frequencies sometimes cluster around a small number of distinct frequency "modes" 
(Nik-Zainal et al., 2012, Shah et al., 2012), suggesting that somatic mutations of similar 
frequencies may reside in the same population of cells and these cells may have descended 
from the same founder cell. For this reason, these mutations are said to belong to the same 
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"clone" or 'subclones", the latter referring to a clonal population of a relatively small cellular 
fraction. This inference task, essentially a deconvolution problem (or Blind Source 
Separation problem), presents many analytical challenges, since both the number of 
subclones and the genomic profile of each need to be estimated simultaneously, and somatic 
copy number alterations (sCNAs) and somatic single-nucleotide variants (SNVs) often reside 
in the same region yet have unknown phase or genealogical order. Currently available 
methods often need to invoke simplifying assumptions and often focus on a subset of the 
issues. For example, ABSOLUTE (Carter et al., 2012) uses sCNA data to estimate the global 
mixing ratio of aneuploid and euploid cells, but only under a tumor-normal, two-population 
assumption. When an sCNA or SNV is subclonal, ABSOLUTE makes the qualitative 
designation of "subclonal" without quantitatively estimating the clonality. Other types of 
compromises also accompany other methods, and I will defer the description of these 
limitations to the Discussion.  
In this work, I developed Clonal Heterogeneity Analysis Tool (CHAT) as a general 
framework for estimating the cellular frequencies of both sCNAs and SNVs. It is suitable for 
analyzing genomewide SNP genotyping and DNA sequencing data for tumor-normal pairs 
(Figure 3.1). CHAT begins by identifying regions of sCNA or by partitioning the genome 
into bins; and for each sCNA or bin, it estimates a local mixing ratio, called segmental 
aneuploid genome proportion (sAGP), between a euploid population and a single aneuploid 
population carrying the local CNA. The assumption of local two-way mixing does not imply 
there are only two cell populations globally. It is akin to the infinite-site model in population 
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genetics, stating that each locus experienced only one copy number alteration, without a 
second overriding alteration or the reversal to the original germline state (i.e., back mutation). 
After calculating sAGP for every sCNA in the tumor, CHAT estimates the cellular prevalence 
of SNVs (also called cancer cell fraction, or CCF, as in (Landau et al., 2013)) by adjusting 
the observed somatic allele frequency (SAF) from sequencing data according to the 
background copy number status, while also considering the sCNA clonality (sAGP), the 
relative order of occurrence between the SNV and its associated sCNA, and their cis- or 
trans- relationship. Through simulation I show that CHAT performs well in quantitatively 
recovering sAGP, CCF, and the underlying evolutionary scenario. I have applied CHAT to 
calculate sAGP for sCNAs, and CCF for SNVs, across 732 human breast tumor samples 
previously analyzed for inter-tumor diversity by TCGA (The Cancer Genome Atlas Research 
Network, 2012b) (Materials and Methods, Section 1), and I will present two vignettes of 
the results. Lastly, I discuss the model identifiability issue and compare CHAT with several 
similar methods. 
 
3.2 Data sources and sCNA identification 
 
From the Cancer Genome Atlas Data Portal 
(https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm) I downloaded (1) the Level-2 copy 
number data derived from the Affymetrix Genome-Wide Human SNP Array 6.0 (the 
“bi-allele” files) for 732 breast tumor DNA and their paired normal tissue DNA, and (2) the 
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VCF files for whole-exome sequencing data for a subset of 522 tumor-normal samples 
analyzed by TCGA (The Cancer Genome Atlas Research Network, 2012b). Of these, 445 
samples have both SNP array and DNA sequencing available. The SNP array data were 
downloaded on 12/12/2012, while the sequencing data were downloaded on 3/22/2013. Each 
VCF file contains variant information for both the tumor and the paired normal sample. The 
procedures for variant calling and identification of somatic variants can be found in the 
Online Supplementary Methods of (The Cancer Genome Atlas Research Network, 2012b). 
Counts for somatic and reference alleles of both tumor and normal samples were extracted 
for use in this study. 
In addition, I also downloaded the clinical annotation file, including the PAM50 designations 
of all the involved patients, on 12/17/2012.  
sAGP estimation (see below) can be performed on two types of user-selected spatial units: (1) 
genomic bins, predefined for each sample, typically consisting of 500 heterozygous markers 
in the germline DNA, (2) naturally observed sCNA segments, which I detect using the 
Circular Binary Segmentation (CBS) method (Olshen et al., 2004), as follows. I 
independently perform segmentation on the LRR and the folded BAF (absolute value of BAF 
minus 0.5) values, using default parameters in the R package DNAcopy [46], except that 
"minimal markers required" was set to 5. With CBS results for both LRR and BAF, the two 
sets of change points are merged as follows: if a BAF change point falls within 5 markers of 
an LRR change point, either upstream or downstream, it is removed, i.e., only the LRR 
breakpoint is kept, under the assumption that the two change points capture the same event, 
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but the BAF change point is less accurately placed due to the greater sparsity of heterozygous 
markers. 
After merging, the mean of LRR and folded BAF values are computed for each DNA 
segment (or the bin) in each sample, and used as input data for AGP and sAGP inference in 
the next step. For binned files, the bin length is on average 5.1Mb, and each sample has an 
average of 502 bins.  
 
3.3 Inference of segmental aneuploidy genome proportion 
 
3.3.1 Preview and hypothesis 
 
The simplest form of intra-tumor heterogeneity is normal cell "contamination", i.e., mixture 
of aneuploid cells in the tumor with euploid cells in the surrounding normal tissue, the latter 
carrying the full and balanced set of chromosomes found in germline DNA. In our previous 
work (Li et al., 2012), I developed a method to calculate the overall fraction of the tumor 
cells, termed Aneuploid Genomic Proportion (AGP), assuming the global mixing of a tumor 
and a normal population. In brief, allelic intensity data from SNP genotyping arrays (or DNA 
sequencing) provide copy number information of the two parental chromosomes: na and nb. 
Since na and nb are both integers, the logarithm of total intensity ratio, LRR ~ log(na+nb), and 
the observed B allele frequency, BAF = nb/(na+nb), adopt a finite number of discrete BAF- 
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LRR combinations for different CNAs, and reside in "canonical positions" in the BAF-LRR 
plot. When aneuploid cells are mixed with euploid cells, logR-BAF positions of tumor 
sCNAs "contract" towards the euploid position; and different mixing ratios result in different 
degrees of contraction. Based on this feature I can quantitatively estimate a genomewide 
tumor mixing ratio (Li et al., 2012). Our algorithm relies on the same type of information, 
and shares the same goal, as several other methods (e.g., ASCAT and ABSOLUTE) (Van Loo 
et al., 2010, Carter et al., 2012). All of these methods assume that there is a single tumor 
population.  
However, intra-tumor heterogeneity may also manifest as the co-existence of multiple tumor 
cell populations, each with its own copy number profile (Oesper et al., 2013). One example is 
shown in Figure 3.2A, where the sCNA segments marked in red show stronger contractions 
to the diploid track, for both LRR and BAF, than those marked in black; whereas those 
marked in green show even stronger contractions (Figure 3.2A-B). As mentioned above, 
since all the sCNAs in black have similar cellular fraction values, I may infer the existence of 
a subclone, defined as a subpopulation of cells carrying the same set of events (the "black" 
sCNAs) due to their descent from a common ancestor tumor cell. This is the most 
parsimonious explanation why different somatic events in the genome could reach the same 
frequency. Meanwhile, another set of events, such as those in red, show a different cellular 
fraction values, suggesting the existence of a second subclone. When a tumor contains K 
tumor populations as well as a normal population, the term "purity" is no longer adequate as 
it requires K+1 mixing ratios to fully describe the tumor composition. Since the sCNA 
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segments with different mixing ratios are interspersed, this regional variation of clonality 
along the genome motivates us to extend the earlier concept of genomewide AGP to a new, 
segment-specific measure: sAGP. 
The estimation of sAGP follows a similar approach as estimating the global AGP described 
in detail in Chapter 2, relying on the degree of contraction of each sCNA (Figure 3.2B). The 
method has the implicit assumption that at each sCNA the mixing involves only two 
populations, one of which is euploid. This assumption is largely satisfied when the somatic 
genome has experienced relatively sparse copy number changes, without global doubling or 
multiple rounds of complex local aberration. In effect, it assumes that, even though different 
sCNAs in the genome may belong to multiple populations of aneuploid cells, at each sCNA 
region there is only one aneuploid state that is mixed with the euploid state.  
 
3.3.2. sAGP inference 
 
As discussed in the main text, I jointly use BAF and LRR values to estimate sAGP for each 
sCNA, under the assumption of regional two-way mixing. The algorithm has three steps: 
i. Data pre-processing 
I assume the allele-specific copy number data are already in bi-allelic format, with the 
following fields in the input file: SNP ID, chromosome, position, A allele count, B allele 
count. To note, the allele counts may not be integer numbers, but could be real-numbered 
values from the original CEL file. SNP markers are first grouped into either bins or merged 
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sCNAs as described above. For each bin/sCNA, the median LRR and median folded BAF are 
calculated, and a segmentation file containing the above information for each segment is 
generated for each sample. 
In the initial normalization of SNP array data the absolute LRR values depend on the 
genomewide average ploidy, which is affected by the relative abundance of different copy 
number states in the genome. For example, in a tumor with a high fraction of cells undergone 
genome-wide doubling, the DNA segment located near the origin of the BAF-LRR plot are 
AABB, instead of the normal diploid configuration AB, and the global ploidy can be well 
above 2. The first step of sAGP estimation is therefore to ascertain the genotype of the 
sCNAs near the origin, following the procedures described in (Li et al., 2012). This allows 
unambiguous assignment (when possible) of copy number states for other sCNAs in the 
genome and the calculation of average ploidy. The deviation of BAF and LRR values of the 
baseline sCNAs from (x0,y0) is also used to quantify !"!"#! !!"#!!"!""!  for use in 
downstream analysis. 
ii. Estimate sAGP and absolute copy numbers 
The method I used to estimate sAGP is extended from our AGP inference algorithm. For an 
sCNA with copy number configuration (nb,nt), where nb is number of minor allele, and nt 
number of total alleles, when mixed with a balanced diploid population its theoretical BAF 
and LRR values are: !"# = !×!! + 1− !!×!! + 2× 1− ! − 0.5 + !! !"" = !"#! !×!! + 2× 1− ! − 1+ !!
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where p is sAGP, and x0, y0 are the coordinates of the (nt = 2, nb = 1) state. When p changes, 
the points (BAF, LRR) follow a family of curved lines on the BAF-LRR plot, starting from 
the origin (x0,y0). Each line corresponds to a unique combination of (nb, nt) and is called a 
canonical line; and each point on this line uniquely corresponds to an sAGP value. The main 
task is to assign each observed segment to a canonical line. Due to noise, an sCNA does not 
locate precisely on a canonical line. Thus for each sCNA, I scan all possible canonical lines 
to find the one satisfying the following criteria: 
(a) Distance to the closest canonical line ≤ 2* !"!"#! + !"!""! ; where sd2BAF, and sd2LRR are 
the estimated standard errors of BAF and LRR values.  
Sometimes multiple lines satisfy (a) and result in multiple sAGP and nt estimates. In such 
cases I apply 
(b) Choose !"#$ = !"#$%&(! = !! − 2×!"#$%& + !! − ! ); where p is sample-wide 
AGP and ploidy is the estimated global average ploidy from step ii). This criterion chooses 
the most probable canonical line as the one that results in a total copy number close to the 
genome-wide ploidy and an sAGP close to the global AGP.  
If no canonical line can be found in (2), i.e., the deviation is greater than the specified 2X 
scale of the standard deviations of BAF and LRR markers, I consider the sCNA not meeting 
the regional two-way mixing hypothesis, and its sAGP is assigned NA, its nb and nt are also 
treated as missing values in downstream analysis. 
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3.4 Macroscopic clonal structure 
 
3.4.1. Statistical modeling to infer macroscopic clonal structure 
 
As explained above, sAGP values can be calculated for either predefined genomic bins or 
identified sCNAs. In the per-bin analysis, the user can choose to filter out the non-sCNA bins 
or those with very small sAGP values, as true sCNAs with length shorter than the bin width 
tend to have reduced sAGP estimates due to the flanking euploid regions. In our analysis of 
the breast tumor data I applied two filtering steps. First, I considered bins with median folded 
BAF ≤ 0.04 and absolute median LRR ≤ 0.16 to be euploid, and assigned sAGP = 0. Second, 
before sAGP clustering, I removed bins with sAGP ≤ 0.05 to remove the contribution of the 
small sAGP values. At this step there is an average of n = 224 bins left per sample. The two 
models of interest are evaluated in a maximal likelihood framework and the biological 
relevance of these models will be discussed in the next section. 
For Model-1, the log likelihood has a uniform and a normal component: ! = ln( !!"#$% ! + (1− !)×!"#$(!! , !,!))!!!!               
where Y is the observed sAGP vector for a given sample, with components yi , i=1,2,…,n, 
where n is the number of DNA segments after filtering. A is a scalar so that A/range provides 
the scaled uniform distribution. µ and σ are the mean and standard deviation of the single 
peak in the model following the normal distribution. I constrain A and µ in the range (0, 1). 
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The parameters A, µ and σ are estimated using the maximum likelihood approach, 
implemented in customized scripts (part of CHAT) written in the R statistical programming 
language.  
Model-2 is fitted using a Dirichlet process Gaussian mixture model to infer the uncertain 
number of peaks and their relative abundances. The parameterization is as follows: !!|!! ,!!~!"#$ !! ,!! , ! = 1,2… ,!!!! ,!!|!~!!!|!,!!~! "(!!!)!!! = !"#$(!|!!,!/!!)!"#$% ℎ!"#(!|!!,!!)             !|!!, !!~Γ(!!, !!)!!!|!!, !!~Γ(!!/2, !!/2) 
Together these expressions describe a standard Dirichlet process mixture of normal model 
(Escobar and West, 1995). The implementation of the MCMC fitting is via R package 
DPpackage (Jara et al., 2011). There are different ways to specify the prior parameters for the 
normal mixture model. The baseline Gaussian distribution G0 relies on three prior parameters, 
µ1, σ and k0, where σ is explicitly modeled by an Inversed Wishart distribution with priors ν1 
and ψ1, and k0 follows a Gamma distribution. In practice, the hyperpriors, ν1, ψ1 and k0 can 
also be allowed to be random variables with a given prior distribution, and the model will 
have higher power to fit minor peaks in the data. In this work I used a conservative setting of 
prior parameters in terms of peak discovery sensitivity.  
Model-1 cannot be included as special case of Model-2, since when y is truly uniformly 
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distributed, Dirichlet process tends to call multiple peaks instead of one peak, even with 
current conservative prior setting. Our solution is to fit both models, then numerically 
compute the likelihood of each model, and use Bayesian Information Criterion (BIC) to 
select the better model. Model-1 has three free parameters: A, µ and σ, while Model-2 has 
seven: a0, b0, k0, ν1, ψ1, τ1 and τ2.  
 
3.4.2 Evolutionary interpretations of statistical models 
 
When there are a sufficient number of sCNAs or bins covered by sCNA, CHAT produces a 
sufficient number of sAGP values; and their distribution could inform the clonal structure of 
the tumor. First, for some tumors the sAGP histogram may contain a single peak, potentially 
accompanied by a flat (nearly uniform) background distribution (Model-1). This pattern can 
arise in a tumor containing a single clone that cover a large fraction of the sCNA-bearing 
portion of the genome, potentially with many other clones that cover much smaller portions 
of the genome and they are undiscernible in the sAGP spectrum. Second, for other tumors the 
histogram may follow a multi-modal distribution (Model-2), representing a number of 
distinct clones, each with a different sAGP, and each covering a comparable portion of the 
genome as to be recognizable in the histogram (an example is shown in Figure 3.2C).  
In all, there are three attributes of each sAGP histogram. (1) The number of the modes 
corresponds to the number of identifiable cell populations, each with a different sAGP value. 
(2) The positions of the modes denote the clonality of each cell population. The right-most 
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peak represents the population with the highest sAGP, and is typically called the dominant 
clone. The peaks to the left of the dominant clones are often called subclone 1, subclone 2, 
etc. (3) The areas under the peaks reflect the number of the sCNAs, or the regularly spaced 
bins, that belong to each cell population. Note that the right-most peak may not have the 
largest area, thus the dominant clone may not cover the widest portion of the genome.  
There are at least two ways to define the spatial unit in the sAGP analysis, and CHAT 
provides both options. The first is to calculate sAGP for regularly spaced bins, either for a 
fixed window width or for a fixed number of SNPs. The resulting sAGP values resemble the 
conventional genetic "markers"; and each tumor has a guaranteed number and density of such 
markers to construct the sAGP histogram, which is interpreted analogously to the allele 
frequency spectrum in population genetics studies. However, the bins don't match the 
naturally occurring sCNAs, which are highly variable in lengths, from tens of kb to entire 
chromosome arms. The sCNAs shorter than the bin width would have their true sAGP values 
"diluted" by flanking euploid segments in the same bin; whereas those longer than the bin 
width would generated a string of correlated sAGP values as the same sCNA is artificially 
divided into multiple adjacent bins, thus violating the assumption that sAGPs are independent. 
In the second option, CHAT will apply the identified sCNA as the naturally occurring spatial 
unit for sAGP calculation. While this has the advantage that all sAGPs are truly independent, 
there are two disadvantages. First, the longer (or shorter) sCNAs provide more (or less) 
precise estimates of sAGP, but this information of confidence was discarded, as it is also the 
case in (Oesper et al., 2013). Two, there will be large tumor-tumor variations in the number 
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of sCNAs, and some tumors may not have enough sCNAs to construct an informative 
histogram for estimating clonal composition. In short, the per-bin sAGPs (option 1) are 
derived from segments of similar length and have similar confidence intervals—they are 
identically distributed but not independent random variables. Conversely, the per-sCNA 
sAGPs (option 2) are independent, but are not identically distributed due to varying lengths. 
Rigorously speaking, neither is suited for analyzing macroscopic clonal architecture but can 
be applied in exploratory analysis, especially when there is no other data type such as the 
SNVs (see below). 
When the primary goal of using CHAT is to accurately estimate CCF, which relies on 
accurate sAGP values, the user is advised to calculate sAGP using sCNAs as the unit rather 
than the bins. Alternatively, when the primary goal is to explore clonal composition of a 
tumor, and if there are too few sCNAs and if most of them are very large, it is beneficial to 
increase the number of informative features, just as the detection of population stratification 
requires many ancestry informative markers. Here the user may choose regularly spaced bins 
to increase the number of available sAGPs. In fact, when sCNAs are few and large, it is more 
advisable to collect sequencing data; and if the mutation rate is high and/or the entire genome 
is sequenced (as opposed to small targeted regions), it is better to rely on the CCF histogram 
to estimate clonal structure. CCF distributions have the important advantage of meeting the 
condition of independent and identically distributed variable. Ultimately, the best approach is 
to integrate the sAGP and CCF distributions in estimating clonal structure.  
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3.5 Estimating cell fractions of somatic mutations 
 
3.5.1 Nature of the problem 
 
The next step of CHAT turns from estimating sAGP of sCNAs to estimating the frequency of 
cells carrying a specific mutation, i.e., single nucleotide variant (SNV) or small 
insertion/deletion (indel). Here the method addresses the case where the tumor DNA has been 
sequenced, either for the whole genome or for a targeted subset, such as the exome. The input 
of the analysis is the observed number of reads in the sequence data containing the mutation 
as well as those containing the un-mutated allele. The relative fraction of mutation-bearing 
reads is termed somatic allele frequency, or SAF. Following (Landau et al., 2013), I adopt 
CCF to denote the percentage of cells in the tumor sample carrying a specific somatic 
mutation. CCF is also termed cellular prevalence in (Roth et al., 2014). The goal is to use the 
observed SAF to estimate the unknown CCF. 
If the mutation resides in a normal diploid region, it typically occurs on the background of 
one of the two parental chromosomes, contributing to about half the sequence reads in this 
region. In this simple case, if the fraction of cells carrying the mutation is CCF, the expected 
fraction of sequence reads carrying the mutation, SAF, is simply a binomial variable with an 
expected value of CCF/2. I therefore can estimate CCF by SAF times 2. However, if the 
mutation resides in an sCNA, the relationship between CCF and SAF depends on the copy 
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number configuration: copy neutral loss-of-heterozygosity (CN-LOH), deletion, 
amplification, etc.) and its sAGP. Further, it also depends on the chromosomal background in 
which the mutation occurs. For example, in a region of heterozygous amplification where one 
of the chromosomes has been duplicated, if the mutation occurs on the duplicated 
chromosome, it will contribute twice the number of sequence reads than the case where it 
occurs on the un-duplicated chromosome. Lastly, if the mutation occurs after the duplication 
has happened and the duplication-bearing clone is undergoing expansion, only a subset of the 
duplication-bearing cells will carry the mutation, and the relative size of this subpopulation 
can be any value in 0-100% and will also affect the relationship between CCF and SAF. In 
this following I systematically consider these possible scenarios. I will make the 
parsimonious assumption that each mutation only occurred once in the evolutionary history 
of the tumor cell population, therefore I will ignore the possibility of recurrent mutation at the 
same position, or simultaneous emergence of the same mutation is different subpopulations 
of cells. I will treat SNVs and indels equivalently, and use the term "mutation" to denote 
both.  
        
3.5.2 Order-phase scenarios between sCNA and SNV 
 
For a somatic mutation revealed by tumor DNA sequencing, with an observed SAF value, I 
consider the task of estimating CCF if this mutation resides in an sCNA, and the sCNA has 
been discovered by either SNP array genotyping data (Van Loo et al., 2010, Carter et al., 
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2012) or by sequencing data (Nik-Zainal et al., 2012, Landau et al., 2013). I assume that the 
sCNA has been well characterized, such that I already know na and nb, the copy number of its 
major and minor alleles, respectively, i.e., na≥nb, and nt=na+nb is the total copy number. I also 
assume that its sAGP has been calculated using the method described above, and that SAF 
has been corrected for known sequencing errors and local biases (Lawrence et al., 2013, 
Cibulskis et al., 2013). Below I present the CCF estimation procedure for the case of 
heterozygous amplification (na = 2, nb = 1).  
When a mutation resides in an sCNA region, there are three main scenarios that describe the 
possible mutation-sCNA combinations in terms of their relative temporal order and the 
chromosomal background of the mutation (Figure 3.3): 
A) The mutation and sCNA emerged sequentially, with the mutation occurring first, and the 
sCNA occurring in a subset of mutation-bearing cells (Figure 3.3A). This led to the 
co-existence of three subpopulations: the original euploid mutation-free cells, with the 
population fraction of r0; cells carrying the mutation only, with a fraction of r1; and cells 
carrying both the mutation and the sCNA (r2). The last subpopulation has two alternative 
outcomes: A1: the duplication occurred on the mutation-bearing chromosome, and A2: the 
duplication occurred on the mutation-free chromosome. Intuitively, A1 will have higher SAF 
than A2 with the same (r0, r1, r2) fractions. 
B) Like A, the mutation and sCNA emerged sequentially; but unlike A, the sCNA occurred 
first, with the mutation occurring in a subset of sCNA-bearing cells (Figure 3.3B). Again I 
have three subpopulations: the original cells (r0), cells carrying only the sCNA (r1) and those 
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carrying both (r2). The last subpopulation has two alternatives: mutation occurring on one of 
the duplicated chromosome (B1) or the un-duplicated chromosome (B2).  
C) The mutation and sCNA emerged independently, i.e., appearing in non-overlapping 
populations of cells (Figure 3.3C). This also led to three subpopulations: the original cells 
(r0), cells carrying only the mutation (r1) and those carrying only the sCNA (r2). Note that I 
do not consider the fourth population that carries both the mutation and the sCNA. This 
outcome would require that the mutation occurred twice, once in the original cells and again 
in the sCNA-bearing cells. Or it requires the sCNA to occur twice. Under the Maximal 
Parsimonious assumption, recurrent appearance of the same mutation or the same sCNA is 
highly unlikely in the same tumor.  
The three scenarios outlined above covered all the possible mutation-sCNA combinations for 
one-copy amplification without recurrence. In Figure 3.4, I show that heterozygous deletion 
and CN-LOH involve similar scenarios A, B and C, and each leads to a similar set of three 
subpopulations as described by r0, r1, and r2, with r0 + r1 + r2 = 1. 
 
3.5.3 CCF as a function of sAGP, SAF and the underlying scenario 
 
When the (na, nb) configuration and evolutionary scenario is known, CCF can be estimated 
from (1) the pre-estimated sAGP of the sCNA (denoted p hereafter for simplicity) on which 
the mutation occurs, and (2) the observed allele frequency, SAF, of the somatic mutation 
(denoted f hereafter). In the following I derive the estimation procedure for heterozygous 
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duplication (na = 2, nb = 1) and formulize general expressions for all sCNA types.   
For amplification, in scenario A1, nt=3, the average total copy number !! = 2× 1− ! +
 !×! = 2+ !. The sAGP ! = !!. The SAF!! = (!! + 2!!) (2+ !). This led to the 
expression !! = ! ∗ 2+ ! − 2!!. Since !!" = !! + !!, I have !!"!! !,!! ,!! ,! = ! ∗ 2+ ! − !! = ! ∗ 2+ ! − ! (1) 
In A2, the situation is similar to A1 except that ! = (!! + !!) (2+ !). This led to !! = ! ∗ 2+ ! − !!, and !!"!! !,!! ,!! ,! = ! ∗ 2+ !  (2) 
In B1 and B2, the sAGP: ! = !! + !!. The SAF: ! = !! (2+ !). This led to !! = ! ∗2+ ! . Since !!" = !!, I have !!"! !,!! ,!! ,! = ! ∗ 2+ !  (3) 
In C1 and C2, the sAGP: ! = !!. The SAF: ! = !! (2+ !). This led to !! = ! ∗ 2+ ! . 
Since !!" = !!, I have !!"! !,!! ,!! ,! = ! ∗ 2+ !  (4) 
Note that equations (2), (3) and (4) are identical. Thus even if I do not know how to 
distinguish among scenarios A2, B and C, CCF still has the same dependency on sAGP and 
SAF, and can be estimated as long as I can recognize A1 and A2/B/C. Thus CCF 
identifiability is easier to achieve than scenario identifiability.  
In the general copy number configuration of na and nb, for scenarios A1, A2, B and C I have 
 !"!! !,!! ,!! ,! = !×! − !×!! + ! (5) !!"!! !,!! ,!! ,! = !!×! − !×!! + ! (6) 
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!!"!/! !,!! ,!! ,! = !!×! (7) 
with!! = 2× 1− ! + !!×! , is the averaged copy number at the locus.  
Thus, for a given pair of mutation and sCNA, with known SAF and sAGP values, once I 
know which scenario applies I can use Eqs. 1-7 to estimate CCF with a statistical approach as 
described in (Landau et al). The distribution of CCF is modeled as Binomial: Pr !!" = ! ∝ !"#$%" ! !,! !,!,Θ  
where S is the read count for the somatic allele and N is the total read depth. G(•) is expected 
value of SAF given CCF value x, sAGP value p, and lineage scenario Θ. G is simply obtained 
by reversing the CCF expressions described in the main text (Eqs. 1-7). I assume a uniform 
prior on x and the expectation and variance of CCF can be calculated as:  
!"# !!" = !"#$%(!|!,!)!"!!! !"#$%(!|!,!)!"!!  !"# !!" = !"#$%(!|!,!)!!!"!! !"#$%(!|!,!)!"!! − !"#(!!")! 
 
 
3.5.4 Joint distribution of (p, f) and scenario identifiability 
 
By definition, f and p are both bounded by (0,1). In any tumor, however, the possible range of 
f is constrained by p as well as by the sCNA type and the individual scenarios. For example, 
in scenario B of amplification, the mutation occurs in a subset of sCNA-bearing cells, thus f 
is always less than p (in this case it is always less than 0.5 p). As I show below, the attainable 
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joint distributions of (p, f) differs among different scenarios and, importantly, this offers the 
possibility to infer the most likely scenario for a given sCNA-mutation pair based on their (p, 
f) values. Further, some "zones" of the (p, f) space overlap with multiple scenarios, thus if the 
observed (p, f) fall into these zones, it is impossible to unambiguously identify the exact 
evolutionary scenarios. Even then, however, because different scenarios sometimes have the 
same expression of CCF as a function of (p, f), CCF may still be uniquely estimated. In the 
following I derive the scenario-dependent (p, f) joint distributions using heterozygous 
amplification as example.   
In A1, for a given p, the observed f of the mutation depends on the relative abundance of the 
r0 and r1 populations (Figure 3.3). When r0 = 0, the mutation occurred so early that all the 
diploid cells carry the mutation and belong to the r1 subpopulation. !! = 1− !, and f reaches 
its upper limit:  !!!! = !!!!!×!!! = !!!!!! (8) 
where !! = 2× 1− ! + 3×!, is the averaged total copy number for the sCNA. On the 
opposite end of the situation is r1 = 0, when the sCNA occurred immediately after the 
mutation such that none of the diploid cells carries the mutation. The lower limit of SAF is 
reached: !!!! = !!!!! (9) 
If I plot the possible (p, f) combinations in an p-f plot with f on the vertical axis, under 
scenario A1, the observed f is bounded by (2p/(2+p), (1+p)/(2+p)), where ! ∈ (0,1), forming 
the zone marked A1 in Figure 3.5A. 
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For A2, I similarly obtain: !!!! = !!!!!!! = !!!! (10) !!!! = !!!! (11) 
The observed f for A2 is bounded by (p/(2+p),1/(2+p)). 
For B, f depends on the relative abundance of the r1 and r2 populations, and the expressions 
are !!! = !!! = !!!! (12) !!! = 0 (13) 
The f is bounded by [0, p/(2+p)]. 
For C, the upper limit of f is reached when r0 = 0, !! = 1− !, and !!! = !!!!! = !!!!!! (14) !!! = 0 (15) 
The f is bounded by [0, (1-p)/(2+p)].  
The results for CN-LOH and deletion are shown in Figure 3.5B-C. 
The task is to use the observed somatic allele frequency (f) and sAGP value to determine the 
most likely scenario among the four scenarios described in the main text. I assume that f has 
a uniform prior, U(0,1), and I am interested in calculating the likelihood that the sSNV 
occurred before the sCNA, given the copy number configuration (nb, nt), known sAGP (ps), 
and the observed allele counts. Let f0 denote the true f. The probability of observing S count 
of the somatic allele is model by Binomial(f0, N) and the likelihood of each scenario is the 
probability of observing S given the scenario is true, integrated over all the possible values of 
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f0: !! = ! !"#$%&'(!! !,!! ,!! ,!, ! = Pr(!,!,!! ,!! ,!)
= Pr!(!|!!,!)×Pr!(! = !!|!,!,!! ,!!) d!! = Pr!(!|!!,!)!!!!!!!!!  
where X is A1, A2, B or C, representing one of the four scenarios, and fXh, fXl are computed 
according to Eqs. 8-15. I then compute the summation of pX: ! = !!! + !!! + !! + !!  
and normalize each likelihood using P: !! = !!!  
I calculate the normalized probability for each scenario, as well as all the possible 
combinations of multiple scenarios. For example, the probability of either scenario A1 or C is !!!! = !!! + !! . There are in total 24 - 1=15 possible combinations. If the normalized 
probability of any of the four scenarios is greater than 0.95, the SNV is assigned to the 
corresponding scenario. If none of the single-scenario probability exceeds 0.95, I ask if any 
of the six two-scenario combinations have probability > 0.95. If this step fails, I next examine 
the four possible three-scenario combinations, and so forth. If all the above steps fail, I report 
the SNV scenario A1/A2/B/C, and no unique CCF can be estimated in this case.  
To state the full estimation procedure: when !,!! ,!! ,!  are known for a mutation-sCNA 
pair, if the (p, f) combination identifies a unique scenario according to Figure 3.5, CCF is 
calculated using Eqs. 3-7. If the (p, f) combination overlaps with multiple scenarios, CCF 
may still be calculated if the expressions are the same across the undistinguishable scenarios. 
Lastly, when the CCF expressions are different among the applicable scenarios, CCF cannot 
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be uniquely determined, however its 2 or more possible values can still be obtained as valid 
alternatives. In implementation, as SAF is a random variable with confidence level depending 
on read depth, there is always uncertainty as to which scenario the observed (p, f) belongs.  
 
3.6 Validation and performance 
 
3.6.1 Performance of sAGP inference 
 
I first tested the performance of CHAT in sAGP estimation. I simulated LRR and BAF values 
for a series of sCNA datasets with two aneuploid tumor populations, which are mixed with 
the euploid population. The first population is the dominant clone, with an assigned sAGP 
value of pdom ~ [0.1,0.2,…,1.0]. The second population is a minor clone, with an assigned 
sAGP value of psub ~ [0,0.1,…pdom-0.1]. The fraction of the euploid population is 1- pdom - 
psub. In all, there are 55 pdom - psub combinations; and for each, I simulated 200 euploid 
segments (nb = 1,nt = 2, sAGP = 0) and 200 sCNA segments, of which 133 (about 2/3) were 
assigned to the dominant clone (sAGP = pdom), and the remaining 67 were assigned to the 
minor clone (sAGP = psub). Within each clone, the sCNAs were assigned to one of four copy 
number configurations with the following ratios: 2/7 for deletion (nb=0,nt=1), 2/7 for 
CN-LOH (nb=0,nt=2), 2/7 for amplification (nb=1,nt=3) and 1/7 for balanced doubling 
(nb=2,nt=4). The BAF and LRR values were generated using the assigned sAGP and copy 
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number configuration with the following formula: !"# = 0.5− !×!!!!!!!! + !"#$%&(0,!!"#)    (16)    !"" = !"#!!! − 1+ !"#$%&(0,!!"")     (17)   
where p stands for sAGP, and nt is the averaged total copy number for the local segment: 2 
(1-p) + nt × p. σBAF and σLRR are the standard deviation values of the per-segment BAF and 
LRR, respectively. For the Affymetrix 6.0 platform, the per-SNP standard deviation for BAF 
is about 0.05, and for LRR is about 0.25 (our observation). Thus the choice of σBAF=0.01 and 
σLRR=0.04 is equivalent to an sCNA of approximately 36 SNP markers. For a 1 million SNP 
platform, 36 SNPs cover approximately 110 kb, therefore ours are conservative choices for 
sCNAs 110 kb or longer, profiled by 1 million SNPs or more. 
After generating the BAF and LRR values using Eqs. 16-17 for the 400 segments for each of 
the 55 pdom - psub combinations, I applied CHAT to estimate sAGP, nb, and nt for each 
simulated segment, and evaluated performance by reporting (1) percent of cases of mistaken 
estimation of sCNA configuration (error in either nb or nt) (Figure 3.6A, top row) for 
dominant and minor clonal events, and (2) the median absolute deviation of the estimated 
sAGPs from the assigned pdom or psub for the dominant and minor clones, for either the 
segments with correct (nt, nb) identification (Figure 3.6A, middle row), or all segments 
(Figure 3.6A, bottom row). With all of these performance metrics, the errors are the largest 
when with the clonal or subclonal sAGPs are small. The overall errors are small in most 
situations, suggesting that CHAT worked well in recovering the sAGP, nb, and nt values. 
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3.6.2 Performance of CCF prediction 
 
Of the 55 pdom - psum combinations described above I selectively tested CCF inference in four 
cases: pdom - psum ~ (0.9,0.8), (0.9,0.4), (0.5,0.3), and (0.3,0.1). For each case, I simulated 
4,000 SNVs, of which ~2,000 fall in the 200 euploid segments, and the other 2,000 fall in the 
200 sCNA regions, with sAGP-nb-nt assignment as described above. In effect I assume that 
the euploid intervals account for 50% of the genome. For all downstream inferences, I used 
the sAGP, nb and nt estimated by CHAT. If the SNV falls in a euploid region, the assigned 
SAF was randomly drawn from uniform(0,0.5) and the assigned CCF = SAF*2. If it falls in 
an aneuploid region, I randomly choose the lineage scenario from (A1, A2, B, C) according to 
the local copy number a configuration. If the sCNA is a CN-LOH or balanced doubling 
region, I limit the scenarios to (A1, B, C). The upper and lower limits of the chosen scenario 
were determined using Eqs.8-15. SAF values were then randomly drawn from uniform(fl, fh), 
where fl and fh were the lower and upper limits. "Known" CCF values were computed using 
Eqs. 1-6 in the main text. Lastly, I simulated the allele counts in two steps. For a mean read 
depth k, the actual coverage at a given SNV, N, was sampled from N ~ Poisson(k). When N 
and f were assigned, the count of the somatic mutation allele was sampled from Binomial(f, 
N). Based on the estimated sAGP, copy number configuration and the simulated somatic 
allele counts I used CHAT to estimate CCF. The estimated values were compared with the 
"known" CCF in Figure 3.6B for both k = 50 and k = 100. 
In all eight cases (four pdom – psub combinations and two k values) the Spearman's rank 
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correlation coefficient between the known and estimated CCF values ranged in 0.946- 0.97, 
indicating that CHAT makes accuracy CCF inference. To compare performance among SNVs 
in different sub-categories, I separated those falling in euploid regions from those in sCNAs, 
and for the latter, separated those in the major and minor subclone events, and those in 
different copy number status. As shown in Figure 3.6C, the error rates are similar across 
these sub-categories, not affected by dominant/minor clonal events or different sCNA types.  
 
3.6.3 Computational requirements 
 
I estimated the time and memory requirement of CHAT using the TCGA dataset for breast 
tumors. The time estimate below is based on allele-specific copy number data with 850K 
SNPs for tumor-normal pairs and whole-exome sequencing data with ~30X average coverage. 
For binned segmentation (~500 heterozygous SNPs per bin), it takes 2 minutes to complete 
the sAGP and CCF estimation for one tumor/normal pair, and it requires about 10 MB 
memory. For detected sCNAs, the computational time increases to an average of 12 minutes 
per sample pair. The above estimation is based on running R scripts with a single processor 
(AMD Opteron 6136, 2.4GHz with 4G RAM) and counting input file reading time. In CHAT, 
the user can apply the R package parallel to enable multi-thread processing. This allows the 
use of as many processors as available. On our server (32 AMD Opteron 6136 CPUs and 
128G RAM), our test run used 14 processors on average, and it took 10 hrs (140 CPU-hours) 
to complete the CBS segmentation, sAGP estimation for 732 breast tumor-normal samples 
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and CCF estimation for 445 samples with downloaded VCF files. 
 
3.7 Application to human breast cancer 
 
I applied CHAT to estimate sAGP for sCNAs identified using Affymetrix 6.0 single 
nucleotide polymorphism (SNP) array data for tumor and germline DNA samples from 732 
breast cancer patients (The Cancer Genome Atlas Research Network, 2012b). Of these, 445 
also have whole-exome sequencing data available, and I estimated CCF for SNVs. 
 
3.7.1 sAGP distribution 
 
I detected sCNAs using circular binary segmentation (Olshen et al., 2004) of LRR and BAF 
data (Li et al., 2012), resulting in the identification of an average of 261 sCNAs per tumor 
(range: 1 - 3,537). The median size of all sCNAs is 1.7 Mb (range 2.5 Kb – 245 Mb). On 
average, each tumor carries 125 sCNAs larger than 5 Mb, a size corresponding to ~1,500 
SNP markers in the 850K SNP array. Given this sCNA size range, I re-calculated sAGP for 
genomic bins containing 500 heterozygous SNPs in the germline DNA, a bin size that is 
approximately 5 Mb, resulting in 502 bins per sample (range: 404 – 794) and constructed the 
sAGP histogram for every tumor. 87 tumors (12%) had sCNAs for <50 bins, too few for 
analyzing the sAGP distribution patterns. For the remaining 645 tumors I fit the sCNAs 
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distribution to either a uni-modal + uniform distribution or a multi-modal distribution using 
methods described above. In the example in Figure 3.2C, a three-mode distribution provides 
the best fit, with sAGP peaks around 0.5, 0.4, and 0.2. The highest peak corresponds to the 
black-colored sCNAs in Figure 3.2A-B, while the second and third peaks correspond to the 
red and green-colored sCNAs, respectively. In total I observed 392 samples (61%) with best 
fit by the multi-modal distribution, while 253 (39%) follow the uni-model + uniform 
distribution. This shows that a majority of the breast tumors analyzed by TCGA contain more 
than one recognizable aneuploid population, suggesting that the co-existence of more than 
one subclone is very common. 
 
3.7.2 sAGP-CCF joint distribution for known cancer genes 
 
The 445 tumors with both SNP array and sequencing data have an average of 311 somatic 
mutations per tumor with CCF values (range: from 15 to 4235, after counting the 8.8% loss 
due to sCNAs with un-estimable sAGP). While 48% of these mutations fall into a zone with 
overlapping scenarios, 93% of them have a unique mathematical expression and can produce 
a valid CCF estimate (Figure 3.7). The remaining 7% are assigned missing CCF values due 
to scenarios with conflicting CCF estimates.  
The calculation of sAGP for most sCNAs and CCF for most SNVs makes it possible to 
examine the joint distribution of clonality for these two types of genome aberrations. A "CCF 
vs. sAGP" plot can be created for all copy number and mutation events in a single tumor, or 
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for events affecting a single gene of interest across many tumors. For a given gene, if a 
sample does not have any somatic mutation in the gene, I assign CCF = 0. Likewise if the 
copy number of the gene is normal, I assign sAGP = 0. Figure 3.8A shows a heatmap 
depicting the density of CCF and sAGP joint distribution for all events in a hypothetical 
sample (or for a hypothetical gene across all samples). In this two-dimension space, the "hot" 
peak near the origin (0,0) is typical for most genes, affected by neither somatic mutation nor 
sCNA. The peak in the upper left (near the sAGP-axis) contains genes with highly clonal 
CNAs but carrying either no mutation or mutations of low clonality. A plausible 
interpretation is that for some of these genes, sCNA is a possible driver event. Similarly, the 
peak at the lower left (near the CCF-axis) contains genes with highly clonal somatic 
mutations and low-clonality sCNAs. Lastly, genes in the upper-right peak have both high 
sAGP and high CCF values, suggesting that both copy number changes and somatic 
mutations may have occurred at very early stages of tumor development, and their joint 
appearance may be necessary to act as a driver event.  
Figure 3.8B allows close inspection of relative clonality between sCNA and mutations for 
four genes known to be related to breast cancer (The Cancer Genome Atlas Research 
Network, 2012b): TP53, PIK3CA and GATA3, which occurred in > 10% of analyzed breast 
tumors, and MAP3K1, which had mutations enriched in the luminal A subtype. For TP53, 
there are two noticeable high-density "zones" in the heatmap: one along the sAGP-axis, the 
other at the upper right, indicating two groups of tumor samples: TP53 CNA-only and TP53 
CNA/mutation, respectively. This pattern, when stratified by the four PAM50 subtypes (The 
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Cancer Genome Atlas Research Network, 2012b, Parker et al., 2009) (Figure 3.8C), shows 
that the TP53 CNA/mutation group is enriched in the Basal and HER2 subtypes (accounting 
for 72 of 94 Basal and HER2 tumors), whereas the TP53 CNA-only group is enriched in the 
Luminal-A (94 of 105), and to a lesser degree, the Luminal-B subtypes (44 of 67). In 
comparison, the other three genes have not only the CNA-only and CNA/mutation groups, 
but also a third, mutation-only group near the CCF-axis. Figure 3.5D shows that for PIK3CA, 
the mutation-only group occurs almost exclusively in the Luminal-A and –B subtypes. 
The CCF - sAGP plot can also be used to compare the clonality distribution between a pair of 
genes. In Figure 3.9, TP53 and PIK3CA are shown in red and blue symbols, respectively, 
with the lines linking the two genes for the same samples. There are three notable patterns of 
TP53 - PIK3CA clonality. First, samples marked by the black lines have both sCNA and 
mutation in TP53 but no aberration in PIK3CA. Second, samples marked by the red and green 
lines tend to have sCNA for both TP53 and PIK3CA and at comparable sAGP, but only 
mutation in TP53 (red lines) or PIK3CA (green). Third, samples marked by the blue lines had 
high clonality for TP53 CNA, but not its mutation, and high clonality for PIK3CA mutation, 
but not its CNA, suggesting co-occurrence of aberrations of these two genes but involving 
different variant types. These patterns are subtype-specific: Pattern 1 is enriched in the Basal 
subtype (OR=4.6 compared to the other three subtypes, P=0.0001 by Fisher’s exact test, for 
red; OR=1.2, P=0.67, for green), so is Pattern 2 (OR=5.3, P=6.4e-8,). Most remarkably, 
Pattern 3 is almost exclusively found in the Luminal A subtype (OR=56, P=4.4e-9). 
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3.8 Improvements of CHAT comparing with previous methods 
 
While CHAT does not solve all the issues facing the cancer genome deconvolution problem, 
it attempts to overcome several important compromises or simplifying assumptions that 
underlie other methods. First, oncoSNP (Yau et al., 2010) and ThetA (Oesper et al., 2013) are 
designed to estimate sCNA clonality, but they do not address the clonality of somatic 
mutations. Second, Ding et al. (Ding et al., 2012) used kernel density estimation method to 
characterize somatic mutations, but only focused on those in the euploid regions of genome, 
staying clear of the complicated relationship between SNV and sCNAs. Third, ABSOLUTE 
infers clonality for both sCNA and mutations but only designate subclonal events, stopping 
short of quantitative estimation. This method was extended in Landau et al. (Landau et al., 
2013) to estimate CCF for somatic mutations even if they are subclonal, but the algorithm 
only considers the case where sCNA occurred before SNV, equivalent to our scenario B 
(Figure 3.3 and 4), and further assumes that the copy number was altered by only one in the 
sCNA. In this regard, CHAT considers a wider array of possible scenarios. Fourth, EXPANDS 
(Andor et al., 2014)works with next-generation sequencing data and jointly estimates the 
absolute DNA copy number, clonality of somatic mutations, and that of sCNAs. However, 
this method only considers scenario A1 and without the intermediate r1 population. In effect, 
it assumes that the mutation and sCNA occur at the same instance and are in phase. Fifth, 
PyClone (Roth et al., 2014) infers clonality of somatic mutations and performs phylogenetic 
analysis. It receives as input the integer copy number profiles estimated from other methods, 
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but only considers scenarios A and B, disregarding the possibility of a branching lineage. 
Furthermore, for scenario A, it assumes co-occurrence of SNV and sCNA, thus also ignoring 
the r1 population. In short, the first key contribution of CHAT is in providing a general 
mathematical framework that enumerates the complete set of scenarios covering the possible 
order and phase of the sCNA and the single-base changes. Like many of the previous 
methods, CHAT has its own limitations, primarily in being unable to resolve extremely 
complex events such as three-way mixing or above. It models two-population mixing at each 
genomic region (a gene, an sCNA, or a bin) and works best when the tumor has not 
experienced extensive and repeated copy number alterationa. In the TCGA breast tumor 
dataset I found that 9.3% of sCNAs do not follow the regional two-way mixing model and do 
not allow sAGP estimation. For the other, permissible sCNAs, CHAT can proceed, and is 
able to infer the coexistence of two or more subpopulations by analyzing the distribution of 
sAGP or CCF values. I wish to re-emphasize that while CHAT invokes two-way mixing for 
each individual genomic region, it is not limited to infer the presence of only two populations 
of cells. Globally, the number of peaks in the sAGP or CCF distribution has no restriction, 
and can be very high when the signal-to-noise ratio is improved, such as with ultra-deep 
sequencing data (e.g., Shah et al., 2012).  
 
3.9 Summary 
 
In this work, I developed a computational framework to estimate clonality for both sCNAs 
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and SNVs. It is built on previous methods both by us (Li et al., 2012) and by others. It lifted 
several unrealistic assumptions in previous methods and clarified some ambiguous concepts. 
A second contribution of CHAT is in systematically assessing the input data combinations 
that lead to "unidentifiable zones", in which the CCF, or "scenarios" (i.e., the evolutionary 
order and phase of the sCNA and SNV), cannot be resolved even with perfect data. I found 
that in many situations, even if the evolution scenario is undetermined, CCF values can still 
be estimated. The ability to objectively evaluate the power of inference in any given dataset 
is an important part of method development.  
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Figure 3.1: Schematic pipeline of tumor subclonality using CHAT. 
 
DNA extracted from tumor mass and paired normal sample were sent for both allele-specific copy 
number profiling and DNA sequencing. CHAT provides two alternative ways to define the spatial 
units for sAGP analysis: by natural DNA segmentation (CBS) or fixed number of heterozygous BAF 
marker bin. Inference on CCF and lineage scenarios relies on two sources of input: sAGP estimations 
with absolute copy number configuration, and the allele counts from the sequencing data for each 
somatic mutations. A wide spectrum of downstream analysis are available with the rich information 
inferred by CHAT, including the macroscopic subclonal structures of tumor populations, joint 
analyses of sAGP and CCF for each cancer gene or for each tumor sample, interactions between 
sAGP and CCF values for different tumor subtypes, etc. 
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Figure 3.2: Evolution model inference for primary tumor sample TCGA-A1-A0SD. 
 
A: Scatter plot for binned segments of BAF and LRR showing different levels of contraction even 
within same type of sCNA. B: BAF-LRR plot for the same sample. C: MCMC fitting of sAGP 
distribution reveals three distinct modes, peaking around 0.5,0.4 and 0.2. The segments in each peak 
are colored black (0.5), red (0.4) and green (0.2) in A and B. Segments sharing similar sAGP values 
and clustered within same peak are likely carried by a same group of cells, namely subclone. In C, 
sAGP distribution is indicated by light blue histogram, while the DP fitted density is shown in dark 
green line.
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Figure 3.3: Paradigms for lineage scenarios A to C for heterozygous amplification. 
 
In scenarioA1, three population of cells are modeled: euploid cell without mutation, euploid cell with 
mutation  (hexagon star) and aneuploid cell with mutation. When mutation occurred before 
amplification of the green allele, both alleles carry that mutation. r0,r1 and r2 are the fraction of each of 
the corresponding cell population (same is true to other scenarios) and sum up to 1. A2 is similar to 
A1 , except that the mutation occurred on the unamplified allele (orange). For scenario B, there are 
two equally possible cases: mutation occurred on the amplified (B1) or unamplified (B2) allele. The 
formulas to compute CCF for either case are identical. For scenario C, where mutation and sCNA 
independently occurred on difference lineages, there are also two possible cases: mutation occurred 
on maternal(C1) or paternal(C2) allele in the euploid cells, and the formulas for either case are also 
identical.  Blue arrow: mutation occurrence; red arrow: sCNA occurrence.
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Figure 3.4: Lineage scenarios for CN-LOH (A) and heterozygous deletion (B). 
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Figure 3.5: Identifiable zones 
 
Identifiable zones for CCF estimation in case of hemizygous amplification (A), cn-LOH (B) and 
hemizygous deletion (C), for four temporal scenarios described in the main text.Somatic mutations 
from 201 diploid tumor samples with percent on point (PoP) greater than 0.05 (a measure of 
prediction accuracy from (Li et al., 2012)) were selected for the analyses. Lineage scenarios are 
bordered with different colors as displayed in the legend. Variants with coverage lower than 20 or 
SAF smaller than 0.05 were discarded. 3382 mutations from hemizygous amplification, 2008 from 
cn-LOH and 4662 from hemizygous deletion regions were plotted respectively for each sCNA type 
against the corresponding sAGP values of the DNA segments. Theoretical boundaries of SAF values 
in each scenario from Eq(8)-(15) were overlaid on the plot to display the unique and unidentifiable 
zones. Each lineage scenario is bordered by a different color, as indicated in the legend of A. Text 
boxes with black color labels the regions on the plot their attributes. Single letter in the box indicates 
that the region is uniquely assigned to that scenario, while multiple letters indicate the region is 
indistinguishable between the corresponding scenarios. Regions without text box of capital letters are 
theoretically impossible, and our results show that the distribution of real data agrees well with most 
of these regions. CCF of somatic mutations in light green areas can be uniquely estimated, while not 
in gray zones due to unidentifiable issue.  
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Figure 3.6: In silico validation of CHAT performances. 
 
 
A. Performance of sAGP inferences. Upper row: percent of error in estimated nb or nt, for the 
dominant (left) and subclonal sCNAs (right), as described in Materials and Methods, Sec8on 7a. 
Middle row: the median absolute difference (MAD) between predicted and simulated sAGP values 
for sCNAs with correctly identified (nb, nt), or for all sCNAs (Bottom row). The psub=0 row of the 
lower-right and middle-right panels had zero error because when psub=0 there is only one clone in the 
tumor population and all subclonal sCNA segments have correctly estimated sAGP = 0. B. 
Performance of CCF inference. Shown are scatter plot of simulated and estimated CCF for four pdom – 
psub cases and two coverage values: Cov=50 (upper panels) and 100 (lower panels). C. Comparison of 
CCF inference accuracy among different SNV categories: euploid vs. aneuploidy regions; and in the 
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latter, between the dominant and the minor clones. Lastly, SNVs were divided by sCNA types. The 
tested case has the following parameter settings: pdom=0.9, psub=0.6, coverage=50, number of SNV 
sampled=4,000, number of sCNA sampled=200. 
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Figure 3.7: Distribution of the percentage of somatic mutations associated with a unique 
scenario (black) and the additional percentage with unique CCF estimates (red). From 
left to right are the results for 445 breast tumor samples, ordered by the 
unique-scenario percentage. 
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Figure 3.8: Single gene summary for sAGP-CCF joint distribution for 445 BRCA 
samples. 
 
A: A made-up example showing characteristic density peaks on the heatmap. B: Realization of A) for 
four breast cancer related genes: TP53, PIK3CA, GATA3 and MAP3K1. C-D: Scatter plot of 
sAGP-CCF for two genes, TP53 and PIK3CA, stratified by PM50 BRCA subtypes. sAGP values for 
euploid regions are added a small random noise for visualization purpose. Numbers after gene 
symbols in B are the number of samples with both sAGP and CCF estimable for the gene across 445 
tumors. For each subtype, in C and D, the number indicates the same. To note, I excluded 7 
Normal-like samples due to low count.
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Figure 3.9: Two-gene CCF-sAGP comparison for TP53 and PIK3CA across 445 
samples and stratified by PM50 gene expression subtypes. 
 
Interactions between CCF and sAGP for TP53 are characterized by interacting types: 1. correlated 
CCF and sAGP value of TP53, mostly enriched in Basal subtype (dashed black line); 2. correlated 
sAGP values for TP53 and PIK3CA (dashed red line); 3. correlated TP53 sAGP and PIK3CA CCF, 
enriched in LumA subtype (dashed blue line); 4. correlated TP53 sAGP and PIK3CA sAGP, with 
PIK3CA somatic mutations (dark green line). 
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Chapter 4. STRfinder: A general tool for detecting and genotyping short 
tandem repeat variation using paired-end next-generation sequencing data 
 
4.1 Introduction 
 
Short tandem repeat (STR) in the genome refers to the consecutive occurrence of the same 2-6 DNA 
base pairs many times in a row. Its allelic variation represents an important class of genetic variation 
in many genome systems, including the human genome and the genomes of many cancers. STR 
variants can affect protein structure or gene regulation (Gemayel et al., 2010, Kozlowski et al., 2010, 
Bolton et al., 2013, Sawaya et al., 2013), and have been implicated in several inherited diseases in 
humans (Mirkin, 2007). Meanwhile, cancer researchers have realized since decades ago that the 
instability in STR alleles may be associated with certain cancers (Wooster et al., 1994), such as 
colorectal cancer (Markowitz et al., 1995, Parsons et al., 1995, Popat et al., 2005). Further, CAG 
repeat polymorphism in androgen receptor (AR) is implicated prostate cancer (Nelson and Witte, 
2002) and male breast cancer (MacLean et al., 2004). Highly polymorphic STR loci have also been 
used as DNA fingerprinting markers for forensic identification purposes (Keats et al., 2012). In 
medical genetics, STRs in coding regions sometimes undergo abnormal expansions and the alleles 
with high numbers of repeat units can increase the risk of certain diseases. There have been many well 
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documented developmental or neuro-degenerative disorders that are caused by STR expansions 
(Gatchel and Zoghbi, 2005), including the Huntington’s disease (Walker, 2007), Fragile-X syndrome 
(Pearson et al., 2005), Machado-Joseph disease (MJD) (Paulson, 2012), and some types of ataxia (Orr 
et al., 1993, Pulst et al., 1996, Campuzano et al., 1996).  
Several methods have been developed to annotate STR location/length (Benson, 1999, Smit, 
1996-2004) in well-assembled sequences, such as the human reference genome. However, a reference 
genome represents a consensus sequence, and does not capture STR variations in a population. In this 
regard, we still lack robust methods for detecting STR variation and genotyping individual samples.  
Experimentally, the detection of STR remains error-prone and difficult to scale up. Traditional Sanger 
sequencing still serves as a gold standard, but it cannot be efficiently applied to genome-wide scans or 
in larger sample cohorts. In recently years, with the arrival of the next-generation sequencing (NGS) 
technologies, it becomes feasible to collect DNA sequence data over a large sample and sometimes in 
exome-wide or genome-wide fashion. Specifically for the short-read NGS data, two methods, lobSTR 
(Gymrek et al., 2012) and RepeatSeq (Highnam et al., 2013), have been recently developed to detect 
STR variation. Both methods rely on an existing database of known STR sites, usually created by 
reference genome annotation methods, such as the Tandem Repeats Finder (Benson, 1999). However, 
both methods are limited by only considering alleles that are shorter than the read length. For the 
Illumina HiSeq system, the typical read length is 101 nt, which covers approximately 33 repeats for a 
tri-nucleotide STR. Many disease-associated alleles are longer than 101 nt. For example, in 
Huntington’s disease, the normal number of CAG repeats in HTT is <26, which can be covered by a 
read; however, the disease-associated expanded allele can reach 40 repeats, or 120 nt, thus cannot be 
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spanned by an Illumina read and cannot be detected by lobSTR or RepeatSeq. A similar situation 
occurs for spinocerebellar ataxia, dentatorubropallidoluysian atropy, myotonic distropy and other 
developmental disorders (Gatchel and Zoghbi, 2005). 
Many medical resequencing studies adopt paired-end (PE) sequencing, in which both ends of 
randomly generated DNA fragments are sequenced. Typically the fragments are 300-500 nt in length, 
and the 101-nt sequences at both ends were determined. When an individual read fails to span a long 
STR allele, the read pair may still flank the STR region, thus providing additional information that 
can be used to detect and genotype STR alleles longer than the read length. Currently no method is 
available to fully extract the available information in PE data to characterize STR variation. In this 
chapter I describe the first algorithm to perform this task. My algorithm, STRfinder, is designed to 
detect and, when possible, estimate the length of both STR alleles using paired end next generation 
sequencing data. STRfinder does not require any prior knowledge of STR locations, and finds STR 
loci based on genomic distribution patterns of mapped reads or read pairs containing repetitive 
portions. Our algorithm is capable of finding novel STR regions that have not been documented in the 
human genome. STRfinder is implemented in Python and is available at 
https://sourceforge.net/projects/strfinder/. 
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4.2 STRfinder pipeline 
 
4.2.1 Scope of STRfinder 
 
In this paper, I constrain our discussion to simple repeats. This is referring to repeat region with only 
one type of unit, no other repeat regions at the upper or lower 300bp regions. Also the region must 
contain fewer than or equal to in total 2 mismatches, gaps or sequencing errors. The repeat allele with 
its flanking regions must appear in the genome only once. Regions violating the above standards are 
referred to as complex regions. Furthermore, in our context, the length of a repeating unit α takes 
values from 2 to 6, and the length of a repeat region has minimum number of repeat 8-α. For example, 
for tri-nucleotide repeat, I require at least 5 consecutive units to be called as a repetitive region.  
 
4.2.2 Definition of STR allele types 
Let D=N×α denote the length of STR allele, where α is length of repeating unit and N the number of 
repeats. Let Lr denote read length, and for data generated from Illumina HiSeq machines, it is a 
non-random parameter. There are in 2 possible ranges that D falls in regarding Lr:  
A 0≤D≤Lr-δ 
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B Lr-δ<D 
δ is the minimum length of bases required for an aligner to map a read allowing soft clipping. For 
example, BWA requires at least 20 bases to properly map a read to the reference genome. In a region 
with repeats, δ is the minimum length of flanking regions. In practice, I allow δ to be user-defined, 
with default 20, following BWA convention.  
 
4.2.3 Positional notations of reads and read pair types (RPTs) 
Consider an STR allele with known start and end coordinates on the reference genome. I introduce 
positional notations for reads. In total, there are four types of reads in the region of an STR allele: at 
junction, inside the allele, outside the allele or traverse the allele. Let j denote junction read which 
contains repeats at either tail, o denote read located outside the STR region, i denote read inside STR 
region so that containing pure repeats and t denote traversal reads that contains repeats only in the 
middle and unique sequences at both ends.  
Each read pair consists of two mates and I seek to denote the positions of both mates using the 
combination of the above notations. As a convention, I always write the left read on the left, and right 
read on the right. For the STR region of interest, let L denote the left boundary, and R denote the right 
boundary. Now I am ready to use the above notations to deliver the positional information of all the 
read pairs mapped within and around an STR region. For example, read pair oLj has left read located 
outside the left boundary of STR region and the right read on the junction of the starting position, and 
jj the junction-junction read pair that span the entire STR region. I enumerate and number of all the 
possible combinations for the above notations (Figure 4.1) and there are in total 13 read pair types 
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(RPTs) that can be generated by different allele types.  
 
4.2.4 Characteristic RPTs for each STR allele type 
Each allele type produces a subset of RPTs. It is intuitive that when D≤Lr-δ, it is impossible to 
produce inside reads. Therefore RPTs 1-5 will be completely missing, and all 6-13 RPTs may be 
observed. When Lr-δ<D, the STR allele can produce RPTs 2-7 and 10-12. Traversal reads will be 
missing in this case. This is because even though D may be shorter than a read, the length of flanking 
regions left to anchor the read is not sufficient. RPT 1 may also be observed when D is long enough.  
 
4.2.5 RPTs distribution for different allele types 
I am interested in learning the behavior of STR alleles of different lengths in terms of what RPTs they 
can produce and what the relative proportions of different RPTs are. It is intuitive that when D is 
shorter than a read, it will produce a different subset of RPTs from when D is much longer than a read. 
To simplify our calculation, I fix insert size to be its mean µ, and assume that the left-most position of 
a read pair is uniformly distributed around the region (st-µ, st+D), where st is the start position of STR 
region and let Lt denote the length of the region: Lt=D+µ. Let θ denote the length of unsequenced 
region between two reads in a pair, i.e. θ=µ-2Lr. In a well-designed library, θ should be positive, 
although the sign of θ does not affect the results. I use Mi, i=1,2,…,13, to denote the expected length 
of range where RPT i can be produced. The values of MI am given in Table 4.1. These values can be 
inferred using a series of tiling read pairs with left-most position approaching from st-µ to st+D. 
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Examples for θ<Lr and D∊(θ,Lr) or D∊(θ+Lr,µ) are shown in Figure 4.2. And the probabilities of 
observing each type of RPT are given by: !! = !!/!! !! = !! = !!/!! !! = !! = !!/!! !! = !!" = !!/!! !! = !! = !!/!! !! = !!! = !!/!! !!" = !!"/!! !!" = !!"/!! 
Given Lr and µ, I can calculate probabilities to observe each of the 13 RPTs for different allele length 
D. Figure 4.3 displays the distributions of P1-P13 with D progresses from 10 to 1000bp (µ=252, 302 
and 352, Lr=101). There are several signatures revealed from Figure 4.3: 1) P8+P9, the probability of 
observing traversal reads, peaks when D is the smallest and decreases to 0 when D exceeds Lr. 2) 
P13+P11+P7+P12, the probability of observing flanking read pairs, is large when D is small and drops 
down to 0 when D exceeds µ. 3) P1+P2+P3+P4+P5, the probability of observing RPTs with at least one 
inside read, remains 0 when D<Lr, and becomes steadily larger with increasing D. The above 
probability distribution provides the basis of our binary classification of the possible genotypes which 
I will discuss below. 
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4.2.6 Genotype classification for a diploid STR locus 
At a STR locus in a diploid genome, there are two alleles with possibly different repeat lengths. Let 
L1 denote the length of shorter allele and L2 the longer allele, so that L1≤L2. Considering different 
ranges of L1 and L2, I can divide the genotypes at a given STR locus into three scenarios, depending 
on the lengths of the two alleles (L1, L2) , Lr: 
AA: L1 ≤ L2 < Lr-δ 
AB: L1 < Lr-δ< L2 
BB: Lr-δ< L1 ≤ L2  
In Table 4.2 I enumerate all the possible RPTs that can be produced under each genotype. It is 
intuitive that I use the existence a subset of these 13 RPTs to distinguish genotypes. Genotype AA can 
be separated out by missing inside reads, while AB and BB can be further distinguished by existence 
of traversal reads.  
 
4.2.7 STR allele length estimation 
Another major task for our method is to provide accurate estimation of L1 and L2 after identification 
of the genotype. Throughout our method development, three length estimation approaches are used 
for different cases: 
A) exact estimation using traversal reads 
B) parametric model based likelihood estimation using insert size distribution 
C) non-parametric model based likelihood estimation using coverage distribution 
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For alleles shorter than Lr, method A) is usually sufficient to estimate D. When allele length exceeds 
Lr I need method B) and C) to provide unbiased estimations.  
 
4.2.8 STRfinder pipeline 
Our goal is to use previously aligned paired-end short read sequencing data to detect STR alleles 
without any prior information, which can be broken down into three specific tasks. The first task is to 
screen for informative reads and locate STR allele. STRfinder profiles all the reads and select partially 
or fully repeat ones to find candidate STR regions characterized by local cluster of partially repeat 
reads. Second, genotyping: using all the informative read pairs around the STR region, STRfinder 
identifies the genotypes of each STR loci. Third, length estimation: using a maximum likelihood 
approach, I am able to provide an estimate of the length of repeat region, even when it is longer than a 
read or insert size. The flowchart of STRfinder can be found in Figure 4.4 and details for each task 
are discussed in Method section.  
 
4.3 Application to simulated datasets 
In order to evaluate the performance of STRfinder, I created in silico datasets with known STR allele 
lengths. To fully restore the complexity of human genome, without losing generality, I use 
chromosome 10 from human g1k v37 assembly as template. Although STRfinder does not rely on 
external information to locate an STR, I use tandem repeat table from UCSC genome browser, which 
was used by lobSTR to call STR variants (Gymrek et al., 2012). For chr10, there are 11,048 STR loci, 
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from which I randomly sampled 30% sites to be heterozygous and control the allele lengths, with the 
remaining 70% sites to be homozygous with reference allele length. For the 30% sites, I further 
sample 80% out of them (24% of total) to be unexpanded alleles, and assign one allele to be the 
reference. The number of repeats of the other allele is given by nref+U, where nref is the repeat content 
for the reference allele, and U is a random integer sampled from [-5,5]. 20% out of the sampled 30% 
sites (6% of total) are expanded alleles, and I still assign one to be the reference. The number of 
repeats of the other allele is given by U'×nref, where U' is a random integer from [2,5].  
After the locations and lengths of STR alleles are chosen, I simulate reads from the simulated chr10 to 
obtain FASTQ files. Paired end simulated Illumina reads were generated using simNGS 
(http://www.ebi.ac.uk/goldman-srv/simNGS/). I set mean insert size to be 300bp, read length 101pb 
and mean coverage to be 50X. Other parameters are set as default. To examine the performance of 
STRfinder on different aligners, I applied two aligners that allow gap mapping, BWA (Li and Durbin, 
2009) and Bowtie2 (Langmead and Salzberg, 2012) to map the reads onto human g1k v37 reference 
genome. I used the complete genome as reference instead of only using chr10, to include scenarios 
when expanded STR alleles are mapped to other chromosomes of the genome, which is possible in 
real datasets. In total, 3384 STR sites are selected to evaluate the performance of STR calling 
algorithm. 
STRfinder was applied on both BWA and Bowtie2 aligned BAM files and generated two lists of STR 
sites. For BWA BAM, STRfinder called 22832 sites in total, with 22815 on chr10, 8770 in the tandem 
repeat table and 2924 in the heterozygous STR list, where for Bowtie2 BAM there were 22460 sites 
called, 22459 on chr10, 8623 in the table and 2825 belonged to the list. In either case, STRfinder 
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found more than 10K STR loci not covered in the tandem repeat table. From those loci, I randomly 
selected ten, manually checked their validity and all of them were proven correct STR regions.  
BWA and Bowtie2 calling results overlapped 21646 in total, and 2806 were in the STR list. I 
compared the length estimations for both sets with the allele lengths in the STR list, and BWA result 
had a Pearson’s correlation of 0.44, slightly larger than Bowtie2 (0.42). The two sets of BAM files 
yield very similar call rates and accuracies, indicating that STRfinder works fine with both methods. 
Since BWA result has slightly better outcome, I use the STR variants called from BWA aligned BAM 
file to compare with other STR callers.  
 
4.4 Performance of STRfinder and comparison with other methods 
 
I applied two other STR detect algorithms, lobSTR and RepeatSeq to the same dataset and compared 
the performances with STRfinder. In order to compare methods fairly, I used the optimum settings for 
each algorithm in our simulation framework. For lobSTR, I used paired-end mode on fastq files. If, 
for a given site, lobSTR provided more than one estimates, I use the one closest to the reference allele 
to reduce noise. For RepeatSeq, BWA aligned reads yield better call rate, and hence I used BWA 
instead of Bowtie2 aligned bam file. Both lobSTR and RepeatSeq required a list of reference STR 
sites, and I used the tandem repeat table for chr10 that has been used to generate the heterozygous 
STR list containing 3384 sites.  
In total, lobSTR called 9410 sites, 9369 of which were on chr10, while RepeatSeq called 8859 in total 
and 8824 were in the tandem repeat table for chr10. 
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I first compare the overall call rates for three methods. Of all the 3384 sites, STRfinder, although is 
blind to the tandem repeat table used for simulation, called 2924 of them, which is the highest, 
followed by lobSTR, calling 2293 sites. RepeatSeq called 2249 sites. The Venn diagram in Figure 
4.5A shows the overlaps out of two-way and three-way comparisons. 1651 sites for the called sites 
from all three methods are shared.  
For the six genotype scenarios, the results are shown in Figure 4.5B. A cut-off of allele length ≤80-nt 
is applied for A allele. For genotype AA, all three methods have comparable high call rates and most 
of the calls are correct. For genotype AB, only STRfinder provided high fraction of correct calls. 
lobSTR and RepeatSeq also called around 60% of the sites, but none of them were correct. For 
genotypes BB, the call rates for lobSTR and RepeatSeq were close to zero, while STRfinder was able 
to correctly genotype 292 out of 536 sites for this genotype. 
Genotype AA and AB are scenarios where STRfinder is capable of allele length estimations and I 
presented the comparisons using violin plots (Figure 4.5C). AA is the most abundant in heterozygous 
STR list, accounting for more than 70% of all sites. Both lobSTR and RepeatSeq were designed to 
predict lengths on short alleles that can be spanned by a read. As expected, allele length predictions 
from all three algorithms were very close to simulated values, and the median absolute prediction 
errors were low, with RepeatSeq being lowest (0.5 repeat units for both short and long alleles). 
lobSTR has the least prediction error for short allele, which is also 0.5 unit, but its prediction error 
(2.0 unit) for long allele is slightly worse than STRfinder (1.0 for both short and long alleles). Length 
predictions for STRfinder have larger variation than other methods. The sites with extreme prediction 
errors were manually examined and most of them were not simple repeat regions. Since STRfinder 
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does not rely on external information to genotype STR loci, its estimations on complex repeat regions 
suffer from low accuracy. For AB genotype, STRfinder have the smallest prediction errors for both 
long and short alleles. For these STR loci, lobSTR and RepeatSeq failed to identify the long allele, 
and usually assigned it with the length of reference allele, and therefore, both of them yield high 
prediction errors. It is also important to note that the call rate of STRfinder is the highest across AA 
and AB genotypes, where lobSTR and RepeatSeq suffered from decreased calling rate as the length of 
the long allele increased. Of the expansion genotype AB, I am particularly interested in tri-nucleotide 
repeats. There are 40 sites simulated in total, and 36 of them were called by STRfinder, with 33 
correctly called, indicating that for tri-nucleotide repeat expansion alleles, STRfinder has around 80% 
calling accuracy, while lobSTR or RepeatSeq, not designed to detect this type of allele, could not call 
any of these sites correctly. 
To conclude, based on an unbiased simulated dataset and comparisons among three STR callers, 
STRfinder consistently has the highest calling rate, and decent accuracies across all six genotype 
scenarios, where the other two callers, which were designed for only short alleles, suffered from 
regressed performances when allele length becomes longer. 
 
4.5 Application to a real exome 
 
The data I simulated using simNGS followed a protocol of whole genome sequencing preparation 
library. While a wide range of research is practiced using whole exome sequencing (WES) for cost 
efficiency considerations, I am interested to understand the performance of STRfinder for WES data. 
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The data I used came from a patient diagnosed with Machado-Joseph disease (MJD). Blood DNA 
sample was collected and sent for whole exome sequencing to 40X using Illumina HiSeq 2000 
platform, and NimbleGen V3 capture kit. The raw paired-end reads were aligned to human reference 
genome g1k v37 using BWA aligner. I applied STRfinder onto this dataset and discovered 9791 STR 
sites. MJD is a neurological disorder known to be related to polygutamine (PolyQ), or CAG repeat 
expansion in certain genes (Paulson, 2012). I looked for pathological expansions of tri-nucleotide 
repeats among the 9791 sites and found seven sites with genotype AB/AC. I manually checked all the 
sites and found all four AB genotyped sites and the first AC genotype site located in complex 
interrupted repeat regions. I therefore excluded these five sites  from our analysis. The sixth signal 
resides in chr13: 70713514-70713560, and targeted gene ATXN8OS, with short allele being 20 
repeats, and long allele ~70 repeats. The last signal is in chr14: 92537353-92537396, affecting 
ATXN3 gene, with expanded allele length ≥70 repeat units and normal allele 20 repeats. For this 
specific patient, clinician has ordered Sanger sequencing on ATXN3 and validated that it has 84 
repeats for the expanded allele. ATXN3 is a known causal gene for MJD, with normal allele range 
13-36 repeats and pathological allele 61-84 repeats (Gatchel and Zoghbi, 2005), so the discovery of 
CAG expansion in this gene concluded the study. However, it will also be interesting to look at gene 
ATXN8OS in the future, since it has been associated with a form of spinocerebellar ataxia (Koob et 
al., 1999). For ATXN3 gene, lobSTR reported 13 repeats for both alleles, while RepeatSeq failed to 
identify the locus. 
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4.6 Methods 
 
Before detailed descriptions of the method, I first specify our tasks. The goal is to use paired-end next 
generation sequencing data, which has been previously aligned to a reference genome, to sequentially 
report (1) existence of STR region; (2) the genotype and (3) lengths for L1 and L2.  
4.6.1 Existence of STR region 
4.6.1.1 Informative read searching 
Our algorithm implements an initial search for all the reads that contain more than 8 repeat units at 
either end, to include junction reads and inside reads. To distinguish the junction read from inside 
reads, I perform a finer scan by searching for reads with auto-similarity larger than or equal to 0.9, i.e. 
if a read sequence shares more than 90% of same bases to itself lagged by α bases (iterating α from 2 
to 6), it is considered to be an inside read and α is the length of repeating unit, while reads with 
auto-similarity smaller than 0.9 are considered to be junction reads. Each read is then paired with its 
mate. Each read pair filtered in contains at least one mate that is partially or fully repetitive. The 
above approach guarantees to find all the read pairs from RPTs 1-7,10-12 that have been assigned by 
aligner as unmapped, low mapping quality, soft-clipped or misplaced due to tandem repeats. For RPT 
1, both mates are fully repetitive, and it is usually impossible for aligner to uniquely place the read 
pair in the genome, I exclude it from downstream analysis unless otherwise mentioned. RPTs 8,9 
contain repeat in the middle of the sequence, and 13 does not contain repeat but spans a repeat region. 
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These read pairs are not included by this step and will be retrieved later. During the initial search, I 
also obtain the mean (µ) and standard variation (σ) of insert size distribution, using properly mapped 
read pairs (mapping quality≥20). To note, the thresholds used to filter in informative read pairs are 
adjustable by users in STRfinder. 
4.6.1.2 Read set discovery 
For each read pair kept from the above screen, I use the left-most mapping position of the mate with 
higher mapping quality and sort these positions along the genome for a linear scan. If in a locus I find 
more than 5 reads with maximum distance between adjacent reads ≤µ, I assign all these reads in this 
locus to be a pre read set (pRS). The discovery of a pRS is an evidence for the existence of STR 
region. The minimum (st) and maximum (ed) mapping locations of reads in this pRS are found and all 
the reads mapped within (st,ed) are retrieved to be assigned as a read set (RS). To note, RS may 
contain mapped read pair types 2-7,10-12, while it may also contain traversal reads 8 and 9, and 
traversal read pair 13, since I extract all the reads in this STR locus, and 8,9,13 read pairs are usually 
properly mapped. 
4.6.1.3 Repeat unit identification 
In the RS defined above there are two types of reads: those with decent amount of repeats 
(auto-similarity>=0.5) and those without (auto-similarity<0.5). I select reads with repeats to identify 
the repeat unit. I first estimate the length of the unit by checking the auto-similarities of these reads, 
where the correct length α results in the highest auto-similarity. I then enumerate all the possible 
α-length units, taking into account base-rotation symmetry and reverse complementary. For example, 
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AGC, GCA, CAG, GCT, CGT and TCG are all considered to be the same, and I take the first one by 
alphabetical order, AGC. For each unique repeat unit candidate, I search for its occurrence in RS, and 
if any read contains more than 8-α repeats for the specific unit, I include it into our repeat unit list 
(RUL). A clean repeat region should have only one unit, but a more complicated region, for example, 
containing two different yet closely located STR regions, may have more than one units. For those 
regions, I process one unit a time to find all the simple repeat regions within (st, ed).  
4.6.1.4 STR coordinates estimation 
I proceed to estimate the precise location of the STR region in the reference genome. I now focus our 
discussion on one unit. For region contains more than one repeat unit, same method applies for each 
unit iteratively. To find the precise start position (st0) of the STR, I first find all the reads that contains 
unique part on the left side and repeat on the right side, namely left junction reads (LJR). To find LJR, 
I iterate all the reads in RS, and for each read, I identify the repeat region, allowing for at most 2 
errors. Two types of errors are tolerated in STRfinder: 1) mismatch and 2) insertion or deletion of one 
base. And these errors may either be due to technical artifacts or slippage or mismatch during STR 
formation (Levinson and Gutman, 1987). That is, if the repeat region contains no more than two the 
above types of errors, it is still considered as a continuous repeat region. This procedure avoids calling 
shortened alleles interrupted by non-perfect matches. Similar approach applies to find right junction 
reads (RJR). LJR are used to estimate st0. For each read in LJR, I estimate where tandem repeat 
begins by finding the left-most position (z) of the consecutive repeat region within the read (0<z<Lr). 
If the mapping position of the read is x, then st0=z+x. It is possible that each LJR gives slightly 
different start position estimation, due to sequencing and mapping errors. I take the median of all the 
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start estimates to be the final st0. Likewise, ed0 is estimated from taking the median of all the end 
estimates from RJR. 
 
4.6.2 Genotype identification 
After a read set (RS) is defined and an STR region is found, I move on to identify which of the above 
three genotypes L1 and L2 belong to. It is intuitive to see in Table 2 that the missing inside reads RPT 
2-5 is a signature for genotype AA, while the existence of RPT 8 or 9 further separates AB from BB. 
Therefore I am able to identify genotypes based on the existence of the above characteristic RPTs.  
Before length estimation for STR alleles, I want to describe our question. The goal is to use read 
length, insert size and coverage information around a diploid STR locus to provide unbiased 
estimation of both parental alleles, under each genotype scenario. The genotype classification of AA, 
AB and BB here is primitive since allele type B covers a large range of values. In allele type B, when 
the STR region is short enough, I expect read pairs to flank the allele (denoted as Bshort), while its 
length exceeds the maximum insert size locally, no flanking read pairs shall be observed (denoted as 
Blong). However, there does not exist a definitive threshold between allele types Bshort and Blong, since 
insert size of read pair is a stochastic variable instead of a fixed parameter. Therefore, it is not 
possible to define a global cut-off to separate the two possible scenarios of allele type B. Instead, I 
choose to analyze genotype AB or BB in a contingent fashion. For each AA genotype locus, I 
distinguish the two possible length ranges by looking for flanking read pairs of the longer allele. If 
these read pairs are found, there is definitive evidence that the longer allele is constraint by insert 
sizes these read pairs (Bshort). If not, it is likely that the allele is too long to be covered by any read pair 
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(Blong). And for BB genotype, I do always not seek to provide length estimations. As mentioned in the 
main text, I have three methods for length estimation, with methods B) and C) for alleles longer than a 
read. Of these two, method B) is only available when the allele length is flanked by a sufficient 
number of read pairs, while method C) is applicable to either length ranges. Theoretically, the 
prediction error for method B) is contributed by the variance in insert size, while for method C), this 
error is contributed by both insert size variance and Poisson sampling error. Therefore, I use method 
B) for the Bshort alleles and method C) for the Blong alleles.  
 
4.6.3 Estimation of L1 and L2 
 
4.6.3.1 Genotype AA: L1≤L2<Lr-δ 
In this case, I expect to find traversal reads from RPTs 8,9 as well as 6,7,10-13 and no inside reads 
from RPTs 2-5. The method I search for t reads is similar to that I look for j reads. I iterate through all 
reads in RS, find reads with more than 8-α consecutive repeats in the middle, with the starting 
location of the repeat larger than α and ending position smaller than Lr-α, and assign them to be t. For 
each t read, I record the number of repeats it contains, and include it into a list (S). In this list I expect 
to see two numbers with high frequencies, and due to noise and errors, there may be other numbers. 
Therefore, I find the top two numbers with highest (f1) and second highest frequency (f2) in S. If 
f2<0.2×f1, I assume the second highest abundant number is noise and this is a homozygous region 
with both alleles the same length, otherwise I report heterozygous region and both numbers of repeats.  
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4.6.3.2 Genotype AB: L1≤Lr-δ<L2 
In this scenario, I expect to observe RPTs 2-13, including t and i reads. I apply method 3.a on t reads 
to estimate L1.I then look for RPTs produced by L2 with definitive evidence. Since L2 is longer than Lr, 
it is possible to find RPTs with repetitive region longer than L1. For example, RPTs containing 
junction reads (6,7,10,11,12) may fall into this category if enough number of repeats are found in one 
or both mates. RPTs 2-5 contain inside reads, and must be generated by L2. I denote read pairs that 
can be uniquely assigned to L2 as L2-RP. Figure 5.6 shows different types of L2-RPs in different 
allele length ranges. For Bshort allele type, I expect to find RPTs 7, 11 and 12 within L2-RPs, which are 
very informative to L2 estimation since they are flanking the STR region. If such read pairs exist, I use 
method B to estimate L2 with following likelihood function: 
!"#$%"ℎ!!" = Pr !"#$!!"#$!!"#$%ℎ!! = !!! + !!|!"#$!!"#$!!"#$%!!"#$%&$'
= !"#$%&(!!! + !!, !,!)!"#$%&(! + !, !,!)!"!!!!!
!
!!!  
where Liu is the length of non-repeat region spanned by read pair i, i=1,2…K, K is the number of L2-
-RP read pairs belonging to RPTs 7, 11 or 12, and δ is the minimum length requirement for a read pair 
to be mapped. For BWA aligner, I choose δ=20. To calculate Liu, I need to know the length of the 
unique part of sequence coming from both mates. For RPT 12, since it travels from one end of STR 
region to the other, it is known that the space between mates is filled with repeats, and Liu=2×Lr-Lp, 
where Lp is the total length of consecutive repeat sequence in the two reads. For RPT 7 and 11, 
Liu=2×Lr-Lp+G, where G is the unique sequence between the two mates. For RPT 7, G=Start position 
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of right read-ed0 and for 11, G=st-Start position of the left read-Lr. The denominator in the likelihood 
formula is the probability that the read pair is observed. Conditioning on the read pair observed and 
belonging to L2, the insert size follows a truncated normal distribution where X has to be greater than 
L2+δ, and given L2, the probability is integral of normal density from L2+δ to infinity. I numerically 
solve L2 to maximize likelihood function and report genotype ABshort as well as both length 
estimations.  
When RPT 7,11 or 12 within L2-RP are missing, it is likely that L2 belong to allele type Blong. I use 
method C, i.e. coverage based likelihood model, to estimate L2. In practice, I find all the reads that are 
known to be produced by L2, knowing that L1<Lr. It is straightforward that RPTs 2-5 are all L2 
generated as well as RPT 6 or 10 containing more repeat units than the shorter allele. Similarly, RPT 
8 and 9 must be produced by L1, since they traverse the shorter allele. I let Nlong denote the number of 
read pairs produced by L2, which is summation of the counts of L2-RPs, and Nshort denote the number 
of read pairs produced by L1, which is the count of RPT 8 and 9. Let Plong and Pshort denote the 
probabilities that I can observe an L2 read pair and L1 read pair respectively. Figure 4.6 shows details 
of Plong and Pshort calculations. Both probabilities need to be mathematically inferred. To simplify the 
calculation, I let insert size to be constant µ. Follow the above discussion, the chance that a read pair 
can be observed as L2-generated is: 
!!"#$
= Pr !"#$!!"#$!!"#$%!!"#$%!!"#$!!!!!"#!!"#$%&#'!!"#$%ℎ!!"#"$%&!!"!!"!!""#$%&'!!"!!!
= !! +  2×! + !! + !! × !! + ! − 2×!!!! + ! = !! + ! − 2×!!2×! + !! + !! 
where the first part is the probability that a read is truly generated by L2, and the second part is the 
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probability that the repeat contain in the read pair is longer than L1 so that it can be assigned to L2 
definitively. Likewise, the chance that a read pair can be observed as L1-generated is: 
!!!!"#
= Pr !"#$!!"#$!!"#$%!!"#$%!!"#$!!!!!"#!!"#$%&#'!!"#$%ℎ!!"#"$%&!!"!!"!!""#$%&'!!"!!!
= Pr!(!"#$%&$!!"#$%"&#'!!"#$) = !! + !2×! + !! + !! × 2×(!! − !!)!! + ! = 2×(!! − !!)2×! + !! + !! 
Let Ntot denote the number of read pairs in RS and it follows Ntot>Nlong+Nshort and Plong+Pshort<1, since 
there are a fraction of read pairs cannot be assigned to either L1 or L2. I build a Multinormial 
likelihood model based on coverage: 
!"#$%"ℎ!!" = !"#$%&'(%)#(!!!!"# , !!"#$, 1 − !!!!"# − !!"#$,!!!!"# ,!!"#$,!!"! − !!!!"# − !!"#$) 
It can be shown that the maximum likelihood estimation for L2 is unbiased.  
I apply this model, obtain an MLE estimation !! and report genotype ABlong and both length 
estimations for this situation. 
 
4.6.3.3 Genotype BB: Lr<L1≤L2 
In this scenario, I do not expect to observe any RPT 8 or 9.There are two possibilities: i) flanking read 
pairs RPT 7,11 or 12 can be observed (BshortBshort or BshortBlong) and ii) no flanking read pairs observed 
(BlongBlong). It is not possible to assign these read pairs to be L1-reads or L2-reads as I did for 3.b. But 
for i), it is still possible to provide some information of allele lengths. I first distinguish two cases: 
flanking read pairs were generated from (1) one allele (BshortBshort homozygous or BshortBlong) or (2) 
two alleles (BshortBshort heterozygous). For (1), I expect to observe the variance of insert size of 
flanking read pairs to be very close to σ. For (2), the flanking read pairs actually come from two 
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distributions with different means, and I expect the observed variance σ’ to be greater than σ. In 
practice, if σ’≥1.2σ, I assert case (2) and report genotype BshortBshort heterozygous. If σ’ is comparable 
to σ, two scenarios may be true: 1) BshortBlong: the longer allele is too long to be covered by flanking 
read pairs, and the observed RPT 7, 11, 12 were all generated from the shorter allele and 2) BshortBshort 
homozygous: the longer and shorter allele are of same length, or L1=L2. I use a ratio (k) of counts for 
RPT 7, 11, 12 over counts for RPT 6 and 10. The expected value of k is (! − !!)/2!! for scenario 
2), and half of that value for scenario 1). Since L1 has not been estimated, I use Lref=ed0-st0 instead in 
the above expression. In practice, if the observed value (!) is greater than the 0.8×Exp[k], I assign 
genotype  BshortBshort homozygous, and I test if L1 is the reference allele length by using one-sample 
student t-test of mapping distance against µ. If P-value ≤0.05, then L1 is estimated to be Lref+Δ, where 
Δ=µ-average insert size of flanking read pairs in the locus. If P-value >0.05, L1=L2=Lref. I report 
Lr<L1=L2<µ for either P-value<=0.05 or P-value>0.05, together with the length estimations. If 
! ≤ !! !, I assign genotype BshortBlong and the insert sizes of flanking reads come from one normal 
distribution. I directly estimate L1 using method B, described in 3.b and report the genotype and the 
estimation for L1 only. 
If no flanking read pairs were observed, I do not seek to make quantitative estimations for either L1 or 
L2 and will just report the length ranges and genotype BlongBlong. 
 
 
4.7 Summary 
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I present STRfinder as a new approach to detect, and when possible, to genotype short tandem allele 
loci in genomes using short read DNA sequencing data. Compared with previously developed 
methods, STRfinder has several advantages: 1) it does not rely on a known list of STR loci to call or 
genotype STRs. Therefore, STRfinder is fully capable of finding true de novo STR sites; 2) it 
integrates all 13 read pair types around a repeat region to robustly call and genotype STR alleles; 3) 
for a wide range of STR allele length, STRfinder provides accurate estimations with high call rates. 
These features make STRfinder a unique tool to detect pathological tandem repeat expansions and find 
the genetic basis of a wide spectrum of neurodevelopmental diseases.  
To date, in our simulation, STRfinder called fewer sites in the tandem repeat table than lobSTR or 
RepeatSeq. This is because in our application, I used a more stringent criterion to call repeats, that the 
allele must contain more than 8 repeats. If I relax this threshold to 6 repeats, STRfinder called 10120 
sites in the tandem repeat table, which is more than either lobSTR or RepeatSeq. In practice, this 
threshold is user-defined. 
STRfinder estimates alleles longer than a read by using the mapping distance distribution of the 
library. I assume it follows a single mode Gaussian distribution. The empirical distribution can be 
used instead to increase accuracy. Larger library size is preferred to detect longer alleles. For example, 
with median insert size 300-nt, it is possible to estimate repeat allele length up to 260-nt, considering 
20-nt is required to anchor the junction reads, which is enough to cover the expanded alleles of 
Huntington’s disease, or various types of Ataxia disorder.    
Application of STRfinder on in silico generated dataset with known number of repeats for a list of 
selected STR loci showed that most sites were accurately genotyped by STRfinder. Comparing with 
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lobSTR and RepeatSeq, STRfinder provides equally good estimations for shorter alleles with 
additional information for expanded alleles, both their genotypes and length estimations. Although 
STRfinder does not perform realignment of repeat reads as lobSTR does, its performance is not 
suffered, since a comprehensive collection of read pair types are utilized around a STR region to 
increase calling accuracy. BWA and Bowtie2 aligners were tested in our simulations and both 
provided similar results. Although I did not test other aligners that support mapping of small 
insertions and deletions, by design they are all valid options to apply STRfinder.  
It took STRfinder 2.8 CPU hour to process the simulated dataset (AMD Opteron 2.4GHz), and 
approximately 5GB memory consumption. The actual memory usage depends on the size of the BAM 
file and parameter settings. More sensitive settings result in high memory consumption. The 
simulated dataset contained 90 million reads for chr10 only, and STRfinder called ~23K STR sites. 
On average, it takes STRfinder 0.43s to fully analyze one site. Multi-thread processing is available for 
STRfinder to call variants on multiple samples in parallel.  
I applied STRfinder to a patient with Ataxia symptom on the whole exome sequencing data, and 
independently discovered the CAG repeat expansion in ATXN3 gene, which had been clinically 
tested and proven expanded. This result indicates that our algorithm is ready for the detection of 
causal STR alleles in susceptible population with NGS data available. I based our methodology 
development on simple repeats, yet since I do not rely on known STR sites as reference, sometimes 
STRfinder will find complex repeat regions and report incorrect results, which is the major 
contribution of prediction errors in our simulation. Future work needs to be done to solve complex 
repeat regions, and to achieve this goal, a DNA fragment library with a wide spectrum of length 
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distribution is helpful to detect long regions with subtle structures.  
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Table 4.1. Distributions of lengths of range where RPTs can be produced. 
A: θ<Lr 
 (0,θ) (θ,Lr) (Lr,θ+Lr) (θ+Lr,µ) (µ,∞) 
M1 0 0 0 0 L-µ 
M2,M5 0 0 L-Lr θ θ 
M3,M4 0 0 0 L-Lr-θ Lr 
M6,M10 L L Lr Lr Lr 
M7,M11 L θ Lr-L+θ 0 0 
M8,M9 Lr-L Lr-L 0 0 0 
M12 0 L-θ L-θ Lr-(L-Lr-θ) 0 
M13 θ-L 0 0 0 0 
B: Lr<θ<µ 
 (0,Lr) (Lr,θ) (θ,θ+Lr) (θ+Lr,µ) (µ,∞) 
M1 0 0 0 0 L-µ 
M2,M5 0 L-Lr L-Lr θ θ 
M3,M4 0 0 0 L-Lr-θ Lr 
M6,M10 L Lr Lr Lr Lr 
M7,M11 L Lr Lr-L+θ 0 0 
M8,M9 Lr-L 0 0 0 0 
M12 0 0 L-θ Lr-(L-Lr-θ) 0 
M13 θ-L θ-L 0 0 0 
Upper table is for case when θ is shorter than a read and the lower table is when θ is greater than a 
read. It is impossible for θ to be larger than µ, since read length is non-negative.  
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Table 4.2: RPT distributions across six genotypes and binary classification of 6 
genotypes. 
  
Notation AA AB BB 
1 
 
ii* •• ••/•√ ••/•√/√√ 
2 
 
oi •• •√ √√ 
3 
 
ji •• •√ √√ 
4 
 
ij •• •√ √√ 
5 
 
io •• •√ √√ 
6 
 
oLj √√ √√ √√ 
7 
 
Ljo √√ •√/√√ ••/•√/√√ 
8 
 
ot √√ √• •• 
9 
 
to √√ √• •• 
10 
 
Rjo √√ √√ √√ 
11 
 
oRj √√ •√/√√ ••/•√/√√ 
12 
 
jj √√ •√/√√ ••/•√/√√ 
13 
 
oo √√ •√/√√ ••/•√/√√ 
•: missing, √: presented, *: RPT1 is unmappable. Existence of RPT 8 and 9 (shaded gray) are used to 
separate AA,AB and AC from the other three. Within the first 3 genotypes, RPT 2-5 (shaded orange) 
are used to further split AA out. Within the last 3 genotypes, RPT 7,11,12,13 (shaded magenta) are 
used to further split CC out. The second column display color legend for each RPT matching Figure 
4.3.  
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Figure 4.1: Thirteen read pair types relevant for STR detection. 
Solid 
thick lines in the middle indicates diploid genomic region with STR (black colored). Black color 
indicates reference genome, reads or regions containing no repeats, while gray color for sequences 
that are at least partial repeats. The upper allele is the longer allele. Paired arrows indicate read pairs. 
Details for the longer and shorter alleles and the RPTs they may produce are discussed in the main 
text.  
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Figure 4.2: Cartoon showing RPT fractions as in Table 1.  
 
Different RPTs generated when A: θ<D<Lr and B: Lr<D<µ and their relative fractions as 
indicated by the tiling reads.  
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Figure 4.3: Distribution of observing the 13 RPTs under different insert size and read length 
configurations, with allele length changing from 10 to 1000bp. RPTs with same probability are 
put next to each other. θ=µ-2Lr, is the between read distance in a pair. 
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Figure 4.4: STRfinder pipeline 
 
The STRfinder algorithm contains three steps. Assuming paired end reads have been aligned to the reference 
genome using indel tolerated aligners, such as BWA or bowtie2, STRfinder screens for repetitive reads, find 
read sets that contain closely located repeat reads, genotype the STR locus using informative read pair types 
(RPTs) and estimates the lengths of alleles when possible. 
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Figure 4.5: Performances comparison of STRfinder, lobSTR and RepeatSeq on simulated 
dataset. 
 
A. Venn diagram showing the two-way and three-way overlaps between STR sites called by different 
callers. B. Table showing call rates and number of correctly genotyped sites by each method, for 
genotypes: AA, AB or AC, BB or BC and CC. C. Violin plots of absolute prediction error in unit of 
repeats for each method and stratified by genotype AA, AB and AC. The X-axis of the plot displays 
the methods and allele. Capital letters are abbreviations for STR callers, “S” for STRfinder, “L” for 
lobSTR and “R” for RepeatSeq, where the following small number designates allele: “s” for short 
allele and “l” for long allele.  
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Figure 4.6: Cartoon demonstration of Plong and Pshort calculation in different scenarios 
A. µ<L2: 
To estimate Plong, consider tiling read pairs with left-most position moving from sto-µ to st0+L2, 
L2-reads can be observed in the region of st0-µ+L1 to st0+L2-L1. Assuming read pairs are uniformly 
distributed in the region, the probability to observe L2-reads is (L2+µ-2L1)/(L2+µ). B. L1<Lr: To 
estimate Pshort, read pairs with left-most position moving from st0-µ to st0+L1 can be observed as RPT 8 
or 9 in the region from st0-µ+L1 to st0-µ+Lr and st0+L1-Lr to st0. The probability to observe L1-reads is 
2(Lr-L1)/(L1+µ). C. L2<µ and L1 is long enough to prevent the observation of L2 flanking read pairs. 
L2 reads can be observed in the range of st0-µ+L1 to st0-µ+Lr+L2-L1 and st0+L1-Lr to st0+L2-L1. 
Therefore, the probability to observe L2-reads is 2(Lr+L2-2L1)/(L2+µ). L2-reads are marked with blue 
color. 
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Chapter 5. Conclusion and Future Directions 
 
5.1 Conclusions 
 
In this dissertation, I have developed a collection of biostatistical and bioinformatics tools to 
study intra-tumor heterogeneity and the evolution of cancer genomes. Overall, I have 
completed three projects under this theme. 
In my first project, I studied the euploid cell mixing ratios in a cohort of human GBM 
samples, using allele-specific SNP array data. I discovered a strong correlation between AGP, 
the fraction of aneuploidy cells in a tumor sample, and gene expression PC1 and PC2, 
indicating that major components of gene expression variation of GBM samples are 
influenced by their levels of normal cell admixture. This is a novel finding, one that was 
ignored in the initial analysis and reporting of TCGA data. With this knowledge, I performed 
a joint analysis on copy number alteration profiles and gene expression differences of these 
samples, and revised the classification of GBM. The new subtypes are more strongly 
associated with patients’ survival than the previously defined subtypes. Furthermore, by 
comparing with known neural cell types, I identified that the euploid cells in the 
Mesenchymal subtype are likely to be infiltrating microglia/macrophage.  
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In the second project, I extended my algorithm developed in the first study from estimating 
whole-genome average mixing ratios to the mixing ratios of individual CNAs. Application of 
this algorithm to a breast cancer cohort revealed that about half of the samples consist of 
more than one subclone. I further integrated DNA sequencing data into my analysis. With a 
model that considers all possible temporal orders and phase relationships between a somatic 
mutation and an sCNA it resides in, I inferred the cancer cell fraction (CCF) for each somatic 
mutation. The collection of tools, named Clonal Heterogeneity Analysis Tool (CHAT), is one 
the few methods in the field that analyze both sCNA and somatic mutations, and estimate 
cellular frequencies for both types of variants. It is more general than other methods by 
considering the widest range of possible evolutionary scenarios. 
Throughout the development of this method, I relied on the regional two-way mixing 
hypothesis, first brought up in oncoSNP (Yau et al., 2010). This hypothesis is equivalent to 
the infinite site assumption used in population genetics, which considers recurrent mutation 
in the same locus of the genome as extremely unlikely. For somatic mutations in most tumor 
samples, this assumption is reasonable due to the large size of human genome and the 
relatively low rate of single nucleotide replacement. However, tumors with large fractions of 
genome altered are likely to have some regions affected by more than one independent events. 
And the exact solution is to allow three-way mixings or higher. While two-way mixing model 
is solvable using allele-specific copy number data, higher-order mixing models are 
mathematically difficult, sometimes becoming intractable when the data are limited. In my 
current approach, if an sCNA does not follow this assumption, its sAGP value will be 
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assigned with a missing value, and no downstream analysis will be conducted for this sCNA.  
My third project is to detect and genotype STR loci.  While it was initially motivated to 
study pathological STR expansions in neurological and developmental disorders, it can also 
be applied to study STR variation in the cancer genomes. Compared to lobSTR and 
RepeatSeq, the advantage of my tool, STRfinder is its capability to detect and genotype 
alleles that are longer than the read length, making fuller use of the information contained in 
paired-end short read sequencing data. Furthermore, unlike lobSTR or RepeatSeq, STRfinder 
can detect novel STR regions, without the need of an existing collection of known STRs in 
the genome. Together, these features make STRfinder a valuable new addition among tools to 
study STR variation. When applied in studies of cancer genomes, it is expected to enhance 
our ability to examine microsatellite instability and its role in tumor progression.  
 
5.2 Future Directions 
 
There are several continuations for the intra-tumor heterogeneity project. Methodologically, 
the tool developed in my thesis, CHAT, estimates cellular frequencies for individual somatic 
events, but without borrowing information from other somatic events. Other approaches, 
including PyClone and THetA, jointly use all the variants to infer the subclonal structure, 
which has the advantage of reducing the noise of individual estimates, but has the drawback 
of forcing the somatic events in the tumor into different subclones even when the true 
population is uniform. An important direction of future development is to appropriately 
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incorporate other sites of the genome but without imposing an arbitrary tumor subclonal 
model in the inference, and this is expected to increase the accuracy of sAGP and CCF 
predictions. 
Translational research that bridges fundamental biological discoveries and clinical 
application is an important area in biomedical science. There are several future directions for 
intra-tumor heterogeneity studies in this field. First, the field would benefit from the 
development of cost-effective validation of subclonal driver lesions discovered using 
high-throughput technologies. These events usually have low prevalence in the population, 
and it requires ultra-deep sequencing or single cell profiling to prove their existence. Second, 
functional analysis of subclonal driver events is desirable and model organisms or cell lines 
that recapitulate the hallmarks of in vivo cancers are in need.  
Besides validations for variant discoveries, intra-tumor heterogeneity studies have close 
connections with clinical practice. In Chapter 2, I have studied the impact of tumor/normal 
mixing in tumor samples, and discovered that it has significant impact over tumor subtype 
classification. And in Chapter 3, I discovered that in breast tumors the clonal patterns for 
tumor related genes show difference across tumor subtypes. In both studies, heterogeneity 
within a tumor cell population influences the observation of inter-tumor diversity. In the 
future, discovery of clinically related tumor subtypes would benefit from accounting for 
intra-tumor heterogeneity characteristics, such as tumor/normal mixing ratios and cellular 
frequencies for somatic events.  
It has been shown that the diversity in tumor cell population is a predictor for clinical 
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outcome (Maley et al., 2006) in esophageal adenocarcinoma patients. While in that study, 
researchers applied the labor intensive karyotyping to profile single cells and report 
subclonlaity, it is possible to apply CHAT on genomics data collected from bulk tissue and 
estimate clonal diversity in a high-throughput manner. In the future it will be particularly 
interesting to study the impact of clonal diversity on patient survival for more cancer types 
and subtypes. 
As mentioned in Chapter 1, cytotoxic therapies rarely eradicate tumor cells, and most deaths 
caused by cancer are due to recurrence or metastases. Intra-tumor heterogeneity has played 
an important role in the relapse by providing multiple subclones carrying different somatic 
events, and the treatment is likely to fail if at least one of the subclone harbors drug resistant 
mutations. Research studying leukemia or lymphoma monitor subclonal dynamics by 
longitudinal sampling greatly helped to understand the evolution of tumor subclones. For 
solid tumors, it will also be interesting to compare the subclonal architectures in primary 
tumors with those in recurrent or metastatic tumors. The field is in need to understand 
subclonal evolution and replacement under various treatment options, to minimize the risk of 
relapse and optimize the clinical outcome. 
In Chapter 4 I developed STRfinder, where I detected and genotyped STR alleles using a 
subset of informative read pair types. In the future, STRfinder will benefit from an exact 
likelihood formulation that uses all the information available for the STR locus. The 
prediction accuracy is expected to improve with a full likelihood model that includes the 
coverage distribution of all 13 read pair types, their insert size distribution, and the split reads 
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mapping. Also, many cancer types are associated with microsatellite instability (MSI), such 
as GBM (TCGA, 2008), colorectal cancer (Boland and Goel, 2010), gastric cancer (Halling et 
al., 1999), melanoma (Kroiss et al., 2001), etc. It will be interesting to apply STRfinder to 
these datasets to identify novel microsatellite alleles that cannot be detected using previous 
methods.  
STRfinder provides poor predictions for regions with complex repeats, which is a major 
limitation for the current method. And these regions can be highly interesting. For example, 
the recently developed technology using clustered regularly interspaced palindromic repeats 
(CRISPR) provides an elegant system to perform gene editing (Wang et al., 2014, Hsu et al., 
2014). And it will be helpful to detect CRISPR loci in bacteria strains whose genome have 
not been fully assembled, using short read DNA sequencing data. To detect the closely 
located interspaced repeats using NGS data is a new bioinformatics challenge and currently 
no software is capable of this task. 
 
5.3 Closing remarks 
 
Since the first cancer genome was sequenced in 2008 (Ley et al., 2008), the paradigm of 
cancer research has been shifted. Cancer genomics data have been collected worldwide with 
an unprecedented speed, resolution and scale. Large cancer cohort studies have strongly 
shaped the landscape of cancer research, with a profound influence over cancer diagnosis, 
patient care, and drug development. Great opportunities have come up with an abundance of 
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cancer datasets, spanning a wide spectrum of cancer types and multiple levels of biological 
regulations, yet along emerged new challenges. One of the greatest challenges is to identify 
driver mutations required for rapid malignancy growth and expansion. Algorithms developed 
in my thesis provide methodological support to quantitatively evaluate the effect of somatic 
events in the context of clonal structure. I also presented a novel approach to discover and 
genotype an understudied type of genetic variation, short tandem repeats, or microsatellites, 
and this tool will be helpful to understand tumor genome evolution. It is foreseeable that 
more genomics data derived from bulk tumor tissue will be collected for a wider range of 
cancer patients and the methods developed in this dissertation are expected to serve the need 
of analyzing and interpreting cancer genomics data.  
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